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INTRODUCTION AND OUTLINE OF THIS THESIS
1
Epidemiology
Vulvar cancer is the fourth most common gynecologic cancer after endometrial, 
ovarian and cervical cancer. It accounts for 5% of all gynecologic cancers with an 
incidence rate of 2.5 per 100,000 women 1, with half of the women aged over 70 years 
at time of diagnosis 2. The most common histological type is squamous cell carcinoma 
(SCC), which accounts for over 80% of the cases. Less common histological types of 
vulvar cancer are basal cell carcinoma, melanoma, adenocarcinoma and extremely 
rare types such as sarcoma and lymphoma 3. In the Netherlands, around 385 new 
patients with vulvar SCC are diagnosed each year 4. Over the past few decades, the 
incidence of vulvar SCC is increasing, in both the younger and elderly population 2. 
Pathogenesis
There are two different etiologic pathways known for the development of vulvar SCC; 
non HPV-related and HPV-related. Both pathways have their own associated premalignant 
lesions 5-8, as shown in Figure 1. The most common type of vulvar SCC is non-HPV 
related, usually occurring in elderly women in a background of the chronic inflammatory 
vulvar skin disease lichen sclerosus (LS) 9. There are strong indicators that differentiated 
vulvar intraepithelial neoplasia (dVIN) is the direct precursor lesion, but the exact 
mechanism of progression from LS and dVIN into vulvar SCC is not yet known.
The second type of vulvar SCC is caused by a persistent infection with high-risk HPV 
and associated with the precursor lesion high-grade intraepithelial squamous lesion 
(HSIL). It primarily affects younger women and is associated with smoking and an 
immunosuppressive state. The pathogenesis resembles the development of cervical 
cancer. 
Figure 1 Pathogenesis of vulvar SCC
LS: lichen sclerosus; HPV: human papilloma virus; dVIN: differentiated vulvar intraepithelial neoplasia; HSIL: 
high-grade squamous intraepithelial lesion; SCC: squamous cell carcinoma
Normal vulva
dVIN Keratinising
vulvar SCC
HSIL
HPV
LS
Non-
keratinising
vulvar SCC
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CHAPTER 1
Staging
The dissemination of vulvar SCC may occur by three different routes; lymphogenic, 
haematogenous and direct extension to adjacent structures. The initial spread occurs 
usually lymphogenic to the inguinofemoral lymph nodes. As soon as the invasion depth
is more than one millimeter, inguinofemoral lymph node metastases can already be 
present 10. Direct extension to adjacent structures and haematogenous dissemination 
is less frequent and generally present in a more advanced stage disease 11, 12. Vulvar 
SCC is staged according to the International Federation of Gynecology and Obstetrics 
(FIGO) 2009, as shown in Table 1. Because prognosis is strongly dependent on the 
inguinofemoral lymph node status, this is an important part of tumor staging. 
Table 1 FIGO stage for carcinoma of the vulva (2009)
FIGO stage Description
Stage I Tumor confined to the vulva or perineum, no nodal metastases
IA Lesions ≤ 2 cm with stromal invasion ≤ 1 mm*
IB Lesions > 2 cm in size or with stromal invasion > 1 mm
Stage II Tumor of any size with adjacent spread to the perineal structures (1/3 lower 
urethra, 1/3 lower vagina, or the anus) and no nodal metastases
Stage III Tumor of any size confined to vulva or with adjacent spread to the perineal 
structures (1/3 lower urethra, 1/3 lower vagina, or the anus) with positive 
inguinofemoral lymph nodes
IIIA (i) with 1 lymph node metastasis ≥5 mm, or
(ii) with 1 or 2 lymph node metastases < 5 mm
IIIB (i) with 2 or more lymph node metastases ≥5 mm, or
(ii) with 3 or more lymph node metastases <5 mm
IIIC With positive lymph nodes with extracapsular spread
Stage IV Tumor invades other regional (2/3 upper urethra, 2/3 upper vagina) or 
distant structures 
IVA (i) Tumor with spread into upper urethra/vagina, bladder, rectal mucosa, 
bone or fixed to pelvic bone
(ii) Tumor with fixed or ulcerated inguinofemoral lymph nodes
IVB Any distant metastases, including pelvic lymph nodes
*The depth of invasion is defined as the measurement of the tumor from the epithelial stromal junction of the 
adjacent most superficial dermal papilla to the deepest point of invasion.
Adapted from the FIGO classification from Pecorelli et al. (2009)13.
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Treatment
The method of treatment for vulvar SCC depends on the extent of the disease and does 
not differ per etiologic pathway. The cornerstone of treatment  is surgery which 
consists of wide local excision (WLE) with or without groin surgery depending on the 
depth of invasion of the vulvar SCC. For WLE of the vulvar tumor, it is recommended to 
obtain surgical tumor free margins of at least one to two centimeters  14-18. The 
pathologic tumor free margin of > 8 mm is considered standard since years. Currently 
there is an ongoing debate on the pathologic tumor fee margin, resulting in the ESGO 
guideline without strict advice.
In patients with primary microinvasive vulvar SCC (depth of invasion ≤1 mm) and a 
diameter of ≤2 cm, treatment entails WLE of the tumor without groin surgery as the risk 
for groin lymph node metastases is very low (< 1%) 19, 20. In patients with primary 
macroinvasive vulvar SCC (depth of invasion > 1 mm), about 20-30% of the patients 
without suspicious lymph nodes at clinical examination appear to have lymph node 
metastases 21-23. There is no non-invasive method with a high enough negative 
predictive value to accurately rule out the presence of inguinofemoral lymph node 
metastases 10. It should be kept in mind that the consequences of not detecting  groin 
metastases are significant because these patients have a 5-year survival of 0-10% 24. 
Therefore, groin surgery is indicated in all patients with a macroinvasive vulvar SCC 
and consists of a sentinel lymph node (SLN) procedure and/or inguinofemoral lymph-
adenectomy (IFL). In patients with a unifocal tumor measuring < 4 cm without suspicious 
lymph nodes in the groin a SLN procedure can be performed and IFL can be safely 
omitted 25, 26. In patients not eligible for the SLN procedure (tumor measuring > 4 cm 
and/or multifocal tumor and/or suspicious lymph nodes in the groin) or if the SLN is 
positive, IFL is indicated. 
Adjuvant treatment
Local re-excision is indicated if the pathologic margin is tumor positive. Radiotherapy 
to the vulva is recommended if the pathologic margin is tumor positive re-excision is 
not possible 15-18. In patients with a close margin, either adjuvant re-excision or 
radiotherapy to the vulva is considered, or close follow up  is performed. 
Adjuvant radiotherapy to the groin is performed in patients with one inguinofemoral 
lymph node metastasis with extranodal growth and/or more than one lymph node 
metastases without extranodal growth. 
Treatment associated morbidity
The treatment of vulvar SCC is associated with high complication rates, especially in 
the groin(s). The past few decades, several adjustments of the surgical technique were 
implemented in order to reduce the morbidity without compromising the prognosis. 
The most important adjustments were the replacement of the classic radical 
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vulvectomy with ’en bloc‘ bilateral IFL by WLE of the tumor combined with IFL by 
separate incisions. In addition, the introduction of the SLN as a safe alternative for IFL 
in a selected group of patients with primary vulvar SCC significantly reduced the 
postoperative morbidity 25, 26. 
Since the introduction of the SLN, the number of patients with an indication for IFL 
decreased. However, IFL is finally indicated in around half of the patients with primary 
vulvar SCC based on multifocal tumors, tumors > 4 cm or a positive SLN and in all 
patients with local recurrent disease if IFL has not been performed previously 27. IFL 
has significant short- and long-term complications of the groin, which are reported in 
up to 85% of the patients 23, 27, 28. Wound breakdown, wound infection and formation 
of lymphoceles are the most documented short-term complications. The development 
of lymphedema and (recurrent) cellulitis or erysipelas are the most documented 
long-term complications. Known risk factors for short- and long-term complications 
are older age, diabetes, ‘en bloc’ surgery and higher drain production on the last day 
of drain in situ 27. Studies concerning the postoperative care including optimal drain 
management in relation to postoperative morbidity are lacking. 
Follow-up 
The follow-up after surgical treatment for primary vulvar SCC is consensus based 
rather than evidence based, and prospective studies are lacking. As the treatment of a 
local recurrence is largely dependent on either further excision or radiotherapy, 
follow-up is performed to detect locoregional recurrences as early as possible to 
achieve better survival rates preferably with limited morbidity. A study of Oonk et al. 
showed that local recurrences detected during a routine follow-up meeting were 
significantly smaller compared to recurrences detected at interval meetings scheduled 
because of complaints 29. Smaller recurrences might lead to less extensive surgery. 
Worldwide, guidelines recommend different follow-up regimens; advised regimens range 
between three- and six-monthly visits during the first two years, six- until 12-monthly for the 
third, fourth and fifth year and all recommend annually thereafter 15-18. However, none of 
these follow-up regimens is individualized  based on the performed treatment and/or 
risk of developing recurrent disease. 
Prognosis
The inguinofemoral lymph node status at initial diagnosis is of critical prognostic 
importance for patients with vulvar SCC 11, 12, 30-32. The five-year survival for early stage 
vulvar SCC is 70-93% and decreases to 25-41% with the presence of lymph node 
metastases 33. In patients suffering from a groin recurrence, prognosis is very poor 
with a 5-year survival rate of 0-10% 24.  
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Local recurrent disease
In patients treated for primary early-stage squamous cell carcinoma of the vulva, local 
recurrence is reported in up to 40% during the first ten years after treatment  and is 
associated with significantly decreased disease-specific survival 34. Treatment of a 
local recurrence consists of WLE combined with IFL if not performed as part of the 
treatment for the primary vulvar SCC 10. As a consequence, patients with a local 
recurrence after an earlier SLN procedure, undergoing an IFL do not perceive the 
benefits of the SLN procedure anymore, in terms of a reduction in morbidity. 
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OUTLINE OF THIS THESIS
The oncogenesis of non HPV-related vulvar SCC remains to be unravelled. DVIN is 
mostly found in a background of LS and can give rise to vulvar SCC, but genetic 
evidence is currently limited. To study the genetic relationship between these lesions, 
we compared genomic abnormalities of vulvar SCC lesions with paired dVIN and/or LS 
lesions in Chapter 2. The depth of invasion predicts biological behavior of vulvar SCC 
and determines the need for groin surgery. A high interobserver agreement is important
to support the prognostic value for the presence of lymph node metastases. In Chapter 3
we assessed the interobserver agreement in the classification of the depth of invasion 
and identified pitfalls in the assessment of the depth of invasion in order to improve 
the inter-observer agreement between pathologists. 
In patients treated for early-stage vulvar SCC, local recurrences are reported in up to 
40% ten years after primary treatment. We summarized the current knowledge on the 
incidence and prognostic factors for local recurrent disease in Chapter 4 and describe 
in Chapter 5 the results of our multicenter study to assess the influence of tumor and/
or precursor lesion free pathologic margins, clinicopathologic and tumor characteris-
tics on local recurrence rate.
In Chapter 6, we focused on the morbidity associated with IFL in patients with vulvar 
SCC. We created an up-to-date summery of the current literature on surgical techniques 
and peri- and postoperative care in relation to morbidity. In Chapter 7 we describe the 
results of our nationwide prospective study, which assessed the feasibility and the 
incidence of postoperative complications after volume-controlled versus short 
drainage of the groin. Subsequently, we focused on the surgical technique of IFL with 
the aim to further reduce morbidity after IFL. In Chapter 8 we present the results of our 
randomized controlled trail comparing two surgical techniques for IFL: LigaSure and 
conventional performance of IFL.
To optimize the follow-up in patients treated for early-stage vulvar SCC, we describe in 
Chapter 9 the efficacy of the addition of an ultrasound of the groin to the routine 
follow-up during  the first two years in patients with a negative sentinel lymph node. 
The general discussion in Chapter 10 gives an overview of the findings presented in 
this thesis, and based on these findings future perspectives in the management of 
vulvar SCC are discussed.
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ABSTRACT
Differentiated vulvar intraepithelial neoplasia (dVIN) is mostly found in a background 
of lichen sclerosus (LS) and can give rise to vulvar squamous cell carcinoma (SCC), but 
genetic evidence is currently still limited. To study the genetic relationship between 
these lesions, we compared genomic abnormalities of vulvar SCC lesions with paired 
dVIN  and/or LS in twelve patients. High-resolution genome-wide copy number 
analysis was performed for six vulvar SCC samples and three paired dVIN samples. 
Copy number alterations were identified in all vulvar SCC samples. One dVIN lesion 
presented with three copy number alterations that were preserved in the paired vulvar 
SCC sample, including a 11q23 high-level amplification. Subsequently, we sequenced 
TP53, a recurrently mutated driver in vulvar SCC, in two patients with acquired 
homozygosity at 17p and six additional patients, and identified mutations in five cases. 
Targeted deep-sequencing in the available precursor lesions revealed that all five 
mutations were traced back in the dVIN (n=5) or the LS (n=1) with frequencies ranging 
from 3 to 19%, suggesting that mosaic subpopulations of cells in the LS and dVIN 
lesions gave rise to the vulvar SCC. Our data provide genetic evidence for a clonal 
relationship between vulvar SCC and dVIN or LS.
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INTRODUCTION
Vulvar cancer is the fourth most common cancer affecting the female genital tract and 
has an increasing incidence of 2.5/100.000 women per year 1. Approximately 80% of 
all vulvar cancers are of squamous origin and can develop following two different 
pathways 2, 3. The minority of vulvar squamous cell carcinomas (SCC) is caused by a 
persistent infection with high-risk human papillomavirus (HPV), inducing the precursor 
high grade squamous intraepithelial lesion (HSIL); the oncogenesis of HPV-related 
vulvar SCC resembles the development of cervical cancer. The second and most 
common type of vulvar SCC is non HPV-related and accounts for over 80% of all vulvar 
SCC 4, 5. These carcinomas arise in a background of the chronic inflammatory vulvar 
skin disease Lichen Sclerosus (LS) and/or differentiated vulvar intraepithelial neoplasia 
(dVIN). The exact role of LS and dVIN in the development of vulvar SCC is not yet 
known, but patients with LS have a lifetime risk of 4-5% to develop vulvar SCC 6. 
There is clinical evidence that dVIN is the precursor lesion of the non HPV-related 
pathway 7. We showed that of all VIN lesions diagnosed in the Netherlands between 
1992 and 2005, only a minority were dVIN in comparison to HSIL; apparently dVIN is 
rarely found as a solitary lesion 8. Remarkebly, dVIN is present around the majority of 
the non HPV-related vulvar SCCs 4, 5. This discrepancy, low incidence of solitary dVIN 
lesions but high incidence of dVIN adjacent to vulvar SCC, can be explained by the fact 
that the diagnosis of dVIN is clinically and histopathologically difficult 9 with an 
assumed short intraepithelial phase, which suggests that dVIN is possibly suffering 
from underdiagnosis 10. On the other hand, it has been hypothesised that dVIN is a 
border phenomenon of vulvar SCC 11. Though the oncogenesis has not been fully 
clarified, there are strong indications that dVIN is a precursor lesion; in recent years the 
incidence of solitary dVIN is increasing 8 and dVIN is more often found in revised 
biopsies previously diagnosed as LS in patients that later developed vulvar SCC 10. 
Furthermore, first indications for a genetic correlation between vulvar SCC, dVIN and 
LS were reported by Nooij et al.12. 
Few studies have investigated genetic abnormalities in non HPV-related vulvar SCC, 
and showed frequent occurrence of TP53 mutations 13-15. The upcoming techniques to 
search for genetic changes are promising to provide more information on the aetiology 
of (pre)malignant vulvar lesions. However, the literature on this topic is limited in 
vulvar (pre)malignancies. In theory, tumours arise from a multistep process of 
accumulated genetic alterations 16. The identification of chromosomal regions most 
frequently affected by copy number alterations or sequence mutations may be relevant 
for determining the relationship between LS, dVIN and vulvar SCC. 
We hypothesise that LS and dVIN are lesions already showing early neoplastic 
alterations which are also present in vulvar SCC together with other accumulating 
events. In order to provide information on the mutations that can be found in vulvar 
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SCC and to provide more evidence for a clonal relation between LS, dVIN and vulvar 
SCC, we aimed to determine genetic abnormalities in vulvar SCC of 12 patients and 
backtrack these abnormalities in the dVIN and LS precursor lesions. 
METHODS
Tissue samples
Twelve patients with a primary vulvar SCC who were primary surgically treated between 
2008 and 2014 in the Radboud university medical center Nijmegen, the Netherlands, 
were included. Inclusion criteria were: a history of LS, presence of dVIN in the surgical 
excision specimen, non HPV-related tumour, and no previous radiotherapy or 
chemotherapy. Clinical data of included patients was retrieved. 
To select for non HPV-related VSSCs, we used the p16INK4A expression of the tumour in 
combination with HPV status and morphologic criteria on hematoxylin and eosin 
(H&E) stained slides. Tumours were considered as non HPV-related if p16 staining was 
negative, dVIN and LS were present, independent of HPV status, or if the HPV status 
was negative in combination with the presence of dVIN and LS. 
For this study, coded residual tissue was used, which was retrieved during regular 
treatment. According to the Dutch law, no specific patient approval is necessary for the 
use of this material. This study was approved by the local ethical committee (CMO 
Regio Arnhem-Nijmegen; registration number 2015-1808) and performed according to 
the Code for Proper Secondary Use of Human Tissue (Dutch Federation of Biomedical 
Scientific Societies (htpp://federa.org).
Microdissection and DNA extraction
The haematoxylin & eosin stained (H&E) slides of the surgical excision specimen were 
reviewed by an expert gynaecopathologist; areas with LS, dVIN and vulvar SCC were 
identified. Formalin-fixed paraffin-embedded (FFPE) blocks were retrieved and re-cut 
at 5 µm. The last re-cut slide was H&E stained and compared with the original slide in 
order to confirm that the lesion was still present. Tumour cells were collected through 
removal of vulvar SCC and dVIN tissue by scraping with a clean scalpel from several 
unstained slide sections. DNA was isolated with TET-lysis buffer (10 mmol/L Tris-HCl, 
pH 8.5; 1 mmol/L EDTA, pH 8; 0.1% Tween-20) containing 5% Chelex-100 (Bio-Rad, 
Hercules, CA). Protein digestion was performed by adding 20 µL of proteinase K to 
each sample following incubation at 56°C for 48 hours. Fresh proteinase K of 10 µL was 
added after 24 hours. Next, DNA was denatured by heat inactivation at 95°C for ten 
minutes. The samples were centrifuged for ten minutes at 14.000 rpm (RT) and 
measured by Picogreen measurements (Invitrogen, Carlsbad, CA, USA).
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Copy number profiling
Genome-wide copy number profiling was performed on DNA from six paired dVIN and 
vulvar SCC lesions using FFPE-compatible Affymetrix Oncoscan arrays (OncoScan 
FFPE Express v.2; Affymetrix, Santa Clara, CA, USA), according to the protocol provided 
by the manufacturer 17-19. The data that passed quality control (MAPD value ≤ 0.6) 
were then analyzed using Nexus Copy Number software Edition 7 (Biodiscovery, El 
Segundo, CA, USA) with NCBI build 37 of the human genome. The SNP-FASST2 
Segmentation Algorithm was used. The significance threshold was set at 5.0E-7 with a 
minimum of 250 probes and a maximum contiguous spacing of 1000 kb to define a 
segment. Thresholds for copy number gains and losses were set to 0.3 and -0.3, 
respectively. Thresholds for high-level amplifications and homozygous losses, indicating 
greater than a single copy number change were set at 1.2 and -1.2 respectively. The 
homozygous frequency threshold was set at 0.85 and the homozygous value threshold 
was set at 0.8 with a minimum loss of heterozygosity (LOH) requirement of 500 kb. 
The heterozygous imbalance threshold was set at 0.4. Allelic imbalance and LOH was 
only scored when larger than 15 Mb, and adjacent sequential calls of allelic imbalance 
and LOH were merged as one region upon visual inspection of the copy number and 
B-allele frequency plots. To allow comparison of vulvar SCC copy number profiles with 
those of the dVIN samples, which were of poorer quality, we performed smoothening 
of the dVIN probe intensity values using a 15x running smoothing of the median
(R package). Copy number plots of vulvar SCC and smoothened dVIN data per 
chromosome were made using GenomeGraphs library 1.28.0 20.
Targeted sequencing of TP53 using molecular inversion probes
For the targeted enrichment of genomic TP53 sequences we used single molecule 
Molecular Inversion Probes (smMIPs), which are 80-nt oligonucleotides with two 
targeting arms at the extreme ends that bind the genomic template in a strand specific 
manner, allowing strand specific amplification and double tiling. Each probe contains 
an 8-nt random molecular tag that enable the identification of unique captures from 
the generated sequencing reads, which is essential in the context of gDNA with low 
quality/quantity, and can correct for amplification bias 21. In addition, the molecular 
tag guided assembly into consensus reads diminishes the number of false positive 
variants due to PCR and sequencing artefacts and thus allows accurate detection of 
low-frequency variants. In total, 50 probes were designed that target >95% of coding 
and splice-sequences (-/+5 nt flanking exon-intron boundaries) in TP53. An equimolar 
pool of these 50 probes was tested and optimized on gDNA controls prior to sequencing 
of the samples (Supplementary Table S1). To prevent allelic drop-out at sites containing 
SNPs, identical smMIPs were designed for the major and minor alleles (referred to as 
‘a’ and ‘b’). Targeted capture with smMIPs was performed as previously described 21
22. Shortly, 100 ng of genomic DNA in a pool containing 5’-phosphorylated smMIPs 
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were annealed overnight to capture the targeted sequences of interest. After annealing, 
the gaps were closed in a 5’->3’ extension reaction, followed by a ligation step to create 
circular DNA. Uncircularised probes and remaining linear genomic DNA were removed 
by exonuclease treatment. Barcoded Illumina primers were incorporated in the PCR 
reaction, following amplification of all pooled samples. Subsequently, the barcoded 
library was sequenced using the Illumina NextSeq500 system, with 2 × 150-bp 
paired-end reads. We used SeqNext software (JSI Medical Systems; version 4.2.0) to 
map and align the reads, create unique consensus reads from PCR duplicates to minimise 
sequencing errors, and perform variant calling (relevant settings are described in 23). 
Identified mutations were validated by Sanger sequencing in LS, dVIN and vulvar SCC 
samples from the same patient (primers available upon request). 
RESULTS
Patient samples
We included twelve patients with a non HPV-related vulvar SCC in this study, of which 
tissues of six patients were included for whole genome copy number profiling. For 
each of the twelve included patients, a paired dVIN and vulvar SCC sample was 
available, for two of them also an LS sample was available for analyses (See Table 1). 
The median age of our patients was 59 years (range 47-83). Eight  patients (67%) had 
FIGO stage IB and four (33%) stage III disease. Five vulvar SCCs were well differentiated 
(42%), three moderate differentiated (25%) and four poorly differentiated (33%). 
Chromosomal alterations in vulvar SCC
The dVIN and vulvar SCC samples of six patients were hybridised to Oncoscan arrays. 
All six vulvar SCC samples generated copy number profiles that passed quality control 
and could be further analyzed (See Supplementary Figure 1). An overview of the 
distribution and number of gains and losses per patient per sample are displayed in 
Figure 1 and Table 2. In vulvar SCCs, we identified a total of 94 copy number alterations 
(Table 2 and supplementary Table S2). These alterations consisted of 55 losses and 39 
gains, including 7 high-level amplifications. Overall, eleven genomic regions were 
affected by copy number alterations in three or more vulvar SCCs (see Supplementary 
Table S3). 
The most frequently found alteration was loss of chromosome 8p, present in all vulvar 
SCC, followed by gain of chromosome 8q in five of six vulvar SCCs, gain of chromosome 
7p and loss of chromosome 18q, both present in four of six vulvar SCCs (Figure 1 and 
supplementary Table S3). 
As shown in Table 3, seven high-level amplifications were seen in three of six vulvar 
SCCs. Five of these encompassed large genomic regions (37-45 Mb), affecting many 
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genes. The others were smaller (1-8 Mb) in size and contained known oncogenes 
including EGFR (7p21.1), FGFR1 (8p11.23), IL11-RA (9p13), and YAP1 (11q22.1). 
Furthermore, 12 regions of allelic imbalance were identified, representing copy neutral 
homozygosity. These regions are known as acquired uniparental disomy, and frequently 
contain mutations in tumour suppressor genes that have become homozygous as a 
result of mitotic recombination. The regions were not completely homozygous, suggesting 
them to be present in a subset of the sample because of the presence of normal cells 
and/or tumour heterogeneity (supplementary Table S3). 
Table 1  Patient demographics, clinical characteristics, and sample availability
Patient Age FIGO stage Samples1 Differentiation tumour
1 83 IB 01VSCC
01dVIN
01LS2
Poor
2 81 IB 02VSCC
dVIN*
Well 
3 54 III 03VSCC
03dVIN
03LS2
Moderate
4 57 III 04VSCC
04dVIN*
Moderate
5 50 IB 05VSCC
05dVIN*
Well
6 47 IB 06VSCC
06dVIN
Well
7 63 IB 07VSCC2
07dVIN2
Moderate
8 55 IB 08VSCC2
08dVIN2
Poor
9 75 III 09VSCC2
09dVIN2
Poor
10 61 IB 10VSCC2
10dVIN2
Well
11 78 III 11VSCC2
11dVIN2
Poor
12 55 IB 12VSCC2
12dVIN2
Well
FIGO stage: stage of tumour classified by the FIGO classification 2009; *sample did not pass quality control, 
1The VSCC and dVIN lesion of each patient was collected at the same point of time. 2samples were only used 
for targeted sequencing of TP53.
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Interestingly, chromosome 17p encompassing, among other genes, the tumour suppressor 
gene TP53, was affected by acquired uniparental disomy in three vulvar SCCs 
(Supplementary Table S3). Targeted sequencing of the TP53 gene using molecular 
inversion probes in two vulvar SCC samples for which sufficient material remained 
indeed identified mutations in patient 1 (c.596G>T, p.Gly199Val) and patient 3 (c.833C>A, 
p.Pro278His). Both mutations were confirmed by Sanger sequencing.
Clonal relationship between vulvar SCC and dVIN
Next, we analysed whether the chromosomal abnormalities detected in the vulvar SCC 
could already be detected in the paired dVIN samples. Three dVIN samples (patients 
1, 3, and 6) passed quality control and could be further analysed. No copy number 
alterations were found the dVIN samples of patients 1 and 6. In contrast, three copy 
number alterations were detected in the dVIN sample of patient 3; a 54-year old female 
with a unifocal lesion of 2.5 cm on the left labium minus localized 1.5 cm left from the 
clitoris. Histopathological examination showed that the dVIN was located in the 
immediate surroundings of a moderately differentiated vulvar SCC with presence of 
lymphovascular invasion, an invasion depth of 9.5 mm and a sentinel node with 
isolated tumour cells (Figure 2). 
The copy number abnormalities in this dVIN included an amplification of 11q22  and a 
deletion at the telomeric region of 12q. Furthermore, chromosome 14 showed a higher 
median probe level, suggesting a gain of this entire chromosome. All these three copy 
Table 2 Overview of gains, losses and acquired uniparental disomy events  
per patient per vulvar SCC sample
Patient Total CNAs Gains1 Losses High-level  
amplifications
aUPD
1 21 11 10 2 2 (10p, 17p)
2 17 9 8 3 2 (5, 12q)
3 33 7 26 2 2 (11q, 17p)
4 9 4 5 0 4 (3q, 6p, 9p, 9q)
5 13 8 5 0 2 (13q, 17p)
6 1 0 1 0 -
Total 94 39 55 7 12
Average 15.7 6.5 9.2 1.2 2
1including high-level amplifications
Abbreviations=CNA: Copy number alteration; aUPD: acquired uniparental disomy
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number alterations were also detected in the paired vulvar SCC sample (Supplementary 
Table S2). Detailed comparison between the dVIN and vulvar SCC showed that the 
boundaries of the 11q22 amplification appeared identical, suggesting that this lesion 
is indeed preserved from dVIN (Figure 3A and 3B). The 12qter deletion was found to be 
larger (~1.9 Mb; 197 probes) in the dVIN sample compared to vulvar SCC (Figure 3C), 
but the quality and amount of available DNA did not allow us to reveal whether this 
difference was due to a technical artefact or it indicates that the 12qter deletions have 
arisen independently in dVIN and vulvar SCC. Importantly, the other copy number 
alterations detected in vulvar SCC (five gains and 25 deletions), including an 8q22-q24.3 
amplification (Figure 3D and Table 3) could not be detected in the paired dVIN sample. 
In conclusion, the shared copy number alterations between the dVIN and vulvar SCC in 
patient 3  provide genetic evidence for a clonal relationship between dVIN and vulvar 
SCC.
Figure 2 Histological overview of the epithelium of patient three; the area on  
the left side shows vulvar squamous cell carcinoma (SCC), the area on  
the right side differentiated vulvar intra-epithelial neoplasia (dVIN).
Micro-dissection was performed in these areas, there is a distance of 2 mm (normal epithelium) between 
both areas. (original magnification x50)
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Subclonal TP53 mutations in dVIN and LS
A clonal relationship between vulvar SCC and dVIN or LS can easily be missed if the 
alteration is present in only a subset of the cells. Since subclonal copy number alterations 
are difficult to detect, we next focused on point mutations using smMIP-based targeted 
deep-sequencing. This technology allows clustering of sequence reads derived from 
the same template to create so-called single molecule consensus reads (smc reads) 21, 24
which have much lower error rates, hence creating higher specificity for detecting low- 
level mosaic mutations. We performed smMIP-based sequencing of vulvar SCC samples 
from six additional patients for the TP53 gene as this gene is known as a recurrently 
mutated driver of vulvar SCC. 
Next to the mutations already found in patients 1 and 3, we identified three additional 
TP53 mutations in the vulvar SCCs of patients 7, 9 and 11 (Table 4). Next, we established 
whether these five TP53 mutations could be traced back in paired dVIN and LS samples. 
In all five patients, the TP53 mutations detected in the vulvar SCC sample were also 
present in dVIN with variant allele frequencies ranging from 3 to 19% (Table 4). 
In patient 1, the mutation was detected by only a single smc-read, likely due to the 
limited availability of material, which makes an estimate of the mutant allele frequency 
rather inaccurate. Interestingly, however, this mutation was also detected in the LS 
sample (6% of the reads), a finding that could be confirmed by Sanger sequencing 
(Figure 4). In conclusion, we here demonstrate that in all five TP53-mutated vulvar 
SCCs, the mutation could be detected at subclonal levels in dVIN or LS, thereby 
confirming a clonal relationship between these lesions in the respective patients.
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Figure 4 Detection TP53 mutations in two vulvar squamous cell carcinoma (VSCC) 
samples and backtracking in differentiated vulvar intra-epithelial neoplasia 
(dVIN) and lichen sclerosus (LS).
Top panel shows the TP53 protein with the transactivating domain (TAD) and the DNA-dinding domain 
(DBD) and the location of the two mutations. Below that are sequence chromatograms of each mutation in 
the respective samples. Mutations are indicated by a black (clonal) or red (subclonal) asteriks.
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DISCUSSION
We investigated genomic alterations of non HPV-related vulvar SCC lesions and pa-
tient-matched dVIN lesions using genome-wide copy number profiling and targeted 
sequencing of TP53. We found that gains of 7p and 8q and losses of 8p and 18q were 
found in most vulvar SCC lesions, and acquired uniparental disomy was common, 
including for chromosome 17p. In one patient, three of the 33 copy number alterations 
found in the vulvar SCC sample were also detected in the paired dVIN sample including 
a high-level amplification on 11q22 and a deletion of 12qter. Furthermore, in five of the 
12 patients (42%) we identified a TP53 mutation in a cellular subset of LS or dVIN, 
which was shared with the paired vulvar SCC. We therefore conclude that, at least in 
five patients, the vulvar SCC originate from single precursor cells in which a subset of 
the genetic alterations, possibly driving premalignant events, were already present in 
the dVIN and/or LS stage, after which additional alterations have resulted in the 
progression towards vulvar SCC.
In patient 3, a clonal relationship between vulvar SCC and dVIN was confirmed by several 
genomic aberrations, including shared copy  number alterations and a TP53 mutation. 
The most pronounced aberration was a high gain on chromosome 11q23, which 
encompassed the BIRC and MMP gene clusters as well as the YES-associated protein 1 
(YAP1) as a possible candidate gene. This latter gene is known to play a role in the 
development and progression of multiple cancers and may function as a potential target 
for cancer treatment 25. YAP1 expression seems to indicate a poor outcome in several 
cancer types 26, 27. Future studies should reveal whether these aberrations are more 
common in dVIN lesions and are involved in the progression from dVIN towards vulvar 
SCC. Importantly, the majority of copy number alterations, among which one high-level 
amplification, were found only in vulvar SCC, and thus may have contributed to the 
progression towards vulvar SCC. Another alteration preserved from dVIN was a mutation 
in TP53, which was found in low levels in this lesion and became homozygous in a major 
fraction of tumour cells in the vulvar SCC. 
Interestingly, TP53 mutations were detected in five patients (42%) and, in all cases, were 
shared between vulvar SCC and dVIN. The mutant allele frequency of these mutations 
was always lower in the dVIN samples compared to vulvar SCC, indicating that they were 
present in only a subset of the cells. Whether this low mosaicism was due to heterogeneity 
of the dVIN lesion or caused by a relatively high load of normal epithelial cells could not be 
established. In patients 1 and 3, the B-allele frequency plots showed homozygosity of 
the TP53 locus in the majority of cells due to acquired uniparental disomy. Our findings 
illustrate how the detection of acquired uniparental disomy facilitated the identification of 
TP53 mutations, but also provide insight into the role of these mutations during tumour 
progression: TP53 mutations can find their origin in precursor lesions, as was recently 
also demonstrated by others 12, and frequently become homozygous in vulvar SCC. 
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One could question whether the copy  number alterations found in the dVIN lesion in 
patient 3 were actually copy  number alterations present in a subset of vulvar SCC cells 
that were present in the dVIN biopsy. However, although the samples were taken from 
the same surgical excision specimen, cells for DNA were collected from a different site 
of the specimen. Furthermore, histological examination of the H&E stained slides 
(Figure 2) showed a distance of 2 mm with normal epithelium between the dVIN lesion 
and vulvar SCC lesion. It is important to note that, due to the low copy number 
intensities in the dVIN sample of patient 3, and the relatively low signal-to-noise ratio, 
it might be possible that other aberrations detected in the vulvar SCC sample were 
simply missed in the dVIN sample. Nevertheless, it is unlikely that the high-level 
amplification at 8q has been missed in dVIN (Figure 3), which indicates that the dVIN 
and vulvar SCC samples share genomic alterations, but are not identical, thereby 
making it less likely that vulvar SCC-derived cells were present in the dVIN sample. 
Liegl and Regauer 11 suggested that the rare identification of dVIN without vulvar SCC 
in their patient group raised the question whether dVIN should be considered a true 
precursor lesion of vulvar SCC or whether it represents an in situ carcinoma component 
adjacent to an invasive vulvar SCC. They suggested that the interpretation of dVIN as 
a precursor lesion needs to be carefully reconsidered. In general, epithelial disorders 
are found adjacent to vulvar SCC in 70-80% of patients. However, evidence that some 
of these disorders are precursors of vulvar SCC is circumstantial 7. Reason to question 
dVIN as being the precursor lesion is the low incidence of solitary dVIN compared to 
HSIL 8, while the majority of vulvar SCCs are not HPV associated. However, this low 
incidence can also be explained by the difficulty of diagnosing dVIN which might result 
in an underdiagnosis 9, as well as by the existence of a shorter intra-epithelial phase 
compared to HSIL 8, 28. Though there are no recent studies concerning the incidence of 
dVIN, we experience a higher incidence of solitary dVIN in daily practice because 
clinicians and pathologists are more aware of the diagnosis.  
The number of studies that tried to find genetic similarities between dVIN and vulvar 
SCC are small and mainly involve a low number of loci investigated 7, 13, 29. Furthermore, 
most studies do not differentiate between HSIL and dVIN-related vulvar SCCs. Lin et al.
30 compared patterns of loss of heterozygosity between different locations of the 
tumour of one patient with a non HPV-related vulvar SCC; the tumour itself scored 
positive for loss of heterozygosity in four of seven loci. Furthermore, one site of dVIN 
shared its locus with the invasive tumour whereas the other dVIN shared one of two 
loci with the vulvar SCC. Normal epithelium and stroma showed no abnormalities. 
These results are suggestive for dVIN being a precursor lesion, though this conclusion 
is based on a single case and only seven genomic loci. Pinto et al. 31 compared 11 
identified loci which scored positive for allelic imbalance in greater than 50% of cases 
from a prior study of vulvar SCC (n=16) 32 to pre-invasive lesions (LS, HSIL, dVIN and 
hyperplasia). This comparison showed a lower percentage of allelic imbalance in 
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pre-invasive lesions, though in this comparison no distinction was made between 
HPV-positive and negative lesions. The advantage of our study is the high number of 
loci investigated in dVIN associated vulvar SCC, which allows us to compare the whole 
genome of dVIN and vulvar SCC which provides more detailed information. 
A noticeable result is the median age of 59 years of the included patients. Vulvar SCC, 
especially non HPV-related vulvar SCC, is a disease occurring in elderly patients. 
In our study, two out of three dVIN samples analyzed by copy number profiling, did not 
show copy number aberrations. This observation might be explained by a higher level 
of contamination with normal cells in these lesions compared to vulvar SCC, or low 
yield and quality of the isolated DNA, which may have resulted in a decreased 
sensitivity to detect these aberrations. In addition, however, it is not unlikely that copy 
number alterations are simply less frequent in these lesions.
In order to provide more evidence for the hypothesis of clonal relationship between 
LS/dVIN and vulvar SCC, the availability of sufficient material is essential. We experienced 
that retrieving enough DNA from FFPE-blocks for genome-wide profiling was challenging, 
and collection of fresh-frozen tissue for future studies is highly recommended. 
Fortunately, we were able to reveal additional support for our hypothesis by using 
smMIP-based targeted sequencing of TP53, which is frequently mutated in vulvar SCC. 
This technology is highly suitable for fragmented (FFPE-derived) DNA, and highly 
sensitive for detecting mutations, even when present in a low percentage of cells. 
However, in order to obtain more information on the correlation between LS, dVIN and 
vulvar SCC, whole exome or genome sequencing in a larger number of lesions might be 
essential, particularly because backtracking of small mutations is less challenging.
In summary, we have investigated the genome-wide aberrations in vulvar SCC and its 
possible genetic relationship with dVIN and LS, and provided genetic evidence for a 
clonal relationship between LS, dVIN and vulvar SCC in 42% of the patients, including 
all patients with TP53 mutated vulvar SCC. These results will provide a basis for more 
comprehensive sequencing studies to identify genetic aberrations in precursor lesions 
that create a risk to the development of vulvar SCC.
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SUPPLEMENTARY DATA
Supplementary Figure 1 Copy number profiles of six vulvar squamous cell 
carcinoma (VSCC) samples.
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Supplementary Figure 1 Continued.
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Supplementary Table 2  Copy number gains and losses in six VSCC samples.
SampleID chr type (*) start end length 
(Mb)
cytoband
01VSCC chr02 CN gain 186.058.638 198.479.196 12,42 q32.1 - q33.1
01VSCC chr02 CN loss 198.950.266 243.199.373 44,25 q33.1 - q37.3
01VSCC chr03 CN gain 101.634.884 198.022.430 96,39 q12.3 - q29
01VSCC chr04 CN gain 0 50.400.000 50,40 p16.3 - q11
01VSCC chr04 CN loss 52.700.771 191.154.276 138,45 q12 - q35.2
01VSCC chr07 CN loss 151.515.051 159.000.000 7,48 q36.1 - q36.3
01VSCC chr08 CN loss 0 43.749.726 43,75 p23.3 - p11.1
01VSCC chr08 CN gain 46.950.145 83.121.643 36,17 q11.1 - q21.13
01VSCC chr08 CN gain 83.121.643 146.364.022 60,22 q21.2 - q24.3
01VSCC chr09 high CN gain 0 21,566,202 21,57 p24.3 - p13.2
01VSCC chr09 CN loss 21.566.202 22.185.516 0,62 p21.3
01VSCC chr13 CN loss 19.308.175 69.687.801 50,38 q11 - q21.33
01VSCC chr13 high CN gain 71.643.837 74.278.611 2,63 q21.33 - q22.1
01VSCC chr13 CN gain 74.278.611 109.061.226 34,78 q22.1 - q33.3
01VSCC chr17 CN gain 29.488.572 35.803.400 6,31 q11.2 - q12
01VSCC chr17 CN loss 41.266.386 57.442.459 16,18 q21.31 - q22
01VSCC chr18 CN gain 54.127.603 56.207.023 2,08 q21.31 - q21.32
01VSCC chr18 CN loss 56.207.023 74.381.966 18,17 q21.32 - q23
01VSCC chr20 CN gain 0 23.222.260 23,22 p13 - p11.21
01VSCC chr22 CN loss 47.191.586 51.304.566 4,11 q13.31 - q13.33
01VSCC chrX CN loss 101.403.500 155.270.560 53,87 q22.1 - q28
02VSCC chr03 CN loss 0 91.000.000 91,00 p26.3 - q11.1
02VSCC chr03 CN gain 94.262.831 198.022.430 103,76 q11.2 - q29
02VSCC chr05 CN gain 37.172.054 50.596.132 13,42 p13.2 - q11.1
02VSCC chr07 CN gain 0 67.523.814 67,52 p22.3 - q11.22
02VSCC chr07 high CN gain 51.965.546 59.863.318 7,90 p12.1
02VSCC chr08 CN loss 0 34.606.454 34,61 p23.3 - p12
02VSCC chr08 high CN gain 34.606.454 39.007.911 4,40 p12 - p11.22
02VSCC chr08 CN gain 48.302.428 146.275.000 97,97 q11.21 - q24.3
02VSCC chr09 CN gain 18.612.221 19.816.014 1,20 p22.1
02VSCC chr09 CN loss 19.816.014 30.708.447 10,89 p21.3 - p21.1
02VSCC chr09 high CN gain 32.862.231 37.441.137 4,58 p13.1 - p13.2
02VSCC chr09 CN gain 93.484.459 141.213.431 47,73 q22.2 - q34.3
02VSCC chr12 CN loss 0 59.271.881 59,27 p13.33 - q14.1
02VSCC chr12 CN loss 75.861.975 94.178.228 18,32 q21.2 - q22
02VSCC chr16 CN loss 20.057.892 32.482.955 12,43 p12.3 - p11.1
02VSCC chr18 CN loss 21.795.295 78.077.248 56,28 q11.2 - q23
02VSCC chrX CN loss 0 155.270.560 155,27 p22.33 - q28
03VSCC chr01 CN loss 204.214.562 249.250.621 45,04 q32.1 - q43
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Supplementary Table 2 Continued.
SampleID chr type (*) start end length 
(Mb)
cytoband
03VSCC chr01 CN loss 204.214.562 249.250.621 45,04 q32.1 - q43
03VSCC chr02 CN loss 95.387.135 241.229.436 145,84 q11.2 - q37.3
03VSCC chr03 CN loss 0 91.000.000 91,00 p26.1 - q11.1
03VSCC chr03 CN loss 138.144.387 143.070.982 4,93 q22.3 - q24
03VSCC chr04 CN loss 0 191.154.276 191,15 p16.3 - q35.2
03VSCC chr05 CN gain 0 52.164.596 52,16 p15.33 - q11.2
03VSCC chr05 CN loss 52.164.596 53.945.232 1,78 q11.2
03VSCC chr05 CN loss 53.945.232 125.355.255 71,41 q11.2 - q23.3
03VSCC chr05 CN loss 125.355.255 174.789.062 49,43 q23.3 - q35.2
03VSCC chr06 CN loss 79.201.333 158.105.143 78,90 q14.1 - q25.3
03VSCC chr07 CN gain 22.017.831 55.402.403 33,38 p22.3 - p11.2
03VSCC chr07 CN loss 61.064.520 151.179.405 90,11 q11.21 - q36.3
03VSCC chr08 CN loss 0 43.749.726 43,75 p23.3 - p11.1
03VSCC chr08 CN gain 49.483.834 100.841.341 51,36 q11.21 - q22.2
03VSCC chr08 high CN gain 100.841.341 146.364.022 45,52 q22.2 - q24.3
03VSCC chr09 CN gain 0 7.916.102 7,92 p24.3 - p24.1
03VSCC chr09 CN loss 9.100.000 10.100.000 1,00 p23
03VSCC chr10 CN loss 0 42.365.680 42,37 p15.3 - q11.21
03VSCC chr10 CN loss 42.365.680 134.749.713 92,38 q11.21 - q26.3
03VSCC chr11 CN loss 0 63.588.519 p15.5 - q13.1
03VSCC chr11 high CN gain 101.221.509 102.634.411 1,41 q22.1 - q22.2
03VSCC chr11 CN loss 102.634.411 135.006.516 32,37 q22.3 - q25
03VSCC chr12 CN loss 127.688.426 133.219.920 5,53 q24.32 - q24.33
03VSCC chr14 CN gain 9.457.933 107.349.540 97,89 q11.2 - q32.33
03VSCC chr15 CN loss 20.083.895 102.531.392 82,45 q11.2 - q26.3
03VSCC chr16 CN loss 0 35.166.094 35,17 p13.3 - p11.2
03VSCC chr16 CN loss 78.702.625 90.354.753 11,65 q23.3 - q24.1
03VSCC chr17 CN loss 0 81.021.937 81,02 p13.3 - q25.3
03VSCC chr18 CN loss 18.535.950 78.077.248 59,54 q11.2 - q23
03VSCC chr19 CN loss 0 59.095.126 59,10 p13.3 - q13.43
03VSCC chr21 CN loss 14.350.083 48.129.895 33,78 q11.2 - q22.3
03VSCC chrX CN loss 2.699.968 58.545.809 55,85 p22.33 - p11.1
03VSCC chrX CN loss 61.830.816 92.615.392 30,78 q12 - q21.31
04VSCC chr03 CN loss 0 95.977.995 95,98 p26.3 - q11.2
04VSCC chr07 CN gain 0 57.877.934 57,88 p22.3 - p11.2
04VSCC chr08 CN loss 0 43.749.726 43,75 p23.2 - p11.1
04VSCC chr08 CN gain 46.950.145 146.364.022 99,41 q11.1 - q24.3
04VSCC chr09 CN loss 8.431.596 9.932.940 1,50 p24.1 - p23
04VSCC chr11 CN gain 57.135.371 135.006.516 77,87 q12.1 - q25
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Supplementary Table 2 Continued.
SampleID chr type (*) start end length 
(Mb)
cytoband
04VSCC chr11 CN gain 57.135.371 135.006.516 77,87 q12.1 - q25
04VSCC chr12 CN gain 0 34.778.715 34,78 p13.33 - p11.1
04VSCC chr18 CN loss 32.054.846 78.077.248 46,02 q12.1 - q23
04VSCC chrX CN loss 2.699.968 58.545.809 55,85 p22.33 - p11.1
05VSCC chr03 CN gain 93.595.962 198.022.430 104,43 q11.1 - q29
05VSCC chr06 CN loss 0 39.215.986 39,22 p25.3 - p21.2
05VSCC chr06 CN gain 39.215.986 58.742.393 19,53 p21.2 - p11.1
05VSCC chr07 CN gain 0 159.138.663 159,14 p22.3 - q36.3
05VSCC chr08 CN loss 0 43.749.726 43,75 p23.3 - p11.1
05VSCC chr08 CN gain 46.950.145 146.364.022 99,41 q11.1 - q24.3
05VSCC chr09 CN gain 0 141.213.431 141,21 p24.3 - q34.3
05VSCC chr12 CN gain 0 133.851.895 133,85 p13.33 - q24.33
05VSCC chr13 CN gain 72.971.234 115.169.878 42,20 q21.33 - q34
05VSCC chr14 CN gain 19.605.413 107.349.540 87,74 q11.2 - q32.33
05VSCC chr20 CN loss 0 26.224.651 26,22 p13 - p11.1
05VSCC chrX CN loss 2.699.968 58.545.809 55,85 p22.33 - p11.1
05VSCC chrX CN loss 61.830.816 155.270.560 93,44 q11.1 - q28
06VSCC chr08 CN loss 0 43.749.726 43,75 p23.2 - p11.21
(*) copy number types indicated in bold represent adjacent gains or losses with different intensities
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Supplementary Table 4  Regions of copy-neutral loss-of-heterozygosity (LOH).
SampleID chr type start end length 
(Mb)
cytoband
04VSCC chr03 LOH 95.977.995 191.154.276 95,18 q11.2 - q29
02VSCC chr05 LOH 0 174.789.062 174,79 p15.33 - q35.2
04VSCC chr06 LOH 0 42.131.807 42,13 p25.3 - p21.1
04VSCC chr09 LOH 0 33.234.269 33,23 p24.1 - p21.1
04VSCC chr09 LOH 80.384.220 141.213.431 60,83 q21.2 -  q34.3
01VSCC chr10 LOH 0 33.544.391 33,54 p15.3 - p11.22
03VSCC chr11 LOH 63.588.519 101.289.628 37,70 q13.1 - q22.2
02VSCC chr12 LOH 94.178.228 133.851.895 39,67 q22 - q24.33
05VSCC chr13 LOH 19.308.175 58.905.048 39,60 q12.11 - q21.1
01VSCC chr17 LOH 0 17.974.077 17,97 p13.3 - p11.2
03VSCC chr17 LOH 0 19.662.176 19,66 p13.3 - p11.2
05VSCC chr17 LOH 0 16.807.475 16,81 p13.3 - p11.2
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ABSTRACT
Aims  The depth of invasion is an important prognostic factor for patients with vulvar 
squamous cell carcinoma (SCC). The threshold of 1 mm distinguishes between FIGO 
stage IA and ≥ IB disease and guides the need for groin surgery. Therefore, high 
interobserver agreement is crucial. The conventional and the alternative method are 
described to measure the depth of invasion. The aims of this study were to assess 
interobserver agreement for classifying the depth of invasion using both methods and 
to identify pitfalls. 
Methods  Fifty slides of vulvar SCC with a depth of invasion approximately 1 mm were 
selected, digitally scanned and independently assessed by ten pathologists working 
in a referral or oncology center, and four pathologists in training. The depth of invasion 
was measured using both the conventional and alternative method in each slide and 
categorized into ≤ 1 and > 1 mm. The percentage of agreement and Light’s kappa for 
multi-rater agreement were calculated and 95% confidence intervals were calculated 
by bootstrapping (1000 runs). 
Results  The agreement using the conventional method was moderate (kappa = 0.57 
(95% confidence interval 0.45-0.68)). The percentage of agreement among the 
participating pathologists using the conventional method was 85.0 versus 89.4% 
using the alternative method. Six pitfalls were identified; disagreement concerning 
which invasive nest is deepest, recognition of invasive growth and where it starts, 
curved surface, carcinoma situated on the edge of the tissue block, ulceration and 
different measurement methods. 
Conclusions  Pathologists reached only moderate agreement in determining the depth
of invasion in vulvar SCC, without a notable difference between the two measurement 
methods.
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INTRODUCTION
It is generally accepted that tumor thickness and/or depth of invasion (DOI) is a reliable 
parameter for predicting the likelihood of regional lymph node involvement and 
survival in many malignancies, such as cervical, head and neck and colorectal cancers 
1-3. The DOI is also an important prognostic factor in patients with vulvar squamous 
cell carcinoma (SCC) and determines the need for groin surgery. Early stage vulvar SCC is 
treated by radical local excision of the tumor, with or without inguinofemoral lymph node 
staging, depending on the DOI 4. In patients with a microinvasive carcinoma (DOI ≤ 1 mm, 
FIGO stage IA), the risk of inguinofemoral lymph node metastases is negligible and 
lymph node staging can be safely omitted 5, 6. In patients with macroinvasive disease 
(DOI > 1 mm, FIGO stage ≥ IB) a sentinel node procedure and/or an inguinofemoral 
lymphadenectomy is indicated. Inguinofemoral lymphadenectomy is associated with 
significant morbidity. This morbidity encompasses short-term morbidity including 
wound infection, formation of lymphoceles and/or wound breakdown in up to 85% of 
the patients and long-term morbidity including lymphedema, cellulitis and erysipelas 
in up to 64% of the patients 7-9. Because of the far reaching consequences of inguino-
femoral lymphadenectomy, classification of the DOI with a threshold of 1 mm is crucial 
and a high interobserver agreement is important.
Wilkinson et al. have described a number of methods for measuring the DOI in vulvar 
SCC 10. The International Federation of Gynecology and Obstetrics (FIGO) recommend 
to ‘measure from the epithelial-stromal junction of the most superficial adjacent dermal 
papillae to the deepest point of invasion’, as shown in Figure 1, method A 11. In  many 
carcinomas such as cervical cancer, the depth of invasion is measured from the 
nearest dysplastic crypt or surface epithelium 1; because logically tumor cells will 
originate from the nearest rete ridges instead of the most superficial dysplastic 
epithelium. In vulvar cancer, this measurement method (measurement from the most 
adjacent dysplastic abnormal rete ridge to the deepest point of invasion) is analogous 
to the method used in cervical cancer (see Figure 1; method B). 
This alternative measurement method has been studied by Van den Einden et al. 12; 
they performed a retrospective study comparing the DOI measured by both the 
conventional and alternative method in a series of vulvar carcinoma, and concluded 
that this alternative method may provide a better reflection of the prognosis. With a 
cut-off of 1 mm for both methods, the alternative method resulted in downstaging of 
the FIGO stage in 9% of the patients (14 of 148). In 13 patients (19%) with FIGO stage IB 
disease, the carcinoma was downstaged to stage IA, in which no groin surgery is 
indicated. In none of patients was there evidence of lymph node metastasis. However, 
in one downstaged patient from FIGO stage IIIA isolated tumor cells were present in 
the lymph node removed by the sentinel node technique. 
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The question was raised of whether there is a difference in the interobserver agreement 
when pathologists use the method recommended by FIGO or an alternative method as 
described above. We aimed to assess the interobserver agreement between pathologists 
using two different measurement methods and to identify pitfalls in the assessment of 
the DOI.
METHODS 
Slides from biopsies and/or surgical resection specimens of patients treated for vulvar 
squamous cell carcinoma at the Radboud university medical center between 2000 
and 2017 were retrieved. An expert gynaecologic pathologist (JB) reviewed and 
selected slides for inclusion; both diagnostically challenging and straightforward 
slides were selected, representing daily practice. In all slides there was a DOI of 
approximately 1 mm: approximately half the slides showed a DOI ≤ 1.0 mm, and half 
Figure 1 Measurement methods for the depth of invasion in vulvar squamous  
cell carcinoma.
Method A: conventional method; measurement(s) from the epithelial-stromal junction of the most superficial 
adjacent dermal papillae to the deepest point of invasion
Method B: Alternative method; measurement from the most adjacent dysplastic abnormal rete ridge to the 
deepest point of invasion
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> 1.0 mm at the initial histopathological examination measured by the conventional 
method. The area of invasion was circled on the slide and all slides were anonymized. 
All slides were assessed independently by all participants; working in either a gynecologic 
oncology center or a referring hospital. The expert pathologist (JB) who selected the 
slides for inclusion did not participate in the study. For each individual slide, participants 
measured the DOI using both the conventional and the alternative methods using a 
digital ruler. The digital ruler measures the distance between two locations and a 
straight line was displayed. Each measurement was reported in mm, with an accuracy 
of one decimal point in an online questionnaire using Castor EDC 13. After assessing 
the slides, the participants recorded how certain they were about each measurement 
and noted any difficulties and/or comments. Furthermore, the participants were asked 
what method they used in daily practice and how many  years of experience they had.
We based our sample size on a previous study which evaluated the interobserver 
agreement when assessing the DOI of vulvar SCC 14. We estimated that the kappa for 
interobserver agreement for the DOI ≤ 1 mm versus > 1 mm using the conventional 
measuring method would be approximately 0.70 (standard deviation 0.10). With ten 
participating pathologists, a power of 80%, an alpha of 5%, a two-sided 95% confidence 
interval (CI) of maximal 0.10, 50 slides were required for pathological assessment 15. 
In addition, we included four pathology residents to assess all 50 slides in order to 
identify differences in the interobserver agreement between residents and pathologists. 
The slides were digitally scanned (Pannoramic P250 Flash II, 3D histech) and distributed
to the participants using tEPIS (Trait Enhanced Pathology Image Sharing-system), 
a digital pathology platform. The participants were not informed about the original 
diagnosis, did not receive any clinical information and were not aware of the 
measurements made by other participants. The participants received Figure 1 as 
instruction on how to perform both measurement methods. The conventional method 
was defined as; ‘measurement(s) from the epithelial-stromal junction of the most 
superficial adjacent dermal papillae to the deepest point of invasion’. The alternative 
method was defined as ‘measurement from the most adjacent dysplastic abnormal 
rete ridge to the deepest point of invasion’.
The annotations made on the slides by each participant were visible to the researcher 
and were reviewed by the expert gynecologic pathologist (JB); this gave the pathologist 
insight into where exactly the measurement had been made and allowed review of the 
discordant slides and to analysis of the reasons for discrepancies to identify pitfalls. 
Statistical analysis
For purposes of analysis, the DOI measurements were dichotomized into two categories, 
DOI ≤ 1.0 mm and > 1.0 mm, as this categorization is clinically relevant. The percentage 
of interobserver agreement was calculated separately for the conventional and the 
alternative methods for diagnostically challenging and straightforward slides, and for 
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pathologists working in an gynecologic oncology center or referring hospital. Light’s 
kappa for multi-rater agreement was calculated for the conventional method and 95% 
CIs were calculated by bootstrapping (1000 runs). Kappa values were interpreted as 
slight (<0.21), fair (0.21-0.40), moderate (0.41-0.60), substantial (0.61-0.80) or almost 
perfect (0.81-0.99) interobserver agreement 16. 
A slide was arbitrarily defined as discordant if there was agreement on the DOI, 
classified as microinvasive (DOI ≤1 mm, FIGO stage IA) or macroinvasive ((DOI > 1 mm, 
FIGO stage ≥ IB ) among fewer than seven of ten pathologists (≤ 60%), using either 
the conventional or the alternative method. The statistical software R was used for 
statistical analysis (version 3.3.2), with the ‘irr’ package. 
Ethics statement
Anonymised residual tissue was used, which was retrieved during regular treatment. 
According to Dutch law, no specific patient approval is necessary for the use of this 
material. This study was approved by the local ethical committee (number 2016-2728) 
and performed according to the Code for Proper Secondary Use of Human Tissue 
(Dutch Federation of Biomedical Scientific Societies (htpp://federa.org).
RESULTS
Of the 50 slides selected, 24 (48%) were diagnosed as microinvasive (DOI ≤ 1 mm, 
FIGO stage IA) and 26 (52%) macroinvasive (DOI >1 mm, FIGO stage ≥IB) at initial histo-
pathological examination. Ten pathologists assessed all 50 slides; there was a median 
of 10 years’ experience as a pathologist (range 0.5-35 years). Five pathologists worked 
in an gynecologic oncology center and five in a referring hospital all within Europe; 
eight in the Netherlands, one in Belgium and one in Spain. Additionally, four residents, 
all working in an oncology center in the Netherlands, assessed all study slides. 
According to the participating pathologists, microinvasive growth (DOI ≤ 1 mm, FIGO 
stage IA)  was present in 32-72% and macroinvasive growth (DOI > 1 mm, FIGO stage 
≥ IB) in 22-66% of the study slides using the conventional method, see Table 1.
The alternative method resulted in downgrading from macroinvasive growth (DOI 
> 1 mm or FIGO stage ≥ IB) into microinvasive growth (DOI ≤ 1 mm, FIGO stage IA) 
in 52-80% of the slides assessed as macroinvasive (DOI > 1 mm or FIGO stage ≥ IB) 
growth using the conventional method, see Table 1.
The agreement among pathologists in the assessment of the DOI was moderate 
(kappa 0.57 (95%CI 0.45-0.68)) using the conventional method. The percentage of 
agreement among the participating pathologists using the conventional method was 
85.0% versus 89.4% using the alternative method. As shown in Table 2, in diagnostically 
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challenging slides the agreement was higher using the alternative compared to the 
conventional method. 
Pathologists working in an oncology center reached higher agreement than those 
from the referring centers for both the conventional method (88.0% versus 83.2%, 
respectively) and the alternative method (91.6% versus 88.8%, respectively), see 
Table 2. Using the conventional method, full agreement by the pathologists was 
obtained in 34% (17 of 50) of the slides and five slides (five of 50, 10%) were considered 
as discordant; in one slide agreement was 40%, in two 50% and in two 60%. For 
measurements made by the alternative method full agreement by the pathologists 
was obtained in 54% (27 of 50) of the slides and four slides were considered as 
discordant; agreement was 50% in one and 60% in the others. One slide was included 
in both groups.
As shown in Table 2, agreement between residents was 93.5% using the conventional 
method and 89.5% using the alternative method. There was full agreement between 
all four residents in 84% (42 of 50) and 72% (36 of 50) of the slides, respectively. There 
were more discordant slides using the alternative method (10%) compared to the 
conventional method (6%).
Table 1 Measurements of pathologists using the conventional method in relation 
to the original diagnosis and the number of slides downgraded from macro-
invasive (DOI > 1 mm, FIGO stage ≥IB) to microinvasive (DOI ≤ 1 mm, FIGO 
stage IA) by using the alternative method to measure the depth of invasion
Pathologist Microinvasive 
N (%) 
Macroinvasive 
N(%)
Not assessed
N (%)
Downgraded
N (%) 
Original diagnosis 24 (48) 26 (52)
1 19 (38) 30 (60) 1 (2) 21/30 (70)
2 21 (42) 29 (58) 0 16/29 (55)
3 19 (38) 31(62) 0 20/31 (65)
4 26 (51) 23 (47) 1 (2) 12/23 (52)
5 20 (40) 30 (60) 0 24/30 (80)
6 17 (34) 33 (66) 0 19/33 (59)
7 36 (72) 11 (22) 3 (6) 6/11 (55)
8 20 (40) 30 (60) 0 23/30 (77)
9 16 (32) 32 (64) 2 (4) 22/32 (69)
10 25 (50) 24 (48) 1 (2) 13/24 (54)
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Of the ten participating pathologists, seven (70%) used the conventional method and 
two (20%) the alternative method to measure the DOI in daily practice. One (10%) 
pathologist used a combination of the two methods, using the alternative method in 
tumors with early stromal invasions or microinvasion.  
Three of the four (75%) residents used the conventional method in daily practice.
One (25%) used a combination of the conventional and alternative methods (the 
alternative method in certain cases with microinvasion). 
All pathologists scored ease of use on a scale from 1 to 5 (1= very difficult, 5= very 
easy). The ease of use for the conventional method was scored as a median 4 of 
5 points (range 1-5), and the alternative method as a median 4 of 5 points (range 1-4). 
Half the pathologists (five of 10) scored both methods equally, three pathologists 
gave the conventional method a higher score and two scored the alternative method 
more highly. 
Table 2 Agreement among pathologists (N=10) and pathologists in training (N=4) 
in assessing the depth of invasion
Subgroups Conventional method Alternative
method
Pathologists
Overall agreement 85.0% 89.4%
Slides
Straightforward  (N=30)
Diagnostically challenging (N=20)
86.3%
83.0%
91.3%
86.5%
Type of center
Oncology (N=5)
Referring (N=5)
88.0%
83.2%
91.6%
88.8%
Slides with full agreement 34.0% 54.0%
Discordant slides (agreement ≤60%) 10.0% 8.0%
Residents
Overall 93.5% 89.5%
Slides
Straightforward  (N=30)
Diagnostic challenging (N=20)
95.8%
90.0%
90.8%
87.5%
Slides with full agreement 84.0% 72.0%
Discordant slides (agreement ≤60%) 6.0% 10.0%
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All pathologists scored how sure they were about their measurement on a scale from 
1 to 5 (1 = not sure at all, 5 = very sure). Eight pathologists were equally sure about 
their measurement using both methods, one pathologist was more sure about the 
measurements using the conventional method and one using the alternative method. 
Overall score was median 3 of 5 points for the conventional method versus median 3 
for the alternative method. 
Discordant slides were reviewed by the expert gynecologic pathologist (JB) to  analyze 
the reasons for discrepancies. This resulted in the identifi cation of six pitfalls in the 
assessment of the DOI: (1) disagreement on which invasive nest is deepest (Figure 2A-C), 
(2) the recognition of whether or not there is in fact invasive growth and where it starts 
Figure 2  Depth of invasion measured by diff erent pathologists in discordant slides. 
Footnote: The yellow and green lines are a measurement of at least one pathologist; macroinvasive (DOI 
>1 mm, FIGO stage ≥ IB) measurements are displayed in yellow, microinvasive (DOI ≤1 mm, FIGO stage IA) 
measurements are displayed in green. In red, the recommended measurement is displayed.
 In A, B, C, G and H, the conventional method was used and in D, E, F and I the alternative method was used 
to measure the depth of invasion. In Figure J, both the conventional and alternative method are displayed.
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(Figure 2B-F), (3) a curved surface (Figure 2G), (4) a carcinoma situated on the edge 
of the tissue block (Figure 2H), (5) ulceration (Figure 2I) and (6) diff erent methods are 
used to measure the DOI (Figure 2J). Subsequently, the recommended measurements 
by the expert gynecologic pathologist are displayed in red in Figure 2. 
Figure 2 Continued.
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Discussion
A threshold of 1 mm in the DOI distinguishes between micro- and macroinvasive 
growth (FIGO stages IA and ≥ IB) and guides the need for groin surgery. Reproducibility of 
this measurement is important and clinically relevant. However, among pathologists 
there is only moderate agreement (kappa 0.57 (95% CI 0.45-0.68)) in the assessment 
of the DOI using the conventional method as recommended by the FIGO.  
The results of our study showing moderate (kappa 0.51) interobserver agreement 
between 11 pathologists for classifying the DOI are in line with another study 14. 
This study encouraged the participants to use the conventional method to measure 
the DOI, but only one of 11 participants was able to use this method in all 45 cases.
This underlines the difficulty of measuring the DOI in vulvar SCC and the variation in 
methods of measurement used by pathologists. Our study confirms the result that 
measuring invasion depth is indeed difficult in vulvar SCC. Additionally, we offer a 
unique insight into the difficulties of measuring the depth of invasion by the use of 
digital pathology. In-depth analyses of all discrepant slides identified six pitfalls. 
Based on the depicted pitfalls, we formulated recommendations for assessing the DOI 
in vulvar SCC, as displayed in Table 3. Besides these recommendations, further 
improvement can be achieved by education, for which the discordant slides and the 
formulated pitfalls and recommendations of our study are an excellent base.
We showed that pathologists reach similar agreement for the classification of the 
DOI into a micro- or macroinvasive carcinoma (FIGO stages IA and ≥ IB) using the 
conventional and alternative methods. In contrast, pathologists in training reached 
higher agreement using the conventional method. This might be explained by recent 
training concerning the conventional method and therefore more homogeneity. 
The strengths of our study are the international participation in the study, the 
participation of pathologists working in both referring and oncology centers and the 
inclusion of slides representing daily clinical practice, i.e. both straightforward and 
diagnostically challenging slides. In addition, for several reasons, a unique strength is 
the use of digital pathology for several reasons. First, digital pathology uses a digital 
ruler and makes it easier for the pathologist to perform the measurements. Secondly, 
digital pathology makes it easy to share pictures of the slides between different 
pathologists for revision and more importantly the point of deepest invasion and the 
measurement made by the pathologist are visible for other consulted pathologists in 
case of doubt. Thirdly, digital images enabled the researchers to perform in depth 
analyses of the measurements made and allowed analyses of discrepant slides and 
identification of pitfalls.
A possible limitation of our study is the statistical method used. We dichotomized the 
measurement of the individual pathologists into ≤ 1 and > 1 mm, as these outcomes are 
clinically relevant. This may have introduced imprecision, as in some slides the DOI 
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was very close to 1 mm. We were not able to compare the kappa for both methods, 
because the kappa is dependent on the distribution of the micro- and macroinvasive 
slides between the groups (DOI ≤1 mm and >1 mm, FIGO stage IA and ≥IB). This 
distribution was different for both methods, as the alternative method is more likely to 
result in more carcinomas being classified as microinvasive (DOI ≤1 mm, FIGO stage IA) 
compared to the conventional method. Another limitation is the selection of slides 
with a DOI of approximately 1 mm instead of consecutive series. This might have 
resulted in an underestimation of the interobserver agreement and an overestimation 
of the percentage of slides downgraded from stage ≥ IB measured by the conservative 
method to FIGO stage IA measured by the alternative method. 
In conclusion, this study showed only moderate agreement between pathologists 
classifying the DOI into micro- and macroinvasive vulvar SCC (FIGO stages IA and ≥ IB) 
Table 3 Recommendations based on the pitfalls in the assessment of the depth  
of invasion in vulvar squamous cell carcinoma.
Pitfalls Recommendations Examples,  
see Figure 2
1. Recognition which invasive nest 
is deepest
• In tumors ≤1 cm; totally embed the 
carcinoma
• If still uncertain, cut at least two 
deeper levels on the block 
A-C
2. Recognition whether or not  
there is in fact invasive growth 
and where it starts
• See recommendations of pitfall 1. 
• Tumors >1 cm; enclose one tissue 
block for every 0.5 cm of the 
carcinoma
B- F
3. Curved surface with two or more 
possible locations of the surface
• Measure from the surface resulting 
in the least favorable depth of 
invasion
G
4. Carcinoma situated on the edge 
of the tissue block
• Locate the carcinoma in the middle 
of the block if possible
H
5. Ulceration • Sample the carcinoma without 
ulceration. If not possible, measure 
from the floor of the tumor ulcer 
I
6. Different measurement methods 
are used
• Use the conventional method. 
Do not routinely use the alternative 
method until validated. But if used, 
state the method of measurement 
used in the pathology report
J
In case of doubt if micro- or macroinvasive growth (FIGO stage IA or ≥IB) is present in  
the carcinoma after following the above recommendations, we advise consultation with an 
expert gynecopathologist.
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using the conventional measurement method recommended by the FIGO, and similar 
agreement using the alternative method. This study showed that the alternative 
method is suitable for pathologists to measure and classify the DOI in vulvar SCC. 
However, before implementing this method in daily clinical practice, future research 
should be performed to determine if the alternative method leads to a better reflection 
of the prognosis, and of whether a new threshold needs to be defined to reflect 
biological tumor behavior. 
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ABSTRACT
Background  In patients treated for early-stage vulvar squamous cell carcinoma local 
recurrence is reported in up to 40% after ten years. Knowledge on prognostic factors 
related to local recurrences should be helpful to select high risk patients and/or to 
develop strategies to prevent local recurrences.  
Objective  This systematic review aims to evaluate the current knowledge on the 
incidence of local recurrences in vulvar carcinoma related to clinicopathologic and cell 
biologic variables.
Data sources  Relevant studies were identified by an extensive online electronic 
search in July 2017.  
Study eligibility criteria  Studies reporting prognostic factors specific for local recurrences 
of vulvar carcinoma were included.  
Study appraisal and synthesis methods  Two review authors independently performed 
data selection, extraction and assessment of study quality. The risk difference was 
calculated for each prognostic factor when described in two or more studies.
Results  Twenty-two studies were included; most of all were retrospective and mainly 
reported pathologic prognostic factors. Our review indicates an estimated annual 
local recurrence rate of 4% without plateauing. The prognostic relevance for local 
recurrence of vulvar carcinoma of all analyzed variables remains equivocal, including 
pathologic tumor free margin distance < 8 mm, presence of lichen sclerosus, groin 
lymph node metastases and a variety of primary tumor characteristics (grade of differ-
entiation, tumor size, tumor focality, depth of invasion, lymphovascular space invasion, 
tumor localization and presence of human papillomavirus).
Conclusions Current quality of data on prognostic factors for local recurrences in 
vulvar carcinoma patients does not allow evidence-based clinical decision making. 
Further research on prognostic factors, applying state of the art methodology is 
needed to identify high-risk patients and to develop alternative primary and secondary 
prevention strategies.
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INTRODUCTION
Vulvar cancer accounts for 5% of all gynecologic cancers with an incidence of 2.5 per 
100,000 women 1. It mostly affects elderly women, with more than half of the patients 
above the age of 70 years at time of diagnosis. The most common histological type of 
vulvar cancer is squamous cell carcinoma 2. There are two different preneoplastic 
lesions known for vulvar carcinoma; differentiated vulvar intraepithelial neoplasia 
(dVIN) and high-grade squamous intraepithelial lesion (HSIL) 3. The dVIN pathway is 
associated with lichen sclerosus, the second pathway is related to HSIL which is 
caused by infection with human papillomavirus (HPV) and associated with immuno-
suppressive state and smoking 4. Over the past few decades, the incidence of vulvar 
carcinoma has increased slowly, but steadily 1. 
Standard treatment for early-stage vulvar carcinoma entails wide local excision of the 
primary tumor and, if the tumor is macroinvasive (depth of invasion > 1mm), either a 
sentinel node (SLN) procedure or an elective inguinofemoral lymphadenectomy, 
depending on tumor size, focality or the presence of suspected metastatic groin lymph 
nodes 5. Despite radical treatment, local recurrences on the vulva are reported in up to 
40% of the patients 6. Of these patients 43-72% will develop a second local recurrence 
and subsequently 57% will have a third or even more local recurrences. It has been 
shown that disease-specific survival decreases from 90% to 69% in patients after a 
local recurrence, as was observed both in SLN-positive as well as in SLN-negative 
patients 6. 
In patients with a local recurrence, first choice of treatment is wide local excision of the 
tumor. An inguinofemoral lymphadenectomy is indicated if a macro-invasive recurrent 
tumor is present and no inguinofemoral lymphadenectomy was performed previously. 
As a consequence, patients who previously had a negative SLN will now suffer from 
significant short and long term morbidity associated with inguinofemoral lymph-
adenectomy 5. For these reasons, knowledge on prognostic factors related to local 
recurrences is of utmost importance. Both clinicopathologic as well as cell biologic 
markers may be of prognostic value for local recurrences of vulvar carcinoma 7, 8.
One of the most debated prognostic factors is the minimal pathologic tumor free 
margin distance. Worldwide a pathologic tumor free margin of ≥ 8 mm has been 
advocated as safe 9, 10. However, the question whether a margin distance < 8mm does 
really increase the number of patients suffering from a local recurrence has not been 
answered unequivocally yet. Furthermore, it is unclear why some patients with lichen 
sclerosus and dVIN develop a primary vulvar squamous cell carcinoma and/or multiple 
local recurrences, whereas other patients do not. 
The aim of this systematic review was to summarize the current knowledge on the 
incidence of local recurrences in patients diagnosed with vulvar squamous cell 
carcinoma related to clinicopathologic and cell biologic variables. 
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METHODS
Information sources and search strategy 
This review was conducted according to the Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA) guidelines, and in accordance with the principles 
outlined in the Cochrane Handbook for Systematic Reviews of Interventions 11, 12. 
Relevant studies were identified by an online electronic search on July 25, 2017 using 
PubMed, EMBASE, Web of Science and the Cochrane library. The search strategies 
were developed by two authors (AWP and NCG) in consultation with a librarian using 
medical subject heading (MeSH) and text words related to vulvar cancer, local 
recurrence and prognostic factors, see Supplementary 1. 
To ensure completeness of included references, we scanned the reference lists of the 
included studies or relevant reviews identified through the search. See Figure 1 for the 
PRISMA flow diagram.
Eligibility criteria and data extraction
Eligible study designs for inclusion were; randomized controlled trials, controlled clinical 
trials, case-control studies, cross-sectional studies and cohort studies. The eligibility 
criteria were: studies evaluating (1) the association between clinicopathologic and cell 
biologic variables and local recurrence of vulvar squamous cell carcinoma (2) including 
patients above the age of 18 years and (3) written in English. Two review authors (AWP 
and NCG) independently screened the titles and abstracts retrieved by the search.
Two review authors (AWP and NCG) independently decided whether these articles met 
our inclusion criteria. Data were extracted independently in duplicate by two review 
authors (AWP and NCG) from eligible studies using a data extraction form designed and 
pilot tested. Any disagreements were resolved with a third review author (MHO or JAH). 
Assessment of quality of included studies
The Newcastle-Ottawa quality assessment Scale for cohort studies was used to 
assess the quality of each included study independently by two review authors. This is 
a validated tool in assessing the quality of non-randomized studies 13. This scale 
measures aspects of methodology in cohort studies and consists of eight questions 
concerning three areas (1) the selection of the study groups (four stars), (2) the 
comparability of cohorts (two stars), and (3) the outcome of study and adequacy of 
follow-up (three stars). Each study can be rewarded with a maximum of nine stars.
Dealing with missing data 
When there were missing data, we contacted the original authors of the studies to 
obtain the relevant missing data.
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Data analyses 
Local recurrence was defined as any newly diagnosed invasive squamous cell carcinoma 
located on the vulva. In patients with simultaneous local and groin and/or distant 
recurrences, these local recurrences were also included. To estimate the incidence of 
local recurrences over time, the local recurrence rate for each individual study was 
displayed in a graph in relation to the length of follow-up. Subanalyses, including for 
studies counting > 100 patients were performed. To evaluate whether a prognostic factor 
was associated with an increased incidence of local recurrence, risk differences (RDs) 
with 95% confidence intervals (95% CIs) were estimated for each individual study and 
each risk factor. 
Due to the differences in study design (e.g. study population, treatment regimens 
(including adjuvant (radio)therapy), FIGO stage) of the included studies, homogeneity 
could not be assumed and therefore no meta-analyses were performed. All authors of 
studies that did not report sufficient data to calculate RDs were contacted to obtain the 
relevant missing data to calculate the RDs, as described above. If these data were not 
provided, the hazard ratios (HRs) of the original report were presented separately. 
Statistical analysis was performed using Review Manager version 5.3 (Copenhagen: 
The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) and IBM SPSS Statistics
for Windows, version 23 (IBM Corp., Armonk, N.Y., USA).  
RESULTS
Study selection
The primary search on July 25, 2017 identified 2259 publications by electronic database 
searching, while another 17 publications were identified by hand searching. Twenty- three 
studies met our inclusion criteria; one study was excluded because the authors excluded 
patients with a positive margin from analysis and did not report sufficient data on other 
prognostic factors for local recurrence 14. See Figure 1 for the PRISMA flow diagram. 
Characteristics of included studies
Data from 3657 patients from 22 studies were included in this review. See Table 1 
‘Characteristics of included studies’.  
Quality assessment
Using the Newcastle-Ottawa score, the included studies scored between three and 
eight stars with a median of 6 stars (range 3-8). See Table 1 ‘Characteristics of included 
studies’ for awarded stars for each individual study. Overall, the lowest number of 
stars was rewarded for comparability, due to a lack of a control group for the studied 
prognostic factors in the included studies.  
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Figure 1  PRISMA flow diagram.
2259 records 
identified through 
database searching
17 records 
identified through 
other sources
1263 records after 
duplicates removed
1263 titles screened
786 titles clearly 
irrelevant
477 abstracts 
screened
369 abstracts 
excluded
108 full text articles 
assessed for 
eligibility
85 full text articles 
excluded
22 records included
1 excluded with 
reason
23 met inclusion 
criteria
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Local recurrence rate 
The local recurrence rate by the median follow-up time is displayed for all studies that 
included > 100 patients, see Figure 2. The estimated median local recurrence rate per 
year was 4%. The longer the duration of the follow-up, the more patients developed a 
local recurrence of vulvar carcinoma. See Supplementary 2 for the local recurrence 
rates by the duration of follow-up of all included studies.
Prognostic factors for local recurrence
Age
Age ≥75 years as a possible prognostic factor was reported by three studies 15-17. 
Two studies reported that increasing age was related with an increased risk for local 
recurrence (age ≥75 as compared to age <75: HR 1.93 (95% CI 0.92-4.07) 16 and a 2% 
increase in the incidence of local recurrence for each additional year of age 15.  Another 
study reported that increasing age was related with a decreased risk for local 
recurrence (age ≥ 75 as compared to age <75; HR 0.35 (95% CI 0.17-0.73) 17. 
Pathologic tumor free margin status
Eleven studies reported local recurrences in relation to pathologic tumor free margin 
distance 8, 9, 17-25, see Figure 3A. All studies except for one used a cut-off value of 8 mm.
Six studies reported a decreased risk for local recurrence in patients with a pathologic 
tumor free margin ≥8mm versus patients with a margin <8mm 9, 17, 20-23. Five studies 
showed no difference in the frequency of local recurrences between the two margin 
groups 8, 18, 19, 24, 25. Of these five studies, only two reported whether the analyzed 
margin distance was after re-excision or not .
Four studies reported HRs for local recurrence by margin distance, but none of them 
showed a relation between margin and frequency of local recurrence 15, 17, 20, 24.
Type of surgery
Eight studies reported no effect when comparing radical vulvectomy versus wide local 
excision as a possible prognostic factor 9, 17, 19, 20, 26-29. See Figure 4A. 
Vulvar lichen sclerosus
The association of lichen sclerosus and local recurrence was analyzed in five studies 
16, 17, 19, 20, 22. Two studies reported more local recurrences in patients with lichen 
sclerosus, while no difference in number of patients with local recurrence was reported 
in four studies 16, 19, 20, 22, see Figure 4B. It was often not reported by the studies how 
the presence of lichen sclerosus was objected (retracted from patient files or by 
reviewing pathology slides). One study with reviewed pathology slides reported 
significantly more local recurrences in patients with lichen sclerosus 17. 
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Regarding studies reporting HRs; in one study the risk for local recurrence in patients 
was increased in patients with vulvar lichen sclerosus (univariate HR 3.39 (95% CI 
1.80-6.38))15, while three more studies reported no eff ect 16, 17, 20. 
Groin lymph node metastases
Nine studies reported on the prognostic relevance of the presence of groin lymph 
node metastases (including a positive SLN) and/or number of groin lymph node 
metastases at primary treatment on local recurrence 6, 15-17, 19, 20, 22, 24, 30. One study 
reported more local recurrences in patients with groin lymph node metastasis 22, six 
studies showed no eff ect of the presence of groin lymph node metastasis 6, 16, 17, 19, 20, 30, 
see Figure 3B. 
Univariate analysis was performed in seven studies; three studies reported a signifi cant 
eff ect whereas Nooij et al. and Te Grootenhuis et al. found more local recurrences in 
patients with positive lymph nodes (HR 2.73 (95% CI 1.15-6.51)) respectively (local 
recurrence rate SLN-negative patients 36.4% versus 46.4% for SLN-positive at 10-years 
(p = 0.03)) 6, 24. Contradictory results were found by Sznurkowski et al., who observed
more local recurrences in patients with negative lymph nodes (HR 0.23 (95% CI 
0.11-0.52)) 17.
The prognostic relevance of the number of lymph node metastases for local recurrence 
was reported in two studies 22, 30. Fonseca et al. showed a signifi cant decreased risk 
Figure 2  Local recurrence rate by duration of follow-up time 
Footnote: displayed for studies including >100 patients. Woelber et al. 201625 was not included in this analysis 
because this study only included lymph node negative patients. Maggino et al. 200028 did not report a 
(median) follow-up time and could therefore not be included in this analysis.
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Figure 3  Risk difference for local recurrence by different pathological factors
A) Risk difference for local recurrence by margin distance, B) Risk difference for local recurrence by presence 
of lymph node metastases, C) Risk difference for local recurrence by the number of lymph node metastases, 
D) Risk difference for local recurrence by grade of differentiation, E) Risk difference for local recurrence by 
depth of invasion, F) Risk difference for local recurrence by presence of lymphovascular space involement
Footnote: mm: millimeters, LR: local recurrence, LN: lymph nodes, SLN: sentinel lymph node, LNM: lymph 
node metastases, LVSI: lymphovascular space involvement
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for local recurrence in patients with none or one lymph node metastasis versus patients 
with two or more lymph node metastases (RD -0.52 (95% CI -0.85, -0.18)), see figure 3C. 
Grade of differentiation
The prognostic value of tumor grade for local recurrence is displayed in Figure 3D. 
None of the studies showed evidence for a relation between grade and number of 
local recurrences.  
Tumor size
Four studies reported the risk for local recurrence by tumor size and divided tumor size 
into two groups; tumor measuring ≤4 cm or > 4 cm (not specified whether the clinical 
or pathological tumor size was used). None of these four studies reported an effect of 
tumor size on the risk for a local recurrence, as shown in Figure 4C 17, 19, 20, 30.  
Two studies reported that increasing tumor size (as a continuous variable) did not 
increase the risk for local recurrence (HR 1.08 95% CI 0.89, 1.30 19, HR 0.91 (95% CI 
0.65, 1.28) 17 . 
Tumor focality
The risk for local recurrence as reflected by the RD showed no evidence of effect, see 
Figure 4D. One study showed a higher risk for local recurrence in patients with 
multifocal disease in the multivariate analysis using patients with unifocal disease as 
a reference (HR 2.98 (95% CI 1.08, 7.26) 17. 
Depth of invasion
Two studies reported the risk for local recurrence by the depth of invasion of the tumor 
17, 20. One study showed more local recurrences in patients with a tumor with a depth 
of invasion >2 mm, see Figure 3E 20. Another study reported the prognostic influence 
of depth of invasion on local recurrence as a continuous variable, but did not report a 
relation with the risk for local recurrence 16.
Lymphovascular space involvement 
The prognostic value of the presence of lymphovascular space involvement (LVSI) in 
the primary tumor for local recurrence was reported in four studies. One study reported 
an increased risk for local recurrence if LVSI was present 23. The other two studies 
reported no evidence of RD, see Figure 3F 16, 19. Yap et al. reported less local recurrences 
when LVSI was present, reducing the incidence of local recurrence by 74% (univariate 
HR 0.28 (95% CI 0.11-0.74), using the absence of LVSI as a reference (HR1.0) 15.
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Tumor localization
Bogani et al. and Woolderink et al. compared the risk for local recurrence in patients 
with a lateralized tumor versus a centralized tumor; both studies did not find any 
effect, see Figure 4E 16, 20. 
Figure 4  Risk difference of local recurrence by different clinical factors 
A) Risk difference for local recurrence by type of surgery, B) Risk difference for local recurrence by presence 
of lichen sclerosus, C) Risk difference for local recurrence by tumor size, D) Risk difference for local 
recurrence by tumor focality, E) Risk difference for local recurrence by tumor localization
Footnote: LR: local recurrence, WLE: wide local excision, LS: lichen sclerosus, cm: centimetres
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HPV status
Two studies described univariate HRs for local recurrences in relation to the presence 
of HPV. Yap et al. reported more local recurrences in HPV negative patients (HR 2.38 
(95% CI 1.15-4.93)) 15, while Nooij et al. reported less local recurrences in HPV positive 
patients (HR 0.24 (95% CI 0.03-1.80)) 24. In conclusion, both studies reported less 
local recurrences in HPV positive patients. 
Remaining factors
The following prognostic factors were reported by only one study and no evidence of 
effect was reported; comorbidity, perineural invasion, mucosal involvement, 
koilocytosis, laterality of lymph nodes, SLN biopsy performed, number of lymph nodes 
yielded, inguinofemoral lymphadenectomy performed, VIN or VIN3 in margin or around 
tumor, adjuvant radiotherapy given 16, 18-20, 22, 28, 30, 31. 
Leonard et al. investigated if DNA methyltransferases (DNMT) expression in the 
invasive component of the tumor was related to the risk of local recurrence of the 
vulvar carcinoma. Over-expression of both DNMT3A and DNMT3B was associated with 
an increased risk of vulvar local recurrence (univariate HR 4.51 (95% CI 1.40, 14.49), HR 
5.69 (95% CI 1.17, 27.57) respectively) 32. Furthermore, Qvick et al. reported on the 
prognostic value of p53 codon 72 polymorphism 33. A similar local recurrence rate in 
tumors with arg/arg genotype and in tumors with arg/pro or pro/pro genotype was 
observed. 
DISCUSSION
Summary of main results
Our review shows that for all variables analyzed the prognostic relevance for local 
recurrence of vulvar carcinoma remains questionable, including pathologic tumor free 
margin distance, presence of vulvar lichen sclerosus, groin lymph node metastases 
and a variety of primary tumor characteristics. 
Despite the fact that the majority of included studies showed a higher risk for local 
recurrence in patients with a pathologic tumor free margin distance < 8 mm, it remains 
unclear if the risk for a local recurrence is also higher when a lower cut-off value is 
applied. Only two studies investigated the risk for local recurrence for different cut-off 
values and these studies did not show a difference in risk for local recurrence 24, 25. 
Currently, different guidelines on vulvar carcinoma are available, all containing largely 
consensus based recommendations 10, 34, 35. In these guidelines, the recommended 
minimal pathologic tumor free margin in relation to whether further treatment is 
needed differs between zero mm and < 10 mm, see Table S3. In addition, also in the 
treatment of cutaneous and head and neck squamous cell carcinoma, different tumor 
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free margins are recommended compared to vulvar carcinoma. In head and neck 
squamous cell carcinoma patients, the pathologic free tumor margins have also been 
at debate for decades. As in vulvar carcinoma, excision is often difficult and limited 
because of the anatomic site of the tumor. The National Comprehensive Cancer 
Network (NCCN) guidelines for head and neck carcinoma defines a clear margin as ≥5 
mm 36. In the treatment of cutaneous squamous cell carcinoma, different surgical 
margins are recommended for low-risk and high-risk lesions. For low-risk lesions, the 
recommended surgical margin varies between 4-6 mm and for high-risk lesions from 
6 to 10 mm 37. Even though certain risk factors for local recurrence are described in 
literature, consensus on the specific tumor characteristics defining these low and 
high-risk lesion has not yet been made, resulting in different definitions in different 
guidelines 37. The NCCN guideline defines high-risk lesions as those >10mm occurring 
in high-risk areas (genitalia, mucosal surfaces, face, and/or neck) or those >20mm in 
other areas and in case of poorly-defined borders, perineural or vascular invasion, 
depth of invasion ≥2mm, rapidly growing, moderate or poorly differentiated, site of 
prior radiotherapy, neurologic symptoms, recurrent lesions or in immunosuppressed 
patients 38.  
From our review it can be concluded that currently available data does not allow real 
evidence-based medicine. Based on our current review there seems to be no lower 
limit (apart from involved margins) below which further treatment (either re-excision 
or adjuvant radiotherapy) to the vulva should be recommended. Considering the 
impressive morbidity associated with adjuvant radiotherapy to the vulva, the equivocal 
prognostic impact of margins on local recurrence rate and in general the principle 
‘primum non nocere’ doctors should be reluctant before deciding to expose their 
patients to these potentially harmful adjuvant therapies. 
Adjuvant therapy, including re-excision and/or radiotherapy for a close or positive 
margin, is a major confounder when it comes to evaluating margin status and local 
recurrence risk. Unfortunately, only two included studies reported whether the margin 
distances after the primary excision or after re-excision were used for the analysis 24, 
25. Inevitably this may have introduced bias in most of the original studies, as adjuvant 
therapy (i.e. re-excision or radiotherapy) most probably will influence the risk for local 
recurrence. 
Regarding adjuvant radiotherapy; most included studies reported the indications and/
or number of patients with adjuvant radiotherapy. However, none of them analyzed the 
subgroup of patients with a close or positive margin with and without adjuvant therapy 
separately. Adjuvant radiotherapy  may result in a lower recurrence risk in the group of 
patients with a margin <8 mm. In conclusion, not reporting outcome for separate 
subgroups of patients with or without adjuvant therapy for a close or positive margin, 
introduced a significant bias and illustrates the lack of uniform reporting on tumor free 
margin and/or adjuvant therapy as prognostic factors for local recurrence.
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Further research is needed in vulvar carcinoma patients to determine the optimal 
cut-off value for the tumor free margin status and risk for local recurrences. A suitable 
study design may be a prospective cohort study with sufficient long follow-up, in which 
pathologic margin distance is measured in a standardized way, adjuvant treatment is 
given according to protocol and finally in which the margin distance as a prognostic 
factor is reported in HR or a Kaplan-Meier. Following the Reporting Recommendations 
for Tumor Marker Prognostic Studies (REMARK) most certainly will help to improve the 
quality of future studies 39. 
Our review indicates an estimated local recurrence rate per year of 4% with no 
plateauing and therefore a higher local recurrence rate with longer follow-up, see 
Figure 2. Most included studies reported crude local recurrence rates. By using this 
method, the local recurrence rate is prone to bias by the fact that at time of diagnosis 
half of the patients is aged over 60 years and therefore more likely to die during 
follow-up. Reporting crude recurrence rates will lead to underestimation of the real 
local recurrence rate. As Figure 2 shows, the longer the follow-up, the higher the 
incidence rate for local recurrences. Thus, studies with a short follow-up time are more 
likely to underreport the local recurrence rate. Our review shows that even many years 
after primary treatment, recurrences still occur, which is important to realize in light of 
follow-up schedules and patient counseling. 
Current literature on vulvar cancer artificially discriminates between two kinds of local 
recurrences; a so-called ‘true’ local recurrence arising from residual cancer cells after 
an irradically treated primary tumor and a ‘de novo’ recurrent tumor arising from a 
premalignant lesion. 
First, based on the localization of the recurrence; a ‘de novo’ tumor has been defined 
as >2 cm away versus a true local recurrence as ≤2 cm from the primary tumor 15, 18. 
Second, based on the time to recurrence; a ‘true’ local recurrence has been defined as 
≤2 years and a ‘de novo’ tumor  >2 years after primary treatment 6, 24. As shown 
previously, local recurrences occurring >2 years after primary treatment tend to have a 
better disease-specific survival (p=0.05) 6. To really distinguish a ‘true’ local recurrence 
from a ‘de novo’ recurrence genetic relationship and molecular profiling analysis 
should be performed. The current division based on e.g. distance of recurrence to 
primary tumor site or time to recurrence is too arbitrary, not reproducible and should 
be abandoned. 
In light of the possible prognostic impact of a premalignant lesion adjacent to the 
malignant lesion, it also seems unjustified to divide ‘de novo’ and true local recurrences 
based on their location.  
Unfortunately, only little research is performed on this subject. Adjacent Vulvar Intra-
epithelial Neoplasia (VIN) has been investigated in few studies, different classification 
systems for VIN (dVIN, VIN I-III) have been used and therefore results cannot be 
compared. Six studies investigated local recurrence rates for patients with and without 
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vulvar lichen sclerosus and found conflicting results 15-17, 19, 20, 22. Only two studies, 
observed more local recurrences in patients when lichen sclerosus was present 15, 17. 
More extensive removal of (adjacent) premalignant lesions may also explain a lower 
risk for local recurrence in patients treated by radical vulvectomy, see Figure 4A. 
Six out of seven studies reported groin lymph node metastasis as a prognostic factor 
for local recurrent disease (Figure 3B). In contrast to these studies; Gadduci et al. were 
the only to find more local recurrences in patients with negative lymph nodes. However, 
they reported a very low two year overall survival rate (38%) for the patients with 
positive lymph nodes, which may have caused the lower local recurrence rate in these 
patients, as their follow-up time was shorter 30.  
Strengths
Our study is the first systematic review on prognostic factors for local recurrences in 
vulvar squamous cell carcinoma, summarizing all currently available evidence on 
prognostic factors for local recurrence of vulvar carcinoma and applying the PRISMA 
guidelines. Furthermore, quality scores (Newcastle-Ottawa) were calculated for each 
included study, thereby minimizing the risk of bias. By calculating a RD and displaying 
these data in forest plots, the outcomes of this review are clarified and more easy to 
interpret. 
Limitations 
Because of the low incidence of vulvar carcinoma the included studies were very 
heterogeneous and therefore meta-analysis could not be performed. 
Conclusions 
Current evidence on prognostic factors for local recurrence of vulvar cancer is not 
sufficiently robust to allow evidence-based medicine. More research of higher quality 
is needed to identify clinicopathologic and cell biologic factors prognostic for local 
recurrence of vulvar carcinoma. More accurate identification of patients at high risk for 
local recurrence should lead to more individualized treatment and/or follow-up 
protocols in these patients.
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SUPPLEMENTARY DATA
Supplementary 1 Search strategies.
1a. Pubmed search
(Vulvar neoplasms[mesh] OR (Vulva*[tiab] AND (neoplasm*[tiab] OR cancer*[tiab] OR 
tumor*[tiab] OR tumour*[tiab] OR carcinoma*[tiab])))) 
AND
((“Neoplasm Recurrence, Local”[Mesh] OR Recurr*[tiab] OR relaps*[tiab] OR reoccur*[tiab]))) 
AND 
((“Prognosis”[Mesh:noexp] OR “Disease-Free Survival”[Mesh] OR “Risk Factors”[Mesh] OR Time 
Factors[Mesh] OR Epidemiology[subheading] OR Survival Rate[MeSH] OR Prognos*[tiab] OR 
predict*[tiab] OR risk factor*[tiab]))
1b. EMBASE search
(Exp vulva cancer/ OR exp vulva carcinoma/ OR exp vulva tumor/ OR ((Vulva*.ti,ab,kw.) AND 
(neoplasm*.ti,ab,kw. OR cancer*.ti,ab,kw. OR tumor*.ti,ab,kw. OR tumour*.ti,ab,kw. OR 
carcinoma*.ti,ab,kw.))) 
AND
Exp tumor recurrence/ OR exp cancer recurrence/ OR Recurr*.ti,ab,kw. OR relaps*.ti,ab,kw. OR 
reoccur*.ti,ab,kw. OR recidiv*.ti,ab,kw. 
AND 
Exp prognosis/ OR exp cancer prognosis/ OR exp local recurrence free survival/ OR exp 
disease-Free Survival/ OR exp risk factor/ OR Prognos*.ti,ab,kw. OR predict*.ti,ab,kw. OR risk 
factor*.ti,ab,kw. 
1c. Web of Science
“Vulva* neoplasm*” OR “Vulva* cancer*” OR “Vulva* tumor*” OR “Vulva* tumour*” OR “Vulva* 
carcinoma*” OR “squamous cell carcinoma of the vulva*” OR “vulva* squamous cell carcinoma*” 
AND 
Recurr*  OR relaps*  OR reoccur*  OR recidiv*  
AND
“Disease* Free Survival”  OR Prognos*  OR predict*  OR “risk factor*“
1d. Cochrane search
Vulva*:ti,ab,kw AND (neoplasm*:ti,ab,kw OR cancer*:ti,ab,kw OR tumor*:ti,ab,kw OR tumour*: 
ti,ab,kw OR carcinoma*:ti,ab,kw)
AND
Recurr*:ti,ab,kw OR relaps*:ti,ab,kw OR reoccur*:ti,ab,kw 
AND
Prognos*:ti,ab,kw OR predict*:ti,ab,kw OR (risk factor*):ti,ab,kw 
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Supplementary 2  Overall local recurrence rate by duration of follow-up
Footnote: no data for Leonard et al. 201632 available, Woelber et al. 201625; only patients with negative groin 
lymph nodes.
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ABSTRACT
Objective To determine the incidence of local recurrence of vulvar squamous cell 
carcinoma in relation to tumor- and/or precursor lesion free pathologic margins.
Methods  Consecutive patients with primary vulvar squamous cell carcinoma surgically 
treated in two Dutch expert centers between 2000 and 2010 were included. All pathology 
slides were independently reviewed by two expert gynecopathologists, and local 
recurrence was defined as any recurrent disease located on the vulva. Time to first local 
recurrence was compared for different subgroups using univariable and multivariable 
Cox-regression analyses. 
Results In total 287 patients with a median follow-up of 80 months (range 0-204) were 
analyzed. The actuarial local recurrence rate ten years after treatment was 42.5%. 
Pathologic tumor free margin distance did not influence the risk on recurrence (HR 
1.03 (95% CI 0.99-1.06)), neither using a cutoff of eight, five, or three millimeters. 
Multivariable analyses showed a higher local recurrence rate in patients with dVIN and 
LS in the margin (HR 2.76 (95% CI 1.62-4.71)), in patients with dVIN in the margin (HR 
2.14 (95% CI 1.11-4.12)), and a FIGO stage II or higher (HR 1.62 (95% CI 1.05-2.48)). 
Conclusions Local recurrences frequently occur in patients with primary vulvar carcinoma 
and are associated with dVIN (with or without LS) in the pathologic margin rather than 
any tumor free margin distance. Our results should lead to increased awareness among 
physicians of an ongoing risk for local recurrence and need for life-long follow-up. 
Intensified follow-up and treatment protocols for patients with dVIN in the margin 
should be evaluated in future research.
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BACKGROUND
In patients treated for early-stage vulvar squamous cell carcinoma, local recurrences 
are reported in up to 40% in the first 10 years after primary diagnosis 1. A recent 
systematic review from our group estimated an annual local recurrence rate of 4% 
without plateauing despite adequate treatment 2. In literature, data on prognostic 
factors related to local recurrences are mostly limited to classical clinico-pathologic 
factors. These data are heterogeneous and not sufficiently robust to propose individualized 
treatment and follow-up guidelines related to the risk on local recurrences 2. 
Even though the current surgical approach has less morbidity than before, radical 
surgery of the vulva is still mutilating. Currently, the recommended surgical tumor-free 
margin distance varies between different guidelines, ranging between one to two 
centimeters 3-5. The pathologic tumor margin distance with cut-off value of eight 
millimeters has frequently been challenged as a prognostic factor. However, studies 
investigating a lower cut-off value are scarce, retrospective and without proper central 
pathologic review. Therefore data available so far are insufficient to draw conclusions 
on which pathologic tumor free margin distance is safe without increasing the local 
recurrence rate 6, 7. 
Besides the tumor-free margin distance, vulvar precursor lesions in the skin adjacent 
to the tumor and/or in the margin could be of prognostic significance. Two different 
pathways with their own precursor lesions have been identified so far in the development 
of vulvar squamous cell carcinoma; the first and most common pathway is associated 
with lichen sclerosus (LS) and differentiated vulvar intraepithelial neoplasia (dVIN). 
The second pathway is caused by a persistent human papillomavirus (HPV) infection 
with high-grade squamous intraepithelial lesions (HSIL) as associated precursor 8. 
Data from recently published studies indicate that the presence of LS in the resection 
specimen of vulvar carcinoma may strongly increase the risk of local recurrences 9, 10. 
Currently no stratification of vulvar carcinoma patients with respect to their risk for 
local recurrence is possible. However, identification of patients at such low risk that 
they can be discarded from follow-up, for example after two or five years, would have 
significant clinical benefit. Simultaneously for high-risk patients new strategies might 
be developed and evaluated to prevent local recurrences.
The main aim of this study was to determine the incidence of local recurrence of vulvar 
squamous cell carcinoma, in a clinically well-defined consecutive patient series from 
two expert centers. The secondary aims were to assess the relation of local recurrence 
to tumor- and/or precursor lesion free pathologic margins determined by extensive 
pathology review, and based on these results to identify different risk groups, allowing 
future individualized treatment and follow-up strategies.
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METHODS
This study is reported in accordance with the Reporting Recommendations for Tumor 
Marker Prognostic Studies (REMARK) 11.
Patients 
Consecutive patients with vulvar squamous cell carcinoma treated at the Radboud 
university medical center and University Medical Center Groningen from January 2000 
– December 2010 were eligible for analysis. Both centers are expert centers for the 
treatment of vulvar carcinoma. Eligibility criteria for this study were: primary diagnosis 
of vulvar squamous cell carcinoma and primarily surgically treated at one of the two 
participating centers. Patients who suffered from multifocal disease, or patients who 
received neo-adjuvant chemotherapy and/or radiotherapy, definitive (chemo) radiation 
or palliative treatment were not included. 
Clinical data of all patients treated for vulvar carcinoma in both centers were prospectively 
stored in a database and completed by retrospective review of the patient charts. 
We identified eligible patients for this study from this database. To ensure completeness, 
we searched the Dutch nationwide registry of histopathology and cytology (PALGA), 
which resulted in nine additional patients in the two centers.
Treatment and follow-up
The surgical treatment of the vulva consisted of either a radical vulvectomy or wide 
local excision of the tumor. For a wide local excision, the intention was to obtain 
surgical tumor-free margins of at least 10 mm. In patients with a macro-invasive tumor 
(depth of invasion > 1 mm), a sentinel node procedure and/or an inguinofemoral lymph-
adenectomy was performed. Adjuvant therapy with re-excision was recommended in 
patients with a tumor-positive margin. When re-excision was not possible, adjuvant 
radiotherapy to the vulva was recommended. In patients with a pathologic tumor free 
margin of < 8 mm close follow-up was performed. When patients had an indication for 
radiotherapy to the groins, adjuvant radiotherapy on the vulva was considered in 
patients with pathologic tumor free margin distance of  < 8mm. Adjuvant radiotherapy 
to the groin was indicated for patients with ≥ 2 metastatic lymph nodes, or in case of 
extra nodal growth. From 2000 until 2006, patients from both our centers participated 
in the GROningen INternational Study on Sentinel Nodes in Vulvar cancer (GROINSS-V) 
I study, while from 2006 onwards patients participated in the GROINSS-V II study. 
Long-term follow-up data of patients with early-stage disease who were included in 
the GROINSS-V I study have been published previously 1. After treatment, patients 
were examined routinely every two to three months during the first two years after 
completion of primary treatment, every six months during the third and fourth year 
and yearly thereafter.
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Histopathologic review
For this study, all formalin-fixed and paraffin-embedded and hematoxylin and eosin 
stained slides, were reviewed in a standardized way by two independent expert gyneco-
pathologists (JB and HH), blinded for the results of treatment and follow-up data.
Eight test cases were analyzed by both gynecopathologists independently,after which 
agreement scores for these eight cases were calculated and a consensus meeting 
was organized to reduce the interobserver variability. Before the consensus meeting 
percentage of agreement was 62-66% for the assessment of the presence of LVSI, 
differentiation grade and the presence of LS in the pathologic margin, 100% for the 
assessment of LS, HSIL and/or dVIN adjacent to the tumor and 100% for the assessment 
of HSIL and dVIN in the pathologic margin. The intraclass correlation coefficient for 
the smallest pathologic margin was 0.98 and for the depth of invasion 0.94. After the 
consensus meeting, interobserver variety was minimal for all variables analyzed. 
Histopathological review of the included patients was performed by one of the two 
expert gynecopathologists and included the following variables: tumor type, pathologic 
tumor free margin distance for the basal and lateral margin separately, presence of 
low-grade squamous intraepithelial lesions (LSIL), high-grade squamous intraepithelial 
lesions (HSIL), lichen sclerosus (LS) or differentiated vulvar intraepithelial neoplasia 
(dVIN) adjacent to the tumor and/or in the pathologic margin (according the ISSVD 
classification 8), depth of invasion, tumor thickness, tumor diameter, presence of lymph-
angio-invasion, growth pattern and grade of differentiation. If re-excision was performed, 
both the slides of the primary excision and re-excision were reviewed. 
Data handling
All data were entered in an anonymous database using Castor EDC in which patient 
identity was protected by study-specific unique patient numbers 12. The codes of these 
specific numbers were only known to two dedicated data managers for each center 
separately. The use of these procedures combined with the fact that patients did not 
object against use of their clinical data or tumor material, meant that, according to 
Dutch law, no further patient or IRB approval was needed. 
Endpoints
The primary endpoint was time to local recurrence of vulvar carcinoma. Local recurrence 
was defined as any newly diagnosed invasive squamous cell carcinoma located on the 
vulva, and time to local recurrence was defined as the period of time in months from 
the date of primary surgery to the date at which recurrence was identified by 
histopathology. The end of follow-up was defined as date of last follow-up or date of 
death. Patients were reported lost to follow-up if no information on the last 24 months 
was available at time of data collection. Follow-up data were collected until January 1st, 
2018. The median follow-up time was 80 months (range 0-204 months).
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Definitions
The tumor specimens were formalin-fixed and paraffin-embedded (FFPE) in tissue 
blocks and all pathologic tumor free margin distances were measured on hematoxylin 
and eosin (H&E) stained slides from these blocks. Multiple sections at the tumor edges 
and margin were performed, and all reviewed in order to detect the smallest pathologic 
margin. The pathologic tumor free margin distance was defined as the distance in 
millimeters from the tumor edge to the end of the specimen, measured along the 
epithelium after formalin fixation using a ruler. All lateral tumor free margins were 
measured. Besides, the basal tumor free margin was measured. We determined the 
closest pathologic tumor free margin by taking into account both the lateral and basal 
margins. In case re-excision was performed, the closest margin after re-excision was 
assessed. The depth of invasion was measured from the epithelial-stromal junction of 
the most superficial adjacent dermal papillae to the deepest point of invasion as 
recommended by The International Society of Gynecological Pathologists (ISGYP) and 
The International Federation of Gynecology and Obstetrics (FIGO) 13. Regarding the 
precursor lesions; we noted the presence of these lesions as 1) adjacent to the tumor; but 
not in the pathologic margin or as 2) precursor lesion in margin; located in the pathologic 
margin. For the variable presence of precursor lesion in the pathologic margin, the latter 
had to be present. For the variable presence of precursor lesion in the excised specimen 
either one of the two previously described variables; a precursor lesion adjacent to the 
tumor or in the margin or both were present. The following patient, tumor and treatment 
characteristics were collected: age, FIGO stage (2009), TNM stage, tumor localization, 
treatment given (primary and adjuvant), histopathologic outcomes and follow-up data.
Statistical analysis methods
Continuous variables were summarized using the median and range, discrete variables 
were described by frequencies. The local recurrence rate was determined using the 
Kaplan-Meier method. Censoring was applied to patients alive without local recurrence 
at last follow-up and patients who died. Time to first local recurrence was calculated 
from the date of primary surgery and compared for each prognostic factor performing 
univariate Cox-regression analysis; hazard ratios (HR) with 95% confidence intervals 
(CI) were presented. A p-value of < 0.05 was considered to be statistically significant. 
Variables that had a p-value < 0.200 or were considered clinically relevant were 
incorporated in a multivariable Cox-regression analysis. The Akaike information 
criterion (AIC) and Bayesian information criterion (BIC) values were analyzed to 
compare the relative quality of the different Cox-regression models. A lower AIC of BIC 
indicates a better fit of the model compared to the other models. Together with the 
significance of the variables, the multivariable model with the best fit was chosen. 
Data analysis was performed using SPSS software (version 25.0, Armonk 2017) 14 and 
the statistical software R (version 3.5.0), with the survival package.
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RESULTS
During the study period, 435 patients were primarily surgically treated for vulvar 
carcinoma. For a variety of reasons, 148/435 patients were excluded, see flowchart in 
Supplementary Figure 1. In total, data from 287 patients were analyzed. Median age 
was 73 years (range 26-100), and all TNM and FIGO stages were represented, except 
FIGO stage IVB. Fifty-two patients were lost to follow-up for at least two years at time 
of data collection; median follow-up of these patients was 64 months (range 0-196). 
Clinical and histopathologic characteristics of the study population are listed in Table 1,
and did not differ between the two centers.
The actuarial local recurrence rates five and ten years after primary treatment were 
28.3% and 42.5%, respectively, see Figure 1. This rate did not differ between patients 
from both treatment centers individually: 5 and 10-year local recurrence rates were 
26,0% and 30,5% and 42,6% and 43,5% respectively (p = 0.679). Median time to local 
recurrence was 32 months (range 0-202 months) and this did not differ significantly 
per precursor lesion subgroup (p = 0.08). 
Pathologic margin in relation to local recurrences
The pathologic tumor free margin distance had no effect on the local recurrence rate 
(continuous HR 1.03 (95% CI 0.98-1.06)). No differences in local recurrence rate were 
observed, neither for the cut-off values ≥8 mm versus <8 mm, nor for different cut-off 
values (3-8 mm) (p = 0.308). Exclusion of patients with adjuvant radiotherapy on the 
vulva also did not indicate more local recurrences in relation to a smaller tumor-free 
margin distance. Because of small subgroups, patients were categorized using the 
cutoff point of eight, five and three millimeters, as shown in Table 2 and Supplementary 
Table 1.  
The local recurrence rate ranged from 28.1% for patients with HSIL, 30.7% for patients 
with no precursor lesion, 44.2% for patients with LS, 44.8% for patients with dVIN, and 
76.4% for patients with both LS and dVIN in the resection margin 10 years after 
treatment, respectively (See Figure 2). Univariable analyses of all included patients 
using binary variables showed that dVIN and/or LS in the margin, was associated with 
more local recurrences compared to no dVIN and/or LS in the margin (dVIN and LS 
present; HR 2.58 (95% CI 1.55-4.32); dVIN present HR 2.39 (95% CI 1.54-372), LS present 
HR 1.56 (95% CI 1.02-2.39), see Table 2. There was no difference in local recurrence rate 
when HSIL was present in the margin compared to no HSIL in the margin. 
Figure 2 shows that patients with dVIN in the margin, with or without LS, have significant 
higher local recurrence rates compared to patients without any precursor lesion in 
the margin (HR 3.32 (95% CI 1.79-6.16) and HR 2.28 (95% CI 1.10-4.71) respectively). 
Furthermore, within the subgroup of patients with dVIN in the excised specimen, 
the local recurrence rate was higher in patients with dVIN located in the margin 
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Table 1 Clinical and histopathologic characteristics of the study population.
Median (range) 
Total 287 patients
N (%)
Clinical characteristics
Age at primary treatment (years) 73 (26-100) 
FIGO stage 2009/ TNM stage 
- IA / T1aN0M0 
- IB / T1bN0M0 
- II / T2N0M0 
- IIIA / T1,2N1a,bM0 
- IIIB / T1,2N2a,bM0 
- IIIC / T1,2N2cM0 
- IVA / T1,2N3M0, T3NanyM0 
- IVB / TanyNanyM1 
- Missing
9 (3)
124 (43)
5 (2)
70 (24)
13 (5)
58 (20)
5 (2)
0(0)
3 (1)
Local surgery at primary diagnosis 
- Wide local excision 
- Radical vulvectomy 
- Exenteratio posterior 
- Skinning vulvectomy 
233 (81)
46(16)
5 (2)
3a(1)
Groin treatment at primary diagnosisb
- SN 
- IFL 
- Primary radiotherapy 
- Debulking 
- No treatment 
168
115
1 
13
15c
Adjuvant therapy 
- Radiotherapy to the vulva 
- Re-excision 
- Chemotherapy 
- None 
49 (17)
17 (6)
2 (1)
219 (76)
Status 
- Alive 
- Died of vulvar carcinoma 
- Died of intercurrent disease 
- Died of unknown cause 
152 (53)
57 (20)
68 (24)
10 (3)
Histopathologic characteristics
Tumor diameterd 29.5 mm (1.5-130.0) 
Depth of invasione 5.6 mm (0.5 – 25.0) 
Location
- Central
- Lateral
- Unknown
211 (74)
72 (25)
4 (1)
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Table 1 Continued.
Median (range) 
Total 287 patients
N (%)
Histopathologic characteristics
Grade of differentiation 
- Grade 1 
- Grade 2 
- Grade 3
- Not assessed
83 (29)
127 (44)
74 (26)
3 (1)
Growth pattern 
- Spray 
- Invasive 
- Confluent 
- Mixed 
- Not assessed*
105 (36)
96 (34)
69 (24)
7 (2)
10 (3) 
LVSI
- No
- Yes
- Not assessed*
221 (77)
62 (22)
4 (1)
Margin after (re)excisionf
- tumor positive
- <3 mm
- <5 mm
- <8 mm
- ≥8 mm
9.0 mm (0 – 35.0)   
14 (5)
36 (13)
59 (21)
130 (46)
155 (54)
Presence of precursor lesion
- Lichen sclerosus and dVIN
- dVIN
- Lichen sclerosus
- HSIL 
- None 
133 (46)
64 (22)
34 (12)
30 (11)
26 (9) 
Presence of precursor lesion in margin  
- Lichen sclerosus and dVIN
- dVIN
- Lichen sclerosus
- HSIL 
- None 
39 (14)
26(9)
104 (36)
15 (6)
103 (36)
a Three patients underwent a skinning vulvectomy because of vulvar intraepithelial neoplasia, coincidentally 
these patients also had invasive squamous cell carcinoma, that was excised sufficiently. b Patients undergoing 
two different groin surgeries are counted in both treatment groups. c Nine patients did not receive groin 
treatment because of a microinvasive tumor, 3 because of comorbidity, 1 wish of the patient, 1 patient had 
advanced metastatic disease and in 1 case the reason was unknown.dNot able to assess in 11 cases.eNot able 
to assess in 4 cases. fNot able to assess in 2 cases *Not able to assess due to small tumors.
Abbreviations: SN: sentinel node, IFL: inguinofemoral lymphadenectomy LS: lichen sclerosus, LSIL: low-grade 
squamous intraepithelial lesions, HSIL: high-grade squamous intraepithelial lesions ,dVIN: differentiated vulvar 
intraepithelial neoplasia, LVSI: lymph-vascular space invasion.
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compared to patients without dVIN in the margin but adjacent to the tumor (10- year 
local recurrence rate 60.5% versus 41.6% respectively, p = 0.002), see Figure 3. 
Presence of precursor lesion in the excised specimen in relation
to local recurrences
Univariable Cox-regression analyses were performed using a binary variable for the 
presence of a precursor lesion in the excised specimen. The presence of dVIN, LS or 
both dVIN and LS in the excised specimen was associated with a higher local 
recurrence rate (HR 1.80 (95% CI 1.08-2.99) and HR 1.61 (95% CI 1.03-2.52), 1.58 (95% 
CI 1.04-2.41) respectively) compared to patients without these precursor lesions 
present. The presence of HSIL was associated with a lower local recurrence rate (HR 
0.32 (95% CI 0.14-0.75) compared to patients without HSIL (see Supplementary Table 2).
Univariable Cox-regression analyses dividing patients in fi ve subgroups based on the 
presence of a precursor lesion in the excised specimen (no precursor lesion, dVIN and 
LS, dVIN, LS and HSIL) showed no diff erence in local recurrence rate between the 
subgroups of precursor lesions and the subgroup without precursor lesions. 
Figure 1  Local recurrence rate
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Table 2 Clinical and histologic characteristics related to local recurrence 
(univariable).
Hazard ratio (95% confidence interval)
Whole cohort 
(n=287)
Vulvar radiotherapy excluded 
(n=236)
Patient- and treatment characteristics
Type of local surgery
- Wide local excision
- Skinning vulvectomy
- Radical vulvectomy
- Exenteratio posterior
1.0
1.90 (0.47-7.77), p=0.369
1.05(0.55-1.97), p=0.887
0.00 (0.00-4.05e+204), p=0.964
1.0
1.83 (0.45-7.51), p=0.398
1.08 (0.52-2.25), p=0.841
0.00 (0.00-4.8e+200), p=0.964
FIGO stage
- IA, IB, II
- IIIA, IIIB, IIIC, IVA
1.0
1.45 (0.95-2.21), p= 0.084
1.0
1.51 (0.96-2.39), p=0.075
Adjuvant radiotherapy  
on the vulva
- No
- Yes
1.0
0.84 (0.46-1.54), p=0.569
- 
-
Location
- Central tumor
- Lateral tumor
1.0
1.17 (0.73-1.85), p=0.508
1.0
1.16 (0.72-1.89), p=0.543
Pathologic margin
Tumor free margin distance 
(continuous)
1.03 (0.99-1.06), p=0.153 1.03 (0.98-1.08), p=0.309
Tumor free margin distance 
- <8 mm 
- ≥8 mm
1.0
1.25 (0.81-1.93), p=0.308
1.0 
1.29 (0.79-2.09), p=0.307
Tumor free margin distance
- <5 mm
- ≥5 mm
1.0
1.13 (0.63-2.05), p=0.678
1.0
0.92 (0.44-1.91), p=0.814
Tumor free margin distance 
- <3 mm 
- ≥3 mm
1.0
0.93 (0.47-1.85), p=0.831
1.0 
0.62 (0.25-1.53), p=0.298
Dvin and lichen sclerosus  
in margin
- No 
- Yes
1.0
2.58 (1.55-4.32), p<0.001
1.0
2.57 (1.47-4.50), p=0.001
dVIN in margin 
- No 
- Yes
 1.0
2.39(1.54-3.72), p<0.001
1.0
2.55(1.58-4.11), p<0.001
Lichen sclerosus in margin 
- No 
- Yes
1.0
1.56 (1.02-2.39), p=0.040
1.0
1.30 (0.83-2.04), p=0.260
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Tumor characteristics in relation to local recurrences
The growth pattern, presence of lymph-vascular space invasion (LVSI), grade of differ-
entiation, tumor diameter and depth of invasion had no effect on the local recurrence 
rate, as displayed in Table 2. 
Multivariable analyses
Our multivariable model shows that the presence of dVIN combined with LS or without 
LS in the margin is associated with a higher local recurrence rate (HR 2.76 (95% CI 
1.62-4.71), p < 0.001, HR 2.14 (95% CI 1.11-4.12), p = 0.023). Furthermore, FIGO stage II 
or higher also resulted in a higher local recurrence rate (HR 1.62 (95% CI 1.05-2.48), p 
= 0.028), displayed in Supplementary Table 3.
Table 2 Continued.
Hazard ratio (95% confidence interval)
Whole cohort 
(n=287)
Vulvar radiotherapy excluded 
(n=236)
Patient- and treatment characteristics
HSIL in margin
- No
- Yes
1.0
0.54(0.20-1.48), p=0.233
1.0
0.46(0.15-1.47), p=0.189
Tumor characteristics
Growth pattern 
- Invasive 
- Spray 
- Confluent
- Mixed
1.0 
1.60 (0.94-2.70), p=0.081
1.36 (0.77-2.41), p=0.292
0.56 (0.08-4.11), p=0.564
1.0
1.46 (0.82-2.59), p=0.201
1.34 (0.74-2.44), p=0.336
0.51 (0.07-3.77), p=0.508
LVSI 
- No 
- Yes
1.0 
1.00 (0.58-1.72), p=0.99
1.0
0.98 (0.54-1.77), p=0.933
Grade of differentiation 
- Good 
- Moderately 
- Poor
1.0 
1.45 (0.88-2.40), p=0.148
1.41 (0.79-2.50), p=0.242
1.0
1.40 (0.82-2.37), p=0.219
1.45 (0.79-2.68), p=0.234
Tumor diameter
(continuous) 
- < 40 mm 
- ≥ 40 mm
1.01 (0.99-1.02) p=0.666
1.0 
0.92 (0.55-1.54), p=0.763
1.00 (0.99-1.02), p=0.865
1.0
0.81 (0.44-1.51), p=0.511
Depth of invasion 
(continuous) 
1.02 (0.97-1.07) p=0.381 1.03 (0.98-1.09) p=0.281
Footnote:  HSIL: high-grade squamous intraepithelial lesions , dVIN: differentiated vulvar intraepithelial 
neoplasia, LVSI: lymph-vascular space invasion.
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Figure 2  Local recurrence rate by presence of precursor lesions in margin
Follow-up time in months
140,00120,00100,0080,0060,0040,0020,00,00
O
ne
 M
in
us
 C
um
 S
ur
vi
va
l
1,0
0,8
0,6
0,4
0,2
0,0
Local recurrence rate
LS+dVIN-censored 
dVIN-censored LS-
censored HSIL-
censored
None in margin-
censored
HSIL
LS
dVIN
LS+dVIN
Precursor lesion in 
margin
None in margin
Months 0
103
39
26
104
15
24
64
20
12
66
15
60
56
9
10
47
10
120
14
3
6
19
6
144
9
1
1
9
5
1.0
3.32 (1.79-6.16), p<0.001
2.28 (1.10-4.71), p<0.042
1.45 (0.84-2.49), p<0.183
0.83 (0.28-2.41), p<0.728
Univariable Cox-regression
Number at risk
- None in margin
- LS and dVIN
- dVIN
- LS
- HSIL
HR (95% CI)
533164-L-sub01-bw-Pouwer
Processed on: 24-7-2019 PDF page: 104
104
CHAPTER 5
DISCUSSION
In this study, we show that local recurrences are not associated with (any) tumor free 
margin distance, but strongly with dVIN in the pathologic margin. Our research was 
carried out on large, clinically well-documented consecutive series of vulvar squamous cell 
carcinoma patients primarily treated with surgery with expert histopathologic revision.
In our study a pathologic tumor free margin distance of < 8, 5 or 3 mm is not associated 
with a higher local recurrence rate compared to a wider tumor free margin. Most guidelines 
recommend a surgical tumor free margin of ≥ 15 mm 3 or 10-20 mm 4. The European 
Society of Gynecologic Oncology (ESGO) guideline recommends a surgical excision 
margin of at least 10 mm, while a narrower margin is considered acceptable when the 
tumor lies close to midline structures (clitoris, urethra, anus) and preservation of their 
Figure 3   Local recurrence rate in patients with dVIN; presence of dVIN adjacent 
to the tumor versus dVIN in the margin
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function is desired 5. For the ESGO vulvar cancer guideline the current (preliminary 
and unpublished) data and data from other more recent studies and reviews that 
questioned the influence of tumor free margin distance were taken into account 2, 6, 7, 15. 
Due to a limited amount of patients with a pathologic tumor free margin of < 3 mm in 
our cohort, we could not determine the prognostic impact of this subgroup. Our data 
in larger number of patients clearly indicates that pathologic tumor fee margins of 
≥ 3 mm do not relate with the local recurrence rate. In our cohort, in which a surgical 
margin distance of > 10 mm was pursued, approximately 7% of the patients had a 
tumor positive margin and 8% a tumor free margin between 0 and 3 mm at primary 
excision. De Hullu et al. previously showed that in case of an intended surgical tumor 
free margin of 10 mm, 50% of the patients have a pathologic tumor free margin of 
≤8 mm 16. This might be due to smaller surgical margin if the tumor was close to 
important midline structures, shrinkage at fixation, but also because not all of the 
tumor is macroscopically visible. Therefore, we now recommend an intended surgical 
tumor free margin of 10 mm, but also not to excise unnecessary tissue close to important 
midline structures such as the clitoris (see flowchart Figure 4). Future implementation 
of a smaller tumor free margin will expose less patients to the potential harmful and 
often mutilating therapies. In selected patients Mohs microsurgery technique, widely 
applied in patients with skin cancer (eg. in the face), where close but free margins are 
accepted, might also be useful in vulvar carcinoma cases where small surgical margins 
are needed because important structures (clitoris, anus) need to be preserved. 
However currently no data on Mohs and vulvar carcinoma exist. 
No differences in local recurrences were found between patients that did or did not 
receive adjuvant radiotherapy on the vulva (Supplementary Table 1). Therefore, one 
should be reluctant with adjuvant radiotherapy on the vulva in case of small pathologic 
margins, since the morbidity of this therapy is high.
Our study shows a significant difference in local recurrence rates related to the 
presence of precursor lesions of the LS related pathway, which is in line with the study 
of Yap et al. 9 DVIN in the margin, whether or not in combination with LS, leads to 
higher local recurrence rates. Therefore, it is important for both the clinician and the 
pathologist to recognize dVIN. Efforts should be made to explore on how to improve 
clinical recognition of dVIN by clinician. Recognition of dVIN by the pathologist is of 
equal importance. Van den Einden et al. described histologic characteristics that are 
most important in the recognition of dVIN 17. In addition, the authors concluded that 
it is of added value to revise specimens with an unclear diagnosis and/or clinical 
suspicion for dVIN by an expert gynaecopathologist. Immunohistochemistry could be 
helpful in some cases; p16 could be used to exclude HPV-related lesions and p53 
might be useful in non-HPV related lesions. However, the exact diagnostic advantage 
of these and other immunohistochemistry stainings should be further researched to 
help identify dVIN. 
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Treatment of precursor lesions should be key in lowering the local recurrence rate.
Our data show that patients with both dVIN and LS or dVIN alone in the pathologic 
margin have significantly higher local recurrence rates. The local recurrence rate 
10 years after treatment is as high as 76% in patients with dVIN and LS in the margin 
compared to 31% for patients with no precursor lesion in the margin (p < 0.001, see 
Figure 2). This might be explained by the concept of field cancerization; the vulva is a 
field with genetically altered cells with a high risk of developing a precursor lesion and/
or carcinoma. Additionally, within the group of patients with dVIN in the resection 
specimen, patients with dVIN in the pathologic margin suffered significantly more from 
local recurrences compared to patients with dVIN adjacent to the tumor (p = 0.002, 
Figure 3). Therefore, we recommend to excise lesions suspicious for dVIN during 
resection of the primary tumor, while re-excision should be considered if dVIN is 
present in the pathologic margin (see flowchart Figure 4).  
Treatment of underlying dermatoses must be one of the major focuses during 
follow-up. In patients with LS treatment with topical corticosteroids may reduce the 
risk for developing vulvar carcinoma 2, 18, 19. Newer treatments such as lipo-injection, 
ablative laser treatment, and photodynamic therapy have been suggested, but no 
data are available on whether these therapies also reduce the malignant potential of 
LS or not. For dVIN, the malignant potential is higher and the time for progression to 
vulvar carcinoma shorter compared to LS 20-23. Local (re)excision of dVIN is first choice 
of  treatment. However, clinically it is often difficult to identify the exact location and 
borders of dVIN. Besides, excision can be mutilating especially when close to functional 
midline structures. In the future, alternative local treatment regimens such as targeted- 
or immunotherapy in these patients should be explored. 
None of the studied histopathologic characteristics of the tumor were associated with 
a higher local recurrence rate. This finding is in line with the hypothesis that mostly 
all local recurrences are ‘de novo’ tumors arising in a premalignant field. In previously 
reported studies, authors artificially classified local recurrence in ‘de novo’ tumors 
and ‘true’ local recurrence based on either the location (> or < 2 cm from primary tumor, 
or ipsilateral or contralateral side of the vulva) or time to local recurrence (< or 
> 2 years) 1, 6, 9, 24, 25. In our opinion, both classifications are too arbitrary and currently 
have no clinical consequences and therefore not used in our study. Future research 
should be performed on clonal or genetic relationship analyses to distinguish a 
‘de novo’ tumor and a ‘true’ local recurrence. 
In our study cohort, we showed an ongoing risk for local recurrence. The first local 
recurrence was diagnosed as long as 202 months after primary treatment. No subgroup 
of patients could be identified with a negligible risk for local recurrence (Figure 2 and 
Supplementary Figure 2) and there were no differences in median time to local 
recurrence between the different precursor lesion groups (p = 0.08) (See Figure 2 and 
Supplementary Figure 2). Therefore, we recommend life-long follow-up for all patients 
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treated for vulvar carcinoma with the aim to identify local recurrences as early as 
possible, but also to identify and treat precursor lesions to prevent a local recurrence.
Oonk et al. reported that 65% of the recurrences were detected at routinely scheduled 
follow-up meetings, indicating the need for patient education regarding the ongoing 
risk for local recurrence 26. In addition, identification of high-risk patients may further 
improve patient empowerment, patient education and may also lead to individualized 
follow-up schedules. The (early) detection of a local recurrence might be improved by 
self-examination by the patient and/or her partner, besides the instruction to contact the 
treating physician at time of any symptoms 26, 27. Currently there is no literature on the 
efficacy of self-examination for early detection of a local recurrence in vulvar carcinoma. 
Our study is the first examining the pathologic margin for both the presence of vulvar 
carcinoma and precursor lesions in a structured way with revision of all slides by two 
independent expert gynecopathologists. Furthermore, our study is performed in 
accordance with the Reporting Recommendations for Tumor Marker Prognostic Studies 
(REMARK) rules. Due to the retrospective character of this study, we were not able to 
reconstruct the exact location of the local recurrence in all patients. Our study did not 
had a prospective nature; therefore, we had to deal with missing data. A high number 
of patients are included with dVIN in the pathological margin without adjuvant treatment, 
due the lack of a standardized treatment protocol for these patients at that time besides
the fact that a part of the dVIN lesions were not detected at initial histopathologic 
examination. As a result of the small number of patients with a pathologic tumor free 
margin < 3 mm, we were not able to determine the prognostic impact of this subgroup 
with small pathologic tumor free margins. 
In conclusion, our study shows a high local recurrence rate in patients surgically 
treated for vulvar carcinoma. No relation was found with pathologic tumor free margin 
distances. Based on our study we advise to lower the recommended cut-off for a save 
pathological tumor free margin distance to ≥ 3 mm. We found the local recurrence rate 
to be especially related to the presence of dVIN (whether or not with LS) and we were 
unable to identify a subgroup with such a low risk that follow-up could be omitted. Our 
data reinforce that patients and their doctors need to be aware of the lifelong increased 
risk for local recurrence after surgical treatment for vulvar carcinoma, especially in 
patients with dVIN in the margin.
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Supplementary Table 2 Presence of precursor lesion in the excised specimen 
related to local recurrence (univariable).
Presence of  
precursor lesion in 
excised specimen
Hazard ratio (95% confidence interval) 
Whole cohort
(n=287)
Vulvar radiotherapy excluded 
(n=236)
dVIN and LS
- No
- Yes
1.0
1.58 (1.04-2.41), p=0.034
1.0
1.42 (0.90-2.23), p=0.129
dVIN
- No 
- Yes 
1.0
1.80 (1.08-2.99), p=0.024
1.0
1.85 (1.06-3.21), p=0.029
LS
- No 
- Yes  
1.0
1.61 (1.03-2.52), p=0.036
1.0
1.39 (0.87-2.22), p=0.172
HSIL 
- No
- Yes
1.0
0.32 (0.14-0.75), p=0.009
1.0
0.27(0.10-0.73), p=0.010
Abbreviations: dVIN: differentiated vulvar intraepithelial neoplasia, LS: lichen sclerosus, HSIL: high-grade 
squamous intraepithelial lesions 
Supplementary Table 3 Multivariable analyses.
Variable Hazard ratio  
(95% confidence interval)
p-value
dVIN and LS present in margin 2.76 (1.62-4.71) p<0.001
dVIN present in margin 2.14 (1.11-4.12) p=0.023
FIGO stage ≥II 1.62 (1.05-2.48) P=0.028
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Supplementary Figure 2 Presence of precursor lesions in the excised specimen 
and the local recurrence rate
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Limiting the morbidity of  
inguinofemoral lymphadenectomy 
in vulvar cancer patients; a review
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ABSTRACT
Introduction Inguinofemoral lymphadenectomy (IFL) is performed in the treatment 
for vulvar cancer. One or more complications after IFL is reported in up to 85% of the 
patients. This review presents an overview of surgical techniques and peri- and post- 
operative care that has been studied in order to reduce the morbidity associated with 
IFL in vulvar cancer patients.
Areas covered Current knowledge on postoperative complications after different surgical 
techniques and peri- and post-operative protocols were discussed. A systematic  literature 
review was conducted using MEDLINE, EMBASE and the Cochrane library on 20 
February, 2017. In order to be eligible for inclusion, studies must report the associated 
post-operative morbidity per surgical technique, or peri- or postoperative care given 
after IFL in vulvar cancer patients.
Expert commentary After the implementation of several new surgical techniques, 
the morbidity after IFL decreased but remains high and clinically meaningful. More 
research is needed on surgical techniques and peri-or postoperative care to further 
reduce the complication rates after IFL in vulvar cancer patients.
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INTRODUCTION
Vulvar cancer is the fourth most common gynecologic cancer after endometrial, ovarian
and cervical cancer. Vulvar cancer is a rare disease with an incidence of 2.4 per 100,000 
women 1. Over the past few decades, the incidence of vulvar cancer increased 2. Vulvar 
cancer mostly affects elderly women, with more than half of the patients being above 
the age of 70 years at the time of diagnosis. The most common histological type of 
vulvar cancer is squamous cell carcinoma (SCC), which accounts for over 80% of the 
cases 3. 
The dissemination of vulvar SCC may occur by three different routes; direct extension, 
lymphogenic spread and hematogenic spread. The initial spread occurs usually to the 
inguinofemoral lymph nodes. As soon as the depth of infiltration is more than 1 mm, 
inguinofemoral lymph node metastases can already be present. Therefore, evaluation 
of inguinofemoral lymph nodes is crucial. The cornerstone in the treatment of primary 
vulvar SCC is surgery, consisting of both local tumor resection and inguinofemoral 
lymph node staging and/or dissection. The treatment for vulvar cancer has developed 
throughout the last decades. For years, radical vulvectomy with ‘en bloc’ bilateral 
inguinofemoral lymphadenectomy was a well established treatment. In the last three 
decades, less radical surgery was introduced to decrease morbidity with comparable 
or improved prognosis. Nowadays, the standard treatment of early stage vulvar SCC 
consists of radical local excision of the tumor combined with a sentinel node (SLN) 
procedure and/or inguinofemoral lymphadenectomy (IFL). The SLN procedure is safe 
to perform instead of an IFL in patients with a unifocal tumor <4 cm without suspicious 
lymph nodes in the groins 4. In patients with a larger tumor, multifocal disease and/or 
a positive SLN and in patients with local recurrent disease without earlier IFL, an IFL is 
indicated. After the implementation of the SLN,  in approximately half of the patients 
with vulvar SCC an IFL is still indicated 5. 
Unfortunately, IFL is  associated with significant short- and long term complications. 
The occurrence of one or more groin wound complications is reported in 66-85% of the 
patients 6, 7. Wound breakdown, wound infection, lymphoceles, lymphedema, cellulitis, 
and erysipelas are the most reported complications. Because IFL will always have a 
place in the treatment of vulvar cancer, it is important to look for adjustments, which 
may reduce the associated morbidity.
The aim of this review is to create an up to date summary of surgical techniques and 
peri- and postoperative care that have been performed to reduce the morbidity of IFL 
in vulvar cancer patients.
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METHODS
Literature search
We performed a systematic search of the literature  on 20 February 2016 using 
MEDLINE, EMBASE, and the Cochrane library. The following search (MeSH)terms and 
synonyms were used for ‘lymphadenectomy’ combined with ‘vulvar cancer’ (lymph-
adenectomy, inguinofemoral lymphadenectomy, groin surgery, groin dissection, lymph 
node dissection, lymph node surgery, lymph node excision;  vulvar cancer, vulvar 
tumor, vulvar carcinoma, vulvar neoplasm, vulvar squamous cell carcinoma). The search 
was restricted to the English and Dutch language. 
Study selection
In order for an article to be eligible, the following predefined criteria had to be met [1]: 
(randomized) (un)controlled trial; controlled or uncontrolled prospective or retrospective 
study [2]; IFL for vulvar cancer patients aged >18 years and [3] report the associated 
complication rate per studied surgical technique or peri- or post-operative care. 
Outcome measures
Our primary outcomes of interest were; 
• Complication rate per surgical technique and/or peri-, or post-operative care
o Short-term complications <8 weeks after surgery 
	 Wound breakdown
	 Wound infection 
	 Lymphocele
o Long-term complications >8 weeks surgery 
	 Cellulitis or erysipelas (recurrent)
	 Lower extremity lymphedema
Secondary outcome of interest was;
o Quality of life
Data extraction and analysis
Relevant data on study population, study design, surgical technique, peri-or postoperative 
protocol, and the complication rates were extracted from the included studies. Similar 
complications were grouped together such as seroma and lymphocele, cellulitis and 
erysipelas, wound dehiscence and wound breakdown. 
Quality of the included studies was categorized according to the levels for intervention 
studies of evidence of the Oxford Centre of Evidence Based Medicine 8. Level one 
evidence included a systematic review of randomized controlled trials (RCT), level two, 
evidence included a randomized trial, level three, a non-RCT, level four, case-series, 
case control studies or historically controlled studies. 
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The aim of this review was to create an up-to-date summary of all available evidence 
regarding surgical techniques and peri- and postoperative care protocols after IFL in 
vulvar cancer patients. Therefore, we included all published articles concerning this 
subject. As both controlled and uncontrolled trials were expected to include in this 
review, we planned not to perform meta-analyses.
RESULTS
Literature search
The search yielded a total of 1988 articles, after removal of duplicates, 1363. One 
author (AP) screened all titles and checked for relevant abstracts; 123 abstracts were 
found to be relevant and were retrieved in full text. The same author assessed the 
articles for eligibility using the predefined criteria as stated in our methods. A total of 
36 studies were included in this review. 
Study characteristics
The research designs of the included studies were mainly retrospective (23 studies), 
six were  prospective uncontrolled studies, five RCTs and two prospective controlled 
studies. Study populations ranged between 5 and 194 patients and were  studied in 
the period from 1955 until 2016. The quality of the included studies was mainly level 
four evidence (31 studies).Two included RCTs were downgraded to level three evidence 
because they did not perform a sample size calculation and both included less than
15 patients 9, 10 (See table 1). 
The following surgical interventions were studied: separate incisions or radical 
vulvectomy with ‘en bloc’ lymphadenectomy, unilateral IFL, sparing of saphenous vein, 
Sartorius transposition, dura mater for femoral vessel coverage, minimally invasive 
technique, preservation of fascia lata, harmonic scalpel or electrosurgery, plasmajet, 
VH fibrin sealant, lymphatic microsurgical venous anastomosis (LYMPHA technique), 
lymphatic flap,  method of skin closure, anticoagulation, postoperative drainage and 
compression garments.  None of the included studies reported data on quality of life. 
For an overview of the association of the above described interventions on post- 
operative morbidity after IFL, see Table 2.
Modifications of surgery 
Type of groin incision 
The morbidity of IFL by type of groin incision was reported by ten included studies, 
both separate incisions and the ‘en bloc’ approach were described. See Table 3.
Only two retrospective studies studied postoperative complications after IFL by 
separate incisions versus the ‘en bloc’ approach 14, 15. Helm et al.14 did report a 
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reduction of patients with wound breakdown using separate incisions but this 
reduction was not statistically significant. The second study described a reduction of 
the wound breakdown rate and an increase in lymphoceles after using separate 
incisions, but did not perform any statistical tests 15. Six other studies report the 
incidence of postoperative complications after the use of separate incisions without a 
control group. Overall, it can be concluded that the occurrence of wound breakdown, 
lymphedema and cellulitis/erysipelas was reduced by using separate incisions with an 
increase in lymphoceles.
To determine further reduction of the morbidity associated by IFL using separate 
incisions, Manci et al. 30 compared skin access above or below the inguinal ligament in 
a RCT and found an advantage for incision above the ligament; wound dehiscence in 
32% versus 17%, lymphocele in 19% versus 6% respectively,  although there was no 
statistically significant difference. 
Laterality of IFL 
Unilateral IFL as an alternative to bilateral IFL was studied in a selected group of 
patients with lateralized tumors (tumor with medial margin >1 cm from the midline) 
without palpable groin lymph nodes. Two studies reported less complications in 
unilaterally treated patients 17, 22. The number of patients with wound dehiscence or 
Table 2 Influence of intervention on the complication rate after IFL per level of evidence
Level of 
evidence
Decrease Increase No association Unclear
Level 1 None None None None
Level 2 None Fibrin 
sealant 
Sartorius transposition
Skin access above or 
below the inguinal 
ligament 
None
Level 3 None None None Plasmajet 
Prophylactic 
compression 
garment
Level 4 Separate incisions 
Unilateral IFL
Sparing saphenous vein
Preservation fascia lata 
LYMPHA* 
Continuous suture
‘en bloc’ 
approach 
Bilateral IFL 
Artificial 
dura mater
Cadaver dura mater (R-)VEIL 
Harmonic scalpel 
or electrosurgery 
Anticoagulation 
Duration of drainage
Lymphatic flap
Footnotes: *: only lymphedema studied, (R-) VEIL: (robot assisted) video endoscopic inguinofemoral lymph-
adenectomy, IFL: inguinofemoral lymphadenectomy, LYMPHA:  lymphatic microsurgical preventive healing 
approach
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lymphedema is significantly reduced by performing a unilateral IFL from 24% to 0% 
and 67% to 8% respectively (p < 0.001)22. In conclusion, unilateral IFL does reduce 
morbidity but can only safely be performed in patients with early stage and lateralized 
vulvar cancer 17. 
Sparing of the saphenous vein
The classic description of IFL includes ligation of the saphenous vein. It was suggested 
that sparing the saphenous vein might reduce the complications associated with IFL. 
Four retrospective studies reported the complication rates after sparing versus ligation 
of the saphenous vein 20, 23, 26, 27. See table 4 for an overview of the outcomes of these 
studies. There was a significant lower number of groins with wound infection 23, 26, 
wound breakdown 20, 23, 26, lymphedema 23, 26, 27 and cellulitis/erysipelas 20, 27 after 
sparing of the saphenous vein. There was no evidence of effect for the reduction of 
lymphoceles. It can be concluded that sparing of the saphenous vein reduces the 
postoperative wound complications after IFL.
Coverage of femoral vessels
The transposition of the Sartorius was first introduced by Way as modification to 
protect the femoral vessels in case of wound breakdown and to decrease the morbidity 
after IFL 41. The effect of transposition of the Sartorius on the complication rate is 
reported in three studies, one RCT 24 and two retrospective studies 18, 23. Judson et al. 24
randomized patients for either Sartorius transposition or not. They found  a statistically 
significant increase of lymphocele formation in patients in the transposition group. 
Other outcomes, such as wound breakdown, wound infection and lymphedema did 
not differ between those two groups of patients. 
One retrospective study reported an increase in patients with lymphedema after 
transposition of the sartorius, with statistical significance 23 and another study 
reported a reduction of wound infections after transposition 18. These studies did not 
report significant differences between wound breakdown and lymphocele.  See Table 5
for an overview of results. 
Another explored surgical technique during IFL to cover the groin vessels is Sartorius 
tendon transposition versus Sartorius transposition as investigated by one 
case-control study 36. Wound breakdown and chronic lymphedema were significantly 
reduced in the Sartorius tendon transposition group, 30% versus 3.6% (p = 0.012) and 
33.3 versus 7.1% respectively (p = 0.022). However, none of the studies report the 
morbidity after tendon transposition versus no tendon or Sartorius transposition.  
In the past, cadaver dura mater was used to cover the groin vessels but this is difficult 
and more time consuming than Sartorius transposition, besides the risk of transmittance
of viral infections 13. The artificial dura mater was not effective and increased the 
complications after IFL 16.
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In conclusion, there is no evidence that covering the femoral vessels by transposition 
of the Sartorius or cadaver or artificial dura mater does reduce the complications after 
IFL in vulvar cancer patients. 
Minimally invasive IFL
The last years, minimally invasive techniques were developed for IFL to reduce the 
postoperative complications. After the introduction in other malignancies such as 
penile cancer and melanoma, video endoscopic IFL (VEIL) was studied in vulvar cancer 
patients. Until now, there is limited English literature on vulvar cancer. Four studies 
concerning VEIL in vulvar cancer patients were included in this review 32, 37, 39, 40. 
These studies were published between 2011 and 2017, two were prospective and two 
retrospective. In total, 87 patients were included (75 patients from China and 12 
patients from India). For results see Table 6. 
Xu et al. used the abdominal approach for VEIL and reported no inguinal wound-related 
complications besides one patient with exhibited lymphorrhea through the drain 
orifice 32. The second study used a hypogastric subcutaneous approach and reported 
only one patient with a lymphocele (5%); furthermore no other inguinal wound 
complications were observed 37. The third study used a 3-incision lateral approach to 
perform VEIL in 37 patients and was the largest published study in vulvar cancer 
patients. They described wound breakdown in 3% of the patients; no other 
complications such as wound infection, lymphocele, lymphedema and cellulitis were 
reported in these patients 39. The last study performed in India used robot-assisted 
VEIL (R-VEIL) to perform IFL. Reported overall complication rate was 75% per patient 
and 60% per groin 40. These overall complication rates reported after R-VEIL  were 
even higher to those reported after open IFL by Gaarenstroom et al. of 66% per patient 
and 52% per groin respectively 6.  Furthermore, it is unclear if (R-)VEIL is safe in vulvar 
cancer patients, given a groin recurrence rate as high as 6% in patients using VEIL 39
comparing to 2.5% after using the conventional procedure 42. 
In conclusion, (R-)VEIL seems to be feasible for the approach of IFL as described in all 
studies, but it remains questionable if (R-)VEIL reduces the postoperative complications, 
and whether this procedure is oncologically safe or not.
Other modifications
More individual studies report modifications on the current surgical techniques of IFL. 
First of all, the preservation of the fascia lata. Two retrospective studies report after 
sparing of the fascia lata lower rates of lymphocele, lymphedema, wound infection, 
and wound breakdown compared to the literature19, 25 and overall short-term 
complication rate of 38% and long term complication rate of 14% 25.  
The device used during IFL is studied as a possible option to reduce the morbidity. 
Pellegrino et al. 29 investigated the differences in postoperative complications of using 
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either the harmonic scalpel or conventional electrosurgery. They did not report 
significant differences between these two groups in the incidence of postoperative 
complication. In this study only one patient had a postoperative complication in the 
harmonic scalpel group (including 22 patients) versus zero patients in the conventional 
electrosurgery group (including 20 patients).  Another study regarding the surgical 
device used is performed by Madhuri et al. 9 using Plasmajet (a surgery system utilizing 
kinetic energy and highly controlled thermal effects to seal the tissue). In a conference 
abstract they described a pilot RCT in 18 patients and concluded that Plasmajet may 
reduce the lymphocele  formation but did not publish the full paper until now. 
Another studied option is the sealing of lymph vessels during IFL, evaluated by Carlson 
et al. 28 in a RCT. They investigated the addition of VH fibrin sealant sprayed in 
the groin before sutured closure. Inguinal infections, wound breakdown, lymphoceles 
and lymphedema did not significantly differ between the two groups. However, they 
reported a significant increase in the number of vulvar infections in patients treated by 
VH fibrin sealant (33% versus 14%, p = 0.0098).The overall complication rate for 
patients treated in the intervention group was 61% versus 59% in the control group.
In conclusion, VH fibrin sealant in the groin did not reduce the groin complications 
after IFL and increased the vulvar wound complications.
The use of lymphatic microsurgical preventive healing approach (LYMPHA)  in the 
prevention of lymphedema during IFL was described by one prospective study in 
23 groins 35.  Before incision of the skin, blue dye was injected in the thigh muscles 
to identify the lymphatic vessels; anatomizes were made between lymphatics from 
the lower limb and one of the collateral branches of the femoral vein. They reported 
lymphedema in 8% of the groins after the LYMPHA technique and 36% in the cohort 
without LYMPHA technique after a mean follow up of 16.7 (SD 6.2) months. Other groin 
wound complications were not reported. More research is needed before implementation
of this technique. Another study used a surgical technique for microsurgical reconstruction 
of the lymphatic drainage in order to prevent lymphatic drainage impairment. In this 
study, a lymphatic flap harvested from the flank was used to create a bridge in the gap 
of lymphatic vessels created by IFL. This technique was used in one groin, while the 
conventional surgical method was used for the other groin. Patients were evaluated 
6 months after surgery, and the limbs treated by the lymphatic flap showed mild 
edema versus moderate to severe edema in the untreated limb 38. 
The method of skin closure was studied by one retrospective study 31: continuous 
subcuticular suture was compared to staples. Lymphocele formation was reduced 
(21% versus 47%, p = 0.05) and also a reduction in chronic lymphedema (6% versus 
29% p = 0.02) by using subcuticular suture compared to staples. Wound infection and 
wound breakdown were not influenced by the method of skin closure. 
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Modifications of perioperative care 
In 1983, one study reported the influence of perioperative prophylactic anticoagula-
tion as a possible cause of lymphocele after IFL. In patients receiving heparin, 42% 
developed a lymphocele versus 2% in patients receiving sodium warfarin, dextran or 
no anticoagulation (p < 0.01).The influence of both treatment regimens on the risk of 
embolism in these patients is unclear. There are no other studies regarding prophylactic 
anticoagulation and the associated risk of complications after IFL besides this dated 
publication. Nowadays, the use of heparin is more and more replaced by the use of 
low-molecular-weight heparin during surgery and postoperative care. No reports 
about usage of low-molecular-weight heparin are published until now. 
The usage of prophylactic intravenous antibiotics is widely accepted during peri- 
operative care, but there were no publications about reducing postoperative (wound) 
complications. 
Modifications of post-operative care 
The postoperative care given might influence the morbidity after IFL. First of all,
the postoperative drainage of the groin after IFL might reduce the morbidity. The optimal 
duration of lymph fluid drainage was studied by only two retrospective studies. Walker 
et al. 31 reported complications in association with the duration of lymph fluid drainage. 
The main reason for removal of the drain was production of < 50ml per 24 hours. 
Wound breakdown and lymphedema were significantly lower in the group of patients 
drained over 7 days compared to shorter drainage. There was no influence on the 
number of patients with a wound infection and lymphocele. Another retrospective 
study showed that higher drain production on the last day in situ was associated with 
an increased risk for any short term complication but there was no effect found on 
duration drain in situ on the complication rate5. Prospective research is needed to 
determine the optimal duration of postoperative drainage in terms of reduction of 
complications after IFL. 
The second studied modification of postoperative care was the use of prophylactic 
compression garments by Sawan et al. 10 in 14 patients. Patients were randomly 
assigned for prophylactic compression garments or best supportive care without 
compression garments. There was no statistically significant difference in postoperative 
complication rate regarding wound breakdown, wound infection, lymphocele and 
lymphedema.  Further (larger) studies are needed to investigate the role of compression 
garments for reducing the morbidity of IFL. 
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Where feasible we advise the implementation of separate incisions, unilateral IFL, 
sparing of the saphenous vein, preservation of the fascia lata and continuous suture 
as the standard care for IFL in vulvar cancer patients. These surgical techniques appear 
to reduce the complication rates. The usage of peri-operative fibrin sealant, the ‘en 
bloc’ approach, bilateral IFL (for lateralized tumors), and artificial dura mater should 
not be used as a standard surgical technique for IFL given the higher complication rates. 
Sartorius transposition, skin access above or below the inguinal ligament, and cadaver 
dura mater did not influence the complication rate and should not be implemented for 
IFL. Minimally invasive approach for IFL is promising in terms of reduced of complication 
rates, but the oncological safety remains unclear. Therefore, minimally invasive techniques 
for IFL should only be used within the protection of a prospective trial. 
Regarding the postoperative care, there is no consensus about optimal drain 
management and it remains unclear if prophylactic compression garments do reduce 
the postoperative complication rates. Peri- and postoperative protocols should be 
studied more extensively before the implementation of new protocols.
Concerning the surgical technique in vulvar cancer patients, the implementation of 
separate incisions decreased the morbidity after IFL. Although, a randomized controlled 
trial comparing the ‘en bloc’ approach versus separate incisions investigating the 
oncologic safety is lacking. However, in a Cochrane review all observational studies 
Table 6 Minimally invasive approach for IFL, complications in percentages
Study N Short term Long term
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Per patient
Xu 2011 17 0 0 0 0 0 0
Wang 2015 21 - - 5 - - -
Wu 2016 37 - 3 0 - 0 -
Jain 2017 12 0 0 33 33 17 75‡
Per groin
Jain 2017 22 0 0 27 27 9 60‡
‡: including prologned lymphhorrhea, - not reported
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concerning separate incisions were pooled and they concluded that separate incisions 
were deemed to be oncologically safe 43. 
Another surgical technique which appears promising in terms of reduction of post-
operative morbidity is minimally invasive IFL. Recently, two reviews were published on 
this subject 44, 45. One review included ten studies including 236 procedures in 168 
patients with penile, vulvar or vaginal cancer or melanoma. They concluded that the 
number of wound infections, wound dehiscences and lymphoceles appeared lower in 
patients operated by the VEIL technique (overall complication rate 4% of the groins) 
compared to the open technique 44. The other systematic review reported an overall 
complication rate of 13% (lymphocele formation 3.6%, wound infection 1.2%, and 
lymphedema 0.4%) 45. This review included nine studies, but only three out of these 
were published in English. One was included in our review 32, the others were excluded 
for this review (one study included also vaginal cancer patients and the other did not 
report data about postoperative complications). So far, no RCTs assessed this new 
minimally invasive surgical technique. Furthermore, none of the studies included 
Caucasian women. Moreover, the usage of an ultracision scalpel, which has proven to 
reduce the incidence of lymphoceles after axillary dissection in breast cancer patients 
46, which is used during VEIL and not during the open procedure may partly explain 
the differences in complication rates. The results on decreasing the incidence of 
postoperative complications by using the minimally invasive approach are promising, 
but the oncologic safety of this technique is still unclear. The main concern is the high 
groin recurrence rate of 6.5% in patients with negative lymph nodes after VEIL 39. 
The oncologic safety of pelvic lymph node dissection by laparoscopy is proven for 
other gynecological malignancies, no differences in number of lymph nodes removed, 
disease recurrence and survival were reported in several studies 47, 48. A large 
prospective trial with adequate follow up of at least 2 years is needed to determine the 
oncologic safety of VEIL and the postoperative outcomes in Caucasian women with 
vulvar cancer.  
IFL is also performed in patients with a melanoma or penis cancer. In  order to reduce 
bias, in our review only studies including patients with vulva cancer were included. 
There were several reasons for excluding other indications for IFL than vulvar cancer. 
First of all, the median age of patients with melanoma is lower than in patients with 
vulvar cancer, older patients are faced with more comorbidity than younger patients 
which plays a role in the incidence of postoperative complications. Furthermore, the 
sex of a patient may influence the complication rate after IFL; therefore studies on 
penis cancer, including only men, were excluded from this review. However, more 
studies on the complications after IFL for melanoma and after axillary dissection for 
breast cancer are published. Regarding the complications after IFL in melanoma 
patients, a review included seven studies described different surgical approaches for 
IFL; applying fibrin sealant in the wound bed, different incision techniques  for separate 
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incisions, local versus general anesthesia, early mobilization or postoperative bed rest 
were studied, but none of these interventions showed a statistically significant 
reduction in complication rates 49. A review concerning seroma formation after axillary 
dissection in breast cancer patients  reported a decrease in complications by using 
ultrasonic scissors, electrotermal bipolar vessel system, suture fixation techniques to 
reduce the dead space, volume controlled suction drainage and active shoulder 
exercise50. 
There are some limitations to this review. First of all, there is a lack of published studies 
with level one evidence. As vulvar cancer is a rare disease, it is hard and not realistic 
to perform a large number of RCTs in vulvar cancer patients. Therefore, this review was 
mainly based on data from retrospective or observational studies, which is a source of 
bias. Another limitation was the different definitions used for  complications after IFL. 
An attempt should be made to standardize the definitions used for postoperative 
wound complications in vulvar cancer patients for this will improve the comparability 
between published studies in the future. 
FIVE YEAR VIEW
Even though new surgical modifications were implemented, the complication rate after 
IFL in vulvar cancer patients remains high. In the near future, more research is expected 
to further reduce this  morbidity.  Besides research on reducing the complications after 
IFL, research will focus on new treatment regimens in order to limit the indication for 
IFL. Reducing the number of patients with an indication for IFL can be achieved by the 
introduction of a repeat SLN procedure and/or radiotherapy on the groin. However,
it should be kept in mind that the consequences of a groin recurrence are significant, 
with a 5-year survival rate of only 0-15% 51-53. Therefore, determination of the lymph 
node status remains an important part in the treatment of vulvar cancer patients. 
The safety of a SLN procedure in patients with a local recurrence of vulvar SCC has not 
been proven yet 54. As a consequence, patients with a local recurrence after an earlier 
negative SLN, do not perceive  the benefits of the  SLN procedure in terms of the 
omission of an IFL. Research concerning the safety of a (repeat) SLN procedure instead 
of an IFL in patients with recurrent vulvar SCC is expected within the upcoming years. 
In 2018, results will be expected of the GROINSS-VII study that will provide more 
information on the safety and efficacy of radiotherapy instead of IFL in patients with 
micro-metastases in the sentinel lymph nodes. 
Replacement of IFL by other treatment options with less treatment related morbidity 
but the same effectiveness and safety will be a step forward in treating vulvar SCC 
patients. For patients who still have an indication for IFL, research is expected on 
minimally invasive techniques for IFL to determine the oncologic safety and the 
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benefits in terms of reduced postoperative morbidity. Furthermore, the device used 
during surgery may be a key factor in preventing postoperative complications. 
Peri- and postoperative care may also play an important role and also affect the 
postoperative complication rates. More prospective studies regarding the peri-and 
postoperative care should be performed. 
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ABSTRACT
Objective Inguinofemoral lymphadenectomy for patients with vulvar squamous cell 
carcinoma is associated with a high incidence of postoperative wound complications, 
which may be influenced by inguinal drain management. The aim of this nationwide 
prospective study (MAMBO: Morbidity And Measurement of the BOdy) was to assess 
the feasibility and the incidence of complications after volume-controlled versus short 
drainage. 
Methods The MAMBO study consisted of two observational studies in all eight oncology 
centers in the Netherlands, conducted between 2012 and 2016. In the first study, 
the drain was removed when the production was <30 ml/24 h, except in the first 48 h, 
and after a maximum of 28 days (MAMBO-IA). In the second study, the drain was 
removed five days postoperatively regardless of production (MAMBO-IB). We assessed 
the complications within eight weeks after surgery using logistic regression to compare 
the incidence of one or more complications between the two drainage protocols, 
adjusting for possible confounders.
Results We included 77 patients (139 groins) for volume-controlled drainage and
64 patients (112 groins) for short drainage. Volume-controlled drainage was associated 
with significant less lymphocele formation. Moreover, we found no difference in wound 
infection or primary wound breakdown. The estimated incidence of one or more 
complications was 46% per groin after volume-controlled drainage versus 75% after 
short drainage, (RD 29% (95% CI 8, 49) p = 0.006).  
Conclusions This prospective study shows that volume-controlled drainage is associated 
with significantly less complications compared to short drainage. We therefore recommend
volume-controlled drainage after inguinofemoral lymphadenectomy in patients with 
vulvar squamous cell carcinoma.
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INTRODUCTION
Vulvar squamous cell carcinoma (SCC) is a rare disease and accounts for approximately 
3-5% of all female genital malignancies 1. The incidence is approximately 1-2 per 100.0002. 
The standard treatment for patients with early stage SCC of the vulva consists of wide 
local excision (WLE) of the tumor combined with a sentinel lymph node (SLN) procedure 
and/or inguinofemoral lymphadenectomy (IFL). In patients with a primary unifocal 
vulvar SCC measuring less than four centimeters without suspicious groin lymph 
nodes; a SLN procedure is indicated and an IFL can be safely omitted 3. Although the 
SLN procedure is the preferred treatment  in the Dutch guidelines, in around half of the 
patients an IFL is still indicated based on multifocal tumors, tumors larger than four 
centimeters, recurrent disease and/or positive SLNs 4. 
Unfortunately, IFL has significant short- and long-term complications. The most common 
short-term complications are wound breakdown, wound infection and formation of 
lymphoceles and are reported in up to 85% of the patients 5.  Development of lymphedema
and cellulitis/erysipelas are the most documented long-term complications. 
Efforts have been made to adjust the surgical technique for IFL in order to reduce the 
associated complications. After the implementation of several new surgical techniques 
such as triple incisions and sparing of the saphenous vein, the morbidity after IFL 
decreased, but still remains high and clinically relevant 6-9. 
The direct postoperative management for patients with vulvar SCC may reduce the 
incidence of complications; however, it has not been described extensively and only 
retrospective studies are published regarding this subject. The usage of prophylactic 
antibiotics or prophylactic compression stockings did not reduce the postoperative 
complications 10-12. Regarding postoperative drain management of the groin in vulvar 
SCC patients, there is no (inter)national consensus on duration of drainage. 
Until now, both volume-controlled and short drainage of the groin are used. Published 
literature used volume-controlled drainage and removed the drain when the output 
was < 30-50 ml/24 h 6, 10, 13. However, the reasons for these specific drain policies were 
not elaborated and none of the studies compared different drain protocols. Removal of 
the drain irrespective of the amount of output after several days, may be accompanied 
by an increase in the incidence of lymphoceles 4. On the other hand, long drainage 
may increase the risk for infection, prolonged hospital stay and gives more discomfort 
for the patient. 
Therefore we conducted a nationwide prospective study (MAMBO: Morbidity And 
Measurement of the BOdy) to start with a volume-controlled drainage protocol to 
assess the feasibility of such a protocol and to assess the incidence of complications; 
this was followed by a short drainage protocol to finally compare complication rates of 
both protocols in order to formulate a standardized national drain protocol.
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METHODS
In this prospective multicenter MAMBO (MAMBO: Morbidity And Measurement of the 
BOdy) study patients were included from eight oncology centers which are united in 
the Dutch Gynaecologic Oncology Group (Radboud university medical center Nijmegen, 
University Medical Centre Groningen, Center for Gynaecologic Oncology Amsterdam, 
location The Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital and 
Academic Medical Centre Amsterdam, Leiden University Medical Centre, Erasmus 
Medical Centre Rotterdam, Maastricht University Medical Centre and Catharina 
Hospital, Eindhoven). All participating centers are expert centers in the treatment of 
vulvar cancer.
Patients aged ≥18 years with a primary or recurrent SCC of the vulva with an indication 
for unilateral or bilateral IFL were eligible to participate in this study. Patients with an 
indication for a SLN procedure only, were not eligible for this study.  Further exclusion 
criteria were previous radiotherapy on the vulva or groins, previous pelvic lymph-
adenectomy, histology other than SCC and an indication for IFL with the ‘en bloc’ 
approach of the vulva and groins. 
Two consecutive protocols were performed to assess the feasibility of the two drainage 
protocols and to compare the incidence of complications.  First, patients were included 
in the volume-controlled drainage protocol (MAMBO-IA) during a period of 21 months 
(October 2012-June 2014). Thereafter the treatment protocol was changed and  patients 
were included  in the short drainage protocol (MAMBO-IB) (March 2015-December 2016). 
There were several reasons why the MAMBO study group has decided not to perform 
a randomized trial but to choose for two study protocols. First of all, the incidence of 
vulvar cancer is low. Secondly, there is no standard treatment regimen defined for the 
duration of drainage. Furthermore, the feasibility of especially the long drainage 
protocol (patients were discharged from the hospital with drains in situ) was unknown. 
Both the design and the treatment protocol of both studies were identical except the 
timing of removal of the drain. 
Patients were asked to participate in the MAMBO study during their initial visit at the 
outpatient clinic. The patient information form was given and all patients had to sign 
for informed consent for collecting data. The local ethical committees approved both 
protocols (registration numbers 2012-246 and 2014-1491). 
The surgical technique of the IFL consisted of separate incisions parallel to the inguinal 
ligament. The extent of the dissection was the inguinal ligament cephalad, the 
adductor longus muscle medially and the sartorius muscle infero-laterally. After 
opening the cribriform fascia, all nodes bearing fatty tissue medial from the femoral 
vein was removed as well. No standard ligation of the saphenous vein nor standard 
sartorius transposition was performed. Thereafter, a high vacuum Redon continuous 
suction drain was placed in the operated groin. Postoperatively, the drain production 
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was measured daily and the groin wounds and drains were inspected by a physician 
during hospital stay and/or by a homecare nurse or general practitioner in discharged 
patients. 
For patients in the volume-controlled drainage group, the drain was removed when 
the production of the drain was < 30 ml/24 h (except for the first 48 h after surgery) 
with a maximum of 28 days. For patients treated by short drainage, the drain was 
removed on the fifth postoperative day (day of operation is defined as day zero) 
irrespective of the drain production. 
The total follow up time was eight weeks after surgery:  two and eight weeks postop-
eratively all patients were seen routinely at the outpatient clinic for a visit and were 
examined by a gynecologic oncologist. All short-term complications were assessed 
and comprised wound infection (purulent exudates and/or positive culture and/or 
erythema, edema and localized pain), primary wound dehiscence (every spontaneous 
disrupted groin wound >2 cm) and the occurrence of a lymphocele (collection of lymph 
fluid in the groin> 5 cm). For a summary of the study protocol see Figure 1.
Statistical analysis
Continuous variables were summarized using the median and range, discrete variables 
were described by frequencies. We performed both intention-to-treat (ITT) and 
per-protocol (PP) analyses to assess the incidence of complications and the differences 
between volume-controlled and short drainage. The ITT analysis was the primary 
analysis. 
To estimate the incidence of wound infection, primary wound dehiscence and 
lymphocele, we used a generalized linear model with a logit link and a binomial 
distribution. In order to quantify the differences between volume-controlled and short 
drainage, risk differences were estimated using this model; and for analysis per groin, 
a random effect was added for patient. In addition, to compare the incidence of ≥1 
complication per patient and per groin between both drainage protocols, we adjusted 
for the following patient and treatment characteristics: diabetes mellitus, active 
smoker, number of lymph nodes removed, IFL and vulva excision on the same day, 
closure technique and ligation of the saphenous vein. Statistical analyses were 
performed using SPSS version 22.0 14. 
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Figure 1  Summary of the MAMBO study protocol 
Abbreviations: IFL = inguinofemoral lymphadenectomy, ml = milliliters, ml/24h = milliliters per 24 hours
Patient eligible for the MAMBO study
Admission/Operation date: 
- Signed informed consent
MAMBO-IA (October 2012 - June 2014)
Drainage policy:
- Volume-controlled drainage (until <30ml/24h,
min. 48h, max. 28 days)
Evaluation after 8 weeks: wound breakdown, 
wound infection and/or lymphocele.
- Every event during these 8 weeks will 
be documented
Patient gets discharged with or 
without drain in situ
If discharge with drain in situ; 
- District nurse notes production
- Removal drain per protocol MAMBO study
Researcher gives the patient:
- Study information
- Informed consent form
MAMBO-IB (March 2015 - December 2016)
Drainage policy:
- Short drainage (until day 5 postoperative)
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RESULTS
We included 141 patients (251 groins) ; 77 patients (139 groins) for volume-controlled 
drainage (MAMBO-IA) and 64 patients (112 groins) for short drainage (MAMBO-IB). 
Table 1 shows that the two groups were similar in terms of patient and treatment char-
acteristics. 
Volume-controlled drainage
In Figure 2 is shown that the median duration of drainage of the groin was 13 days 
(range 2-40 days) and  the median production on the last day of drainage was 25 ml 
(range 0-720 ml). The duration of hospital stay was median five days (range 1-22 days) 
and 57/77 (74%) patients went home with at least one drain in situ.
In 79/139 (57%) groins in the volume-controlled drainage group, the drain was 
removed in deviation of the criteria prescribed in the protocol. In 34/79 (43%) groins, 
drainage was a shorter period than prescribed (removal before the production of <30 
ml/day) and in 39/79 (49%) groins drainage was performed for a longer period 
(removal after the production was < 30 ml/day). In 6/79 (8%) groins, it was unclear 
when the drain was removed. 
Reasons for drainage for a shorter period than prescribed were: in 12 groins wound 
complications (infection or dehiscence), in five groins drain problems (pain, clotted 
drain) and in 13 groins drain fell out spontaneously. In groins that were drained for a 
longer period than prescribed; this was mainly (36/39, 92%)) due to logistic difficulties 
(homecare nurse did not remove the drain, patients waited until their appointment at 
the outpatient clinic and/or doctors/nurses were not sufficiently familiar with the 
research protocol). 
Short drainage
For groins in the short drainage group, the median duration of drainage was five days 
(range 3-24 days) with a median production of 60 ml (range 0-380 ml) on the last day 
of drainage, see Figure 3. The median duration of hospital stay was six days (range 
1-26 days) and 10/64 (16%) patients were discharged with at least one drain in situ. 
The drain was removed in deviation of the protocol in 13/112 (12%) of the groins. Of 
these groins, 8/13 (62%)  were drained longer and 5/13 (38%) were drained shorter 
than five days. Reasons for longer drainage were in two groins high drain production 
on day five, in the other groins the reasons were unknown. Five groins were drained 
shorter than five days; in two groins the drain fell out spontaneously and in one groin 
the drain was removed due to pain. For the other two, the reason for early removal was 
unknown.  
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Figure 2  Duration of drainage in days after volume-controlled drainage
Figure 3 Volume of drained lymph fluid in milliliters on the last day in situ after  
short drainage
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Intention-to-treat analysis
Short-term complications per patient
The estimated incidences of short-term complications after volume-controlled versus 
short drainage are shown in Table 2. The estimated incidence of a lymphocele was 16% 
after volume-controlled drainage versus 60% after short drainage (RD 45% (95% CI 30, 
59),  p<0.001). The estimated incidence of a wound infection was 52% in both drainage 
groups and primary wound dehiscence of 8% after volume-controlled drainage versus 
11% after short drainage (RD 3% (95%CI -7, 13) p=0.534). The adjusted incidence of one 
or more complications (wound infection, primary wound dehiscence or lymphocele) 
was 67% after volume-controlled drainage versus 91% after short drainage (RD 24% 
(95% CI 7, 41), p=0.006). 
After volume-controlled drainage, 36/77 (47%) patients with a complication needed 
treatment such as  antibiotics, incision and drainage, wound exposure, necrotectomy, 
or a combination of these treatments. After short drainage 42/64 (66%) of the patients 
needed any treatment for a complication. In total 21/77 patients (27%) after vol-
ume-controlled drainage needed to be readmitted because of a complication versus 
21/64 (33%) after short drainage. 
Secondary wound healing, as a result of one of the previous described complications 
or the treatment given for a complication, was present in 25/77 (32%) patients after 
volume-controlled drainage versus in 33/64 (52%) after short drainage.
Short-term complications per groin
Table 2 shows the estimated incidences of short-term complications per groin after 
volume-controlled versus short drainage; it shows an estimated incidence of lymphoceles 
in 10% of the groins after volume-controlled drainage compared to 52% after short 
drainage (RD 42% (95% CI 31, 52), p < 0.001). The estimated incidence of a wound 
infection was 40% after volume controlled drainage versus 43% after short drainage 
(RD 3% (95% CI -9, 15, p = 0.650), the incidence of primary wound dehiscence was 
estimated in 5% versus 7% of the groins respectively (RD 2% (95% CI -4, 8), p = 0.565). 
One or more complications (wound infection, primary wound breakdown or lymphocele) 
per groin was estimated, after adjustment, in 46% of the groins after volume-con-
trolled drainage versus 75% after short drainage (RD 29% (95% CI 8, 49), p=0.006). 
Secondary wound healing, as a result of one of the previous described complications 
or the treatment given for a complication, was present and in 42/139 (30%) after vol-
ume-controlled drainage versus 52/112 (46%) after short drainage. After 8 weeks of 
follow up, 110/139 (79%) of the groin wounds were healed in the volume-controlled 
drainage group versus 68/112 (61%) in the short drainage group.   
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Table 2 Estimated incidence of short-term complications after volume-controlled 
versus short drainage; intention-to-treat analysis
Volume-controlled 
drainage
%  (95% CI)
Short drainage
% (95% CI)
Risk difference 
RD (95% CI), p-value
Per patient N = 77 N = 64
Wound infection 52% (41, 63) 52% (39, 64) 0% (-17, 16) p = 0.959
Primary wound 
dehiscence
8% (2, 14) 11% (3, 19) 3% (-7, 13) p = 0.534
Lymphocele 16% (8, 25) 60% (48, 72) 45% (30, 59) p < 0.001
≥1 
complication* 
67% (44, 84) 91% (71, 98) 24% (7, 41) p = 0.006
Per groin N=139 N=112
Wound infection 40% (32, 48) 43% (34, 52) 3% (-9, 15) p = 0.650
Primary wound 
dehiscence
5% (1, 9) 7% (2, 12) 2% (-4, 8) p = 0.565
Lymphocele 10% (5, 15) 52% (43, 61) 42% (31, 52) p < 0.001
≥1 
complication*
46% (9, 88) 75% (24, 97) 29% (8, 49) p = 0.006
Table 3 Estimated incidence of short-term complications after volume-controlled 
versus short drainage; per-protocol-analysis
Volume-controlled 
drainage
%  (95% CI)
Short drainage
% (95% CI)
Risk difference 
RD (95% CI), p-value
Per groin N=52 N=99
Wound infection 32% (19, 45) 45% (36, 55) 13% (-3, 30) p = 0.104
Primary wound 
dehiscence
2% (-2, 6) 7% (2, 12) 5% (-1, 11) p = 0.119
Lymphocele 10% (2, 18) 54% (44, 63) 44% (31, 56) p < 0.001
≥1 
complication* 
30% (2, 88) 71% (11, 98) 41% (16-64) p < 0.001
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Per-protocol analysis
Short-term complications per groin
For groins treated to the study protocol, the estimated incidence of complications is 
shown in Table 3. The estimated incidence of a lymphocele was 10% after volume-
controlled drainage versus 54% after short drainage (RD 44% (95% CI 31, 56), p<0.001). 
In addition, the incidence of wound infection (32% versus 45%) and primary wound 
dehiscence (2% versus 7%) did not significantly differ between the two groups. 
The adjusted incidence of one or more complications was 30% in the volume-controlled 
drained groins versus 71% in the short drained groins (RD 41% (95% CI 16, 64), p<0.001). 
Drainage longer or shorter than the study protocol 
In Figure 4 is shown that the incidence of complications differs between groins drained 
for a longer period or for a shorter period than prescribed by the study protocol.
Figure 4 Incidence of complications per groin displayed by drainage for a longer or 
shorter period than described by the volume-controlled or short drainage 
study protocol
Footnote: * including  wound infection, wound breakdown, lymphocele
Drain removed in 
deviation with the 
protocol
N=79
79/139 (57%)
Drainage for a  
longer period than 
prescribed
N=39
Drainage for a  
shorter period 
than prescribed
N=34
One or more 
complications*
N=14
14/39 (36%)
One or more 
complications*
N=26
26/34 (76%)
Drain removed in 
deviation with the 
protocol
N=13
13/112 (12%)
Drainage for a  
longer period than 
prescribed
N=8
Drainage for a  
shorter period 
than prescribed
N=5
One or more 
complications*
N=3
3/8 (38%)
One or more 
complications*
N=4
4/5 (80%)
MAMBO-IA
Volume-controlled 
drainage
N=139
MAMBO-IB
Short drainage
N=112
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In the volume-controlled drainage study group, 39/79 (49%) of the groins were drained 
for a longer period than the protocol described and 34/79 (43%) groins for a shorter 
period. In the longer drained groins, one or more complications were present in 14/39 
(36%) of the groins; in the shorter drained groins 26/34 (76%). However, in these 
shorter drained groins reasons for early removal was a complication in 12 groins. 
In the short drainage study group 8/13 (62%) groins were drained longer than 5 days 
and 5/13 (38%) were drained shorter. One or more complications were present in 3/8 
(38%) of the longer drained groins versus 4/5 (80%) of the shorter drained groins.  In 
none of the groins which were drained shorter than prescribed a complication was the 
reason for removal.
DISCUSSION
Our study is the first prospective study concerning drain management after IFL in 
vulvar cancer patients. We show that volume-controlled drainage results in a significant 
reduction of complications compared to short drainage; this difference was mainly 
related to less lymphoceles. Moreover, the incidence of postoperative wound infections 
and wound breakdown did not significantly differ between the two groups. Moreover, 
this study showed that both drainage protocols are feasible; however, the volume-
controlled drainage protocol is more difficult to follow. As this study shows the 
advantages of volume-controlled drainage in terms of a significant reduction of 
complications, we propose introducing volume-controlled drainage as a standard 
protocol after IFL.
This study showed that in the volume-controlled treatment group, only 37% of the 
groins were drained according to the study protocol. Therefore, we performed both an 
intention-to-treat and per-protocol analyses. However, the intention-to-treat analysis 
reflects clinical practice.
As shown in Figure 4, the incidence of complications differs between groins drained 
according protocol or for a shorter or for a longer period than prescribed. In the 
volume-controlled drainage study group, the lowest complication rate (one or more 
complications) was after drainage according to the protocol (estimated incidence 
30%) or for a longer period (14/39, 36%); the highest complication rate was in groins 
drained  for a shorter period than prescribed (26/34, 76%).  However, this shorter 
period of drainage does not fully explain the higher complication rate, as one third of 
the drains which were removed earlier than the protocol prescribed were removed 
because of a complication. In conclusion, this study shows that drainage for a longer 
period,  does not seem to harm the patient in terms of complications. However, the 
longer the duration of drainage, the longer the patient experiences discomfort. 
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This study was not designed to define an optimal cut-off level for drain production and 
removal of the drain in which the complication rate  is lowest. However, the median 
production of the drain on the last day in situ after short drainage was 60 ml (see 
Figure 3). As short drainage was associated with complications in 91% of the patients, 
we expect  the optimal cut-off level for removal of the drain to be at least below 60 ml. 
Not much literature has been published on drainage protocols after IFL in vulvar 
cancer. In addition to the indication for vulvar cancer patients, IFL is also commonly 
performed when treating melanoma patients. In these patients, early wound 
complication rates are reported in 50% - 72% of cases 15, 16. As shown in our study and 
reported in the literature, the complication rate in vulvar cancer patients is much 
higher than in melanoma patients. This difference can be partly explained by patient 
characteristics, as patients in our study had a higher median age (10 years) than 
melanoma patients, and several have reported older age as a statistically significant 
risk factor for a complication 15, 16. Additionally, it is likely that the higher the patients 
age, the greater the presence of co-morbidity. As co-morbidity, such as diabetes, 
affects the complication rate, this could also explain the difference in complication 
rates between vulva cancer and melanoma patients.  
Besides, lymphadenectomy is also performed in the axilla. In patients treated for 
breast cancer, the postoperative drain management after axillary lymphadenectomy 
has been studied in more detail. It covers different aspects of drain management after 
axillary lymphadenectomy; the need for suction drainage, the amount of negative 
pressure and the duration of drainage. These studies concluded  that suction drainage 
is mandatory in decreasing lymphocele formation, but that the different amounts of 
pressure applied is of less value 17-20. A trend towards decreased lymphocele formation 
and a decrease in wound healing problems after closed suction drainage was reported 
21-24. Furthermore, several studies and a meta-analysis compared early with late drain 
removal  and concluded that early drain removal was safe, but the incidence of 
lymphoceles tends to be higher and reported no difference in the incidence of wound 
infections 25-31. 
There are differences in  the treatment of axillary lymphoceles and groin lymphoceles. 
In axillary lymphoceles (repeated) percutaneous drainage is performed. As the 
anatomy of the groin and axilla differs, the treatment of groin lymphoceles is more 
complex; this is possible due to more pockets of lymph fluid in the groin. Therefore, it 
is important to prevent formation of a groin lymphocele. As previously described, both 
literature on breast cancer and our study showed less lymphocele formation using 
volume-controlled drainage. 
The past decades, new surgical techniques for IFL were implemented. This resulted in 
a decrease of the incidence of complications. However, even after using the vol-
ume-controlled drainage, the incidence of complications still remains considerable. 
Future research should focus on other factors that may play a role in complications 
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after IFL. Besides postoperative care, modifying the surgical technique might be the 
key factor to decrease the complication rate.
A novel and promising surgical technique is video endoscopic inguinal lymphadenectomy 
(VEIL). A study in penile cancer patients compared the open procedure versus VEIL in 
30 groins (21 patients) and reported complications (skin related events, lymphatic 
complications, hematoma) in 20% of the groins that underwent VEIL versus 70% in 
open procedure groins (p=0.015). The average number of hospitalization days was 
reduced from 6.4 days to 24 h after VEIL (p<0.001) 32. In 21 patients with vulvar cancer 
undergoing VEIL a complication rate (wound necrosis, lymphocele) of only 4.8% is 
reported 33. These results show a much lower complication rate compared to our study 
population. VEIL appears to be a promising technique to decrease the short-term 
morbidity, although there is a need for more data regarding oncological safety of this 
method.
In conclusion, this nationwide prospective study showed that mainly due to the 
reduction in lymphoceles,  volume-controlled drainage of the groin after IFL is feasible 
and is associated with a significant reduction in the incidence of one or more short-term 
complications compared to short drainage. We therefore propose that volume-
controlled drainage after IFL becomes the standard protocol for vulvar cancer patients. 
However; the incidence of complications still remains considerable. To further elucidate 
the emerging and remaining questions future research might focus on surgical techniques 
and/or other postoperative care protocols to define the optimal care for patients with 
an indication for IFL in order to further reduce the short-term complication rate. 
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ABSTRACT
Objective IFL is part of the surgical treatment of different malignancies of the genital 
tract and/or the lower limb including vulvar carcinoma, penile carcinoma and melanoma.
IFL is associated with morbidity in up to 85% of the patients. The aims of this MAMBO-IC 
study (Morbidity And Measurement of the Body) are to study the feasibility of using 
LigaSure for inguinofemoral lymphadenectomy (IFL) and to assess the differences in 
the incidence of short-term complications using LigaSure versus conventional IFL 
randomized within each individual patient.
Methods  In this multicenter randomized controlled trial (RCT), women diagnosed 
with squamous cell carcinoma of the vulva with an indication for bilateral IFL were 
included. It was randomly assigned for which groin the LigaSure was used; the other 
groin was treated with conventional IFL (sharp/diathermia). We estimated the incidence 
of ≥ 1 complication(s) per groin using logistic regression and compared this between 
the two surgical methods, adjusting for possible confounders.
Results We included 40 groins of 20 patients. The estimated incidence of ≥1 complication(s) 
was 29% after LigaSure versus 70% after conventional IFL (risk difference 41% (95% CI 
19-62), p < 0.001). Patients’ reported restriction of daily living activities and maximum 
pain score were equal for both treatment methods. There were no differences in the 
surgeon reported workload scores. 
Conclusions This RCT shows that LigaSure for IFL is feasible and associated with 
significantly less short-term surgical complications compared to conventional IFL. 
Further studies with a larger sample size are needed to validate our findings. 
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INTRODUCTION
Inguinofemoral lymphadenectomy (IFL) is part of the surgical treatment of malignancies 
of the genital tract and/or the lower limb such as vulvar carcinoma, penile carcinoma 
and melanoma. This procedure is associated with surgery related morbidity in up to 
85% of the patients. This morbidity concerns short-term (wound infection, formation 
of lymphoceles, wound breakdown) and long-term morbidity  (lymphedema, cellulitis, 
erysipelas) 1-4. Advanced age and comorbidity including diabetes are risk factors for 
postoperative complications after IFL 3, 5, 6.
We have demonstrated in two consecutive national prospective studies ‘Morbidity 
And Measurement of the Body’ (MAMBO-IA and IB) that volume-controlled drainage of 
the groin resulted in a reduced short-term complication rate when compared to short 
drainage. Nevertheless, complications are still present in 67% of the patients after 
volume-controlled drainage, and 53% of these patients needed to be readmitted to 
the hospital 7.  As a consequence, these complications lead to a significant increase in 
health care costs, which  supports the urgent need for additional effort to reduce surgical 
morbidity.
Adaptations in the surgical approach may play a key role in reducing morbidity associated 
with IFL. Several modifications in the surgical approach have been explored, such as 
separate incisions, unilateral IFL, sparing of saphenous vein, preservation of the fascia 
lata and continuous skin closure, but only a limited reduction of morbidity was 
achieved 8, 9. Last decade, new surgical devices have been developed  including: 
energy-based ultrasonic, bipolar vessel or electrothermal vessel sealing. These 
devices can seal blood and lymph vessels, and may subsequently reduce postoperative 
leakage of lymph fluid which may reduce surgical morbidity. Although these new 
surgical devices are increasingly used in clinical practice in addition to conservative 
surgery (sharp knife dissection, mono- or bipolar electrocautery), comparative studies 
are limited.
In  one randomized controlled trial (RCT) published as a conference abstract, harmonic 
scalpel was compared with clips, electrosurgery or ligatures in IFL. In this study less 
postoperative complications (lymphocele, wound breakdown or infectious 
complications requiring surgery) were reported in the harmonic scalpel group (38%) 
compared to the control group (61%), p=0.059. Unfortunately, this study was 
interrupted after 61 instead of the sample size of 125 patients due to slow accrual and 
therefore underpowered 10. RCTs comparing LigaSure versus conventional axillary 
dissection in breast cancer patients reported significant less intra-operative blood 
loss, reduction in the amount of drained lymph fluid, less days of suction drainage and 
shorter hospitalization in patients treated using LigaSure. No differences were reported 
in the rate of hematomas, reoperations or infections 11-13.
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In the current RCT (MAMBO-IC) we aim to study the feasibility of LigaSure for IFL and 
to assess the  incidence of short-term complications, using LigaSure versus the 
conventional performance of IFL randomized within each individual patient. Moreover 
we will evaluate patients’ and surgeons’ experience. 
METHODS
Patients
We conducted this RCT, the MAMBO-IC study (MAMBO: Morbidity And Measurement 
of the BOdy), in two gynecologic oncology centers:  the Radboud university medical 
center and the University Medical Center Groningen. All patients aged ≥ 18 years with 
vulvar squamous cell carcinoma (SCC) with an indication for bilateral IFL were eligible 
for inclusion. Patients were excluded if they received radiotherapy to the vulva, groins 
and/or pelvis previously, pelvic lymphadenectomy, or if there was an indication for IFL 
with the ‘en bloc’ approach or other histology than SCC. Patients were informed about 
this study and approached to participate during a regular visit at the outpatient clinic. 
Written informed consent was obtained from all included patients before enrollment. 
The study was conducted according to the principles of the Declaration of Helsinki 
(2008) and to the Medical Research Involving Human Subjects Act (Dutch: WMO). 
The study protocol was medical-ethically approved to be conducted by the Medical 
Ethical committee of Arnhem-Nijmegen (NL62326.091.17), and registered in the ISRCTN 
registry (ISRCTN15057626).
Randomization process
Patients were randomized to the intervention (LigaSure™ Small Jaw Open Sealer/
Divider LF1212A (Medtronic)) for either the left or right groin with a 1:1 allocation ratio. 
We used a variable block randomization method, with a block division of 2, 4 using 
Castor EDC. The outcome of randomization was blinded for the patients, doctors, 
nursing staff and caregivers, except for the performing surgeons.
Surgical procedure
All patients underwent a bilateral IFL. The LigaSure devices were partly provided by 
the manufacturer. It was randomly assigned for which groin the LigaSure was used to 
perform this surgical procedure and for the other groin, the conventional method 
(scalpel and/or electrocautery) was used.  Preoperative antibiotic prophylaxis 
consisted of 2000mg Cefazoline and 500 mg Metronidazole intravenously. The IFL was 
a standard procedure as described previously 14. A high vacuum Redon drain (775 
mmHg, 0.9 bar negative pressure) was placed in the groin just before closure. None of 
the surgeons was trained specifically for using LigaSure. IFLs were performed either 
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subsequently by the same surgeon or, to reduce operating time, simultaneously by 
two different surgeons. 
Postoperative care
The groin drain was removed when the production of the drain is <30ml/day with a 
minimum of three days, according to the MAMBO-IA protocol 7. After each surgical 
procedure, the surgeon was requested to complete the online questionnaire regarding 
their experience regarding the surgical procedure containing SURG-TLX 15. In the 
SURG-TLX, surgeons rate six dimensions of workload: mental-, physical- and temporal 
demands, task complexity, situational stress, and distractions, on a 20-point Likert 
scale, anchored between low and high. 
Follow-up
Follow-up for the study was completed eight weeks after surgery. Patients were 
routinely seen at two and eight weeks after surgery by a gynecologic oncologist, both 
groins were examined and any complication was reported. All included patients were 
approached at eight weeks postoperatively by the investigator to complete a telephone 
questionnaire regarding pain and restriction of daily activities. The maximum 
postoperative pain and the restriction of daily activities was scored on a visual 
analogue scale (VAS) between zero (low) and ten (high).
Outcomes
The primary objective was to study the feasibility of LigaSure and to determine the 
incidence of any short term complication i.e.: wound breakdown and/or wound 
infection and/or lymphocele, within eight weeks after IFL after using LigaSure or the 
conventional method. Wound breakdown was defined as every spontaneous disrupted 
groin wound > 2cm, wound infection as purulent exudates and/or positive culture and/
or erythema and lymphocele as the collection of lymph fluid > 5cm. 
The secondary objectives were to determine the differences between the two surgical 
methods in duration of drainage and volume drained, operating time, to evaluate 
patients’ experience regarding postoperative pain and restriction of daily activities, 
and to evaluate the surgeon’s experience of both surgical procedures using a questionnaire.
Statistical analysis
The incidences of wound infection, primary wound dehiscence and lymphocele are 
displayed by frequencies and compared with the McNemar test. To estimate the incidence 
of ≥1 complication per groin, we used a generalized linear model with a logit link and a 
binomial distribution, and a random effect for patient. In order to quantify the differences 
between conservative IFL and Ligasure, risk differences were estimated using this model, 
adjusted for the number of lymph nodes removed per groin. Continuous variables are 
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summarized using the median and range and compared between the two treatments 
using the Wilcoxon Signed-rank test. Discrete variables were described by frequencies. 
Two-sided p-values <0.05 were regarded as statistically significant. Analyses were 
performed using SPSS version 22.0 16.
RESULTS
Twenty patients with 40 groins were included and randomized in this MAMBO-IC 
study; ten patients were allocated to IFL with LigaSure in the left groin and ten patients 
to IFL with LigaSure in the right groin. The IFLs were performed between October 2017 
and October 2018 in either the Radboudumc (N=9) or the University Medical Center 
Groningen (N=11). Patient- and tumor characteristics are shown in Table 1, and did not 
notably differ between the two treatment centers. The indication for bilateral IFL was a 
tumor with a diameter of more than 4 cm in eight (40%) patients, pathologically proven 
lymph node metastases in five patients (25%), a positive SLN in three patients (15%) or 
local recurrent disease (without earlier IFL in primary treatment) in four patients (20%). 
In 17 patients, the IFL was performed concomitantly with vulvar surgery, and in three 
patients there was a positive SLN in the treatment of the current primary carcinoma 
and IFL was performed in a second procedure ranging between 34 and 60 days after 
the SLN procedure. The IFLs were performed by 11 different surgeons without differences
in the applied standardized surgical technique, the number of dissected groins per 
surgeon ranged between one and 11.
Surgical outcomes
The median duration of the IFL was 56 minutes (range 27-105) for groins dissected with 
LigaSure and 57 minutes (range 36-90) for groins dissected conservatively, p=0.570. 
The median number of lymph nodes removed per groin was 9.5 (range 2-18) in groins 
treated with LigaSure versus median 10 (range 5-14) in groins treated by the conservative 
IFL, p=0.692. Operative characteristics are summarized in Table 2.
Postoperative outcomes
The duration of drainage did not differ between LigaSure compared to conservative 
IFL, median 16.5 days (range 5-54) versus median 19.5 days (range 4-34) respectively, 
p=0.727. The median volume drained per day for each treatment group is displayed in 
Figure 1. The total volume drained during the period of drainage was not significantly 
different between groins treated by LigaSure or conservative IFL, median 1037 ml 
(range 200-5030) and median 1533 ml (range 325-6020) respectively, p=0.156. 
Analyzing only groins drained according protocol (N=21), the total drain production 
was significantly lower in the groins treated by LigaSure compared to conservative IFL, 
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median 1180 ml (range 750-2760) and median 1885 ml (range 1430-3340) respectively, 
p=0.043 without a difference in the duration of drainage between the two treatment 
groups, p=0.180.
Table 1 Patient- and tumor characteristics of the study population
Median (range) N (%)
Patient characteristics
Age (years) 75 (53-88)
Body  mass index (kg/m2) 29.3 (22.5-42.0)
Diabetes Mellitus
Yes
No
3 (15)
17 (85)
Smoking
Yes
No 
unknown
3 (15)
13 (65)
4 (20)
Tumor characteristics
Diameter (mm) 37.5 (9-80)
Location tumor
Central
Lateral
19 (90)
2 (10)
Depth of invasion (mm) (1.7-21.0)
Focality
Unifocal
Multifocal
20 (100)
0 (0)
Lymphovascular space 
involvement
Yes
No
unknown
6 (30)
13 (65)
1 (5)
Pathological tumor free margins
Yes
No
19 (95)
1 (5)
Presence of precursor lesion
None
HSIL
LS
dVIN
dVIN and LS
5 (25)
0 (0)
3 (15)
5 (25)
7 (35)
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Table 2 Operative characteristics of the included groins
LigaSure (N=20) Conservative(N=20)
Median 
(range)
N (%) Median 
(range)
N (%)
Duration of procedure (minutes) 56 (27-105) 57 (36-90)
Method of closure
Intracutanous
Stitches and intracutanous
Staples
5 (25)
4 (20)
11 (55)
5 (25)
4 (20)
11 (55)
Previous SLN procedure
Yes
No 
7 (35)
13 (65)
4 (20)
16 (80)
Number of lymph nodes removed  
per groin
9.5 (2-18) 10.0 (5-14)
Number of groins with lymph nodes 
metastases
9 (45) 7 (35)
Figure 1  Volume drained per day by surgical method used for IFL
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Short-term complications
The incidence of a wound infection, primary wound dehiscence and lymphocele per 
groin did not differ between the two surgical treatment methods. The estimated 
incidence of ≥1 complication per groin was 29% (95% CI 13-52) after LigaSure compared 
to 70% (95% CI 47-85) after conservative IFL (RD 41% (95% CI 19-62)), p < 0.001.
See table 3 for an overview of the outcomes.  
One or more complications of the groin occurred in 70% (14/20) of the patients and are 
equally distributed between the two treatment centers. As shown in Figure 2, in six 
patients a bilateral complication was present, and in eight patients an unilateral 
complication. In all patients with a unilateral complication, the groin in which the 
complication occurred was treated by conservative IFL. 
In 6/20 (30%) groins, treatment was necessary following a short-term complication 
after LigaSure. In groins treated with conservative IFL, treatment was given in 11/20 
(55%) of the groins. Eight (8/20; 40%) patients were readmitted because of a 
complication of the groin with a median duration of 7.5 days (range 3-26). Four of these 
patients had a bilateral short-term complication of the groin, and four a unilateral 
complication. Secondary wound healing was reported in four groins of two patients. 
Adjuvant radiotherapy to the groins was given to 11/20 (55%) patients and postponed 
due to groin complications in 2/11 (18%) patients.
Table 3 (Estimated) incidence of short-term complications per groin
Incidence of short-term complications per groin
Conservative
N=20
LigaSure
N=20
p-value
Wound infection 50% 30% p = 0.125
Primary wound 
dehiscence
5% 5% p = 1.0
Lymphocele 25% 20% p = 1.0
Estimated incidence of short-term complications per groin
Conservative LigaSure Risk Difference 
(95% CI)
≥1 complication* 70% (95% CI 47-85) 29% (95% CI 13-52) 41% (95% CI 19-62), 
p < 0.001
*adjusted for number of lymph nodes removed
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Surgeons’ experience
Figure 3 shows the workload scores for each dimension for both surgical methods. 
There were no notable differences in the surgeons’  reported workload scores. Of the 
surgeons performing IFL using LigaSure, 75% had used this device previously. All 
surgeons who performed the conservative IFL would recommend this method to their 
colleagues, versus 15/20 (75%) surgeons who used LigaSure. Reasons for not 
recommending LigaSure to their colleagues were: conservative method is more easy, 
LigaSure is less precise compared to conventional IFL, prefers to use a combination of 
both LigaSure and the conservative method. 
Patients’ experience
Restriction of daily activities and maximum pain score were scored equally by the 
patients for both treatment groups. After LigaSure, the maximum pain score was 
median 3 (range 0-8) and after conventional IFL median 3 (range 0-9), p=0.844. The 
restrictions of daily activities was scored median 0 (range 0-8) after LigaSure versus 
median 0 (range 0-8) after conservative IFL, p=0.655.
Figure 3  Surgeons’ workload score (median) by surgical method used for IFL
Physical demands Temporal demands Task complexity Situational stress Distractions
4
2
0 
Mental demands
6
W
or
kl
oa
d 
sc
or
e
LigaSure
Conservative
533164-L-sub01-bw-Pouwer
Processed on: 24-7-2019 PDF page: 170
170
CHAPTER 8
DISCUSSION
This multicenter RCT is the first study comparing LigaSure and conventional IFL in 
vulvar SCC patients. The use of LigaSure for IFL is feasible and  significantly reduce the 
estimated incidence of  ≥1 complication(s) per groin compared to conventional IFL. 
However, the incidence of a wound infection, primary wound dehiscence and 
lymphocele per groin did not differ between the two surgical treatment methods, 
probably due to lack of power.  The duration of surgery, number of removed lymph 
nodes, duration of drainage and volume drained did not notably differ between the 
two surgical methods. In addition, the patients’ and surgeons’ experience did not 
differ between both treatment methods.
Although RCTs comparing LigaSure versus conventional axillary dissection in breast 
cancer patients reported reduced volume drained, shorter period of drainage and 
reduction of duration of postoperative hospital stay after LigaSure 11-13, this study did 
not confirm these results in vulvar SCC patients. However, in groins drained according 
protocol, the total drain production was significantly lower in the groins treated with 
LigaSure compared to groins treated with conservative IFL, without a difference in the 
duration of drainage. Due to our study design, with both treatments randomized within 
a patient, we were not able to assess the difference in days of hospital stay or 
readmission for the two surgical methods. 
Using LigaSure, the simultaneous sealing and cutting of the vessels and tissue without 
the need of changing instruments might reduce the operating time. In breast cancer 
patients, the use of LigaSure for axillary lymphadenectomy significantly reduced the 
operating time with 15 minutes in a study including 100 women randomized for either 
LigaSure or conventional axillary lymphadenectomy 11. 
In our study, there was no difference in operating time comparing Ligasure versus 
conventional IFL. In contrast, Pellegrino et al. 17 reported, in a study comparing the 
harmonic scalpel to conventional electrosurgery in 42 patients with vulvar cancer, a 
significant reduction of 25 minutes in operating time in favor of the harmonic scalpel. 
Operating time included radical local excision of the tumor combined with uni- or 
bilateral IFL. The reduction of operating time might be partially due to the use of the 
harmonic scalpel for the wide local excision of the vulvar tumor. 
Although the introduction of the SLN procedure has become a big step forward in 
terms of reduced morbidity, IFL will always keep a place in the treatment of vulvar SCC 
patients, eg. in patients with a multifocal tumor and/or a diameter more than four 
centimeters. Therefore, attempts should be made to further reduce postoperative 
morbidity. In previous years, minimally invasive techniques are developed to reduce 
postoperative morbidity of IFL and promising results are published. A systematic 
review including nine retrospective studies and 249 video endoscopic inguinofemoral 
lymphadenectomy (VEIL) procedures reported a complication in 6% of the groins, 
533164-L-sub01-bw-Pouwer
Processed on: 24-7-2019 PDF page: 171
171
LIGASURE COMPARED TO CONVENTIONAL INGUINOFEMORAL LYMPHADENECTOMY
8
including a lymphocele in 3.6%, wound infection in 1.2% and lymphedema in 0.4% of 
the groins 18. Recently, an RCT, randomizing for either VEIL with the limb subcutaneous 
approach (N=8) or with the hypogastric approach (N=17), compared the postoperative 
morbidity to a historical cohort of 21 patients undergoing open IFL showed significantly 
less complications in the groin were reported after VEIL (infection 8% vs 19%, 
lymphocele 8% versus 10%, wound dehiscence or skin necrosis 0% versus 14%) 19. In 
contrast, one study including 12 patients and 22 groins reported the rate of ≥1 
complication after robot-assisted VEIL (VEIL-R): 59% per groin and 75% per patient 20. 
In spite of the small number of patients, these complication rates are even higher 
compared to the rate of ≥1 complication in previously reported studies after open IFL 7, 
21. In addition, none of the mentioned studies included Caucasian women, and neither 
reported data concerning the oncologic safety of this procedure. A large prospective 
trial with adequate follow- up of at least 2 years is needed to determine the oncologic 
safety of VEIL and to determine the postoperative morbidity in  women with vulvar 
SCC. In addition, VEIL is preferably compared to open IFL using either a energy-based 
ultrasonic, bipolar vessel or electrothermal vessel sealing device, as the device used 
might be key to lowering postoperative morbidity.
Based on the results of this study, the use of LigaSure is feasible to perform IFL and the 
surgeons’ workload was equal. However, treatment with LigaSure leads to additional 
costs (about €250/$285 per disposable device) compared to the less costly diathermia 
and/or scalpel. These additional costs are counterbalanced by reduced costs of 
postoperative care, such as treatment of complications and readmissions, as result of 
reduced surgical morbidity after IFL using LigaSure. Future research including a cost-
effectiveness analysis may give the answer if LigaSure is cost-effective in the treatment 
of vulvar SCC patients. 
Besides the obvious limitation of a small number of included patients, the surgical 
procedures in our study were performed by different surgeons. However, this reflects 
daily clinical practice and shows that there is a very short learning curve. Another 
limitation is the follow-up of eight weeks after surgery. Therefore, long-term follow-up 
data is not available to evaluate long-term complications such as lymphedema. 
The strengths of this study are the multicenter design, prospective nature and the 
randomization within a patient. Randomization within  one patient results in the 
reduction of many patient-related potential confounders. In addition, another strength 
is the standardization of both the surgical procedure and postoperative drainage of 
the groin. 
In conclusion, we have demonstrated that LigaSure is feasible for IFL and shows 
promising results in terms of reduced postoperative morbidity compared to 
conservative IFL. Validation in a large cohort is needed  to implement this new 
technique in clinical practice. 
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ABSTRACT
Objective To determine the efficacy of the addition of an ultrasound of the groins in 
routine follow-up of patients with vulvar squamous cell carcinoma (SCC) after a negative 
sentinel lymph node (SLN).
Design Prospective single-center study.
Setting A tertiary expert  oncology center for the treatment of vulvar cancer.
Population All vulvar SCC patients with a negative SLN, treated between 2006 and 2014.
Methods We prospectively collected data of 139 vulvar SCC patients treated with an 
SLN procedure. We analyzed data of 76 patients with a negative SLN. Three-monthly 
follow-up visits consisted of physical examination combined with an ultrasound of 
the groins by a radiologist. 
Main outcome measures The diagnostic value of ultrasound in the follow-up of vulvar 
SCC patients with a negative SLN during the first two years after treatment.
Results During a routine visit, two asymptomatic isolated groin recurrences were detected. 
Both patients were treated by inguinofemoral lymphadenectomy and adjuvant radio-
therapy, and are alive without evidence of disease 39 and 120 months after diagnosis. 
In total, 348 ultrasounds and 29 fine needle aspiration were performed. The sensitivity 
of ultrasound to detect a groin metastasis was 100% (95% CI 16%-100%) and specificity 
92% (95% CI 89%-95%).
Conclusions Routine follow-up including ultrasound of the groin led to early detection 
of asymptomatic isolated groin recurrences. Further research is necessary to determine 
the exact role of ultrasound in the follow-up of vulvar SCC patients with a negative SLN. 
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INTRODUCTION
The sentinel lymph node (SLN) procedure has been integrated as standard care for a 
subgroup of patients with early stage vulvar squamous cell carcinoma (SCC) after the 
publication of the GROINSS-V-I and GOG-173 study 1, 2. If the SLN contains metastatic 
tumor, a inguinofemoral lymphadenectomy (IFL)  is indicated. In patients with a 
negative SLN, close follow-up is advised with the primary aim to identify locoregional 
recurrences as early as possible.
 The largest long term follow-up study of 377 patients with an SLN for primary vulvar 
SCC, showed isolated groin recurrences in 2.3% of the SLN negative patients 3. In 
smaller, mainly retrospective, studies the isolated groin recurrence rate varied between 
zero and 6.6%  4, 5. 
The main purpose of close follow-up in patients with a negative SLN was to detect 
groin recurrence in asymptomatic patients as early as possible to achieve better 
survival, preferably with limited morbidity. As lymph node palpation is difficult to 
interpret for small nodes, especially in people who are overweight, the question rises 
whether an ultrasound of the groins during follow-up has additional value for early 
detection of a groin recurrence.
Until now, there is no literature evaluating the additional value of ultrasound in the 
follow-up of vulvar SCC patients with a negative SLN. The current guidelines for 
follow-up after the SLN procedure in vulvar SCC are based on expert opinions rather 
than evidence. The Dutch guideline and The European Society of Gynaecological 
Oncology (ESGO) recommend follow-up in the first two years, including clinical 
examination of the groins but do not mention routine use of imaging of the groins 6, 7. 
Furthermore, the Royal College of Obstetricians and Gynaecologists (RGOC) states 
that recognition of recurrence as early as possible seems logical because salvage is 
largely dependent on either further excision or radiotherapy. However, there are no 
recommendations on performing an ultrasound or not 8. This implies the need for 
more knowledge with respect to the efficacy of an ultrasound of the groin in the 
follow-up after a negative SLN in vulvar SCC patients. 
The primary aim of this study was to determine the diagnostic value of ultrasound in 
the follow-up of vulvar SCC patients with a negative SLN during the first two years after 
treatment. Furthermore, our secondary aims were to determine: the adherence to the 
follow-up protocol and to estimate the costs of performing ultrasound for the detection 
of a recurrence. 
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METHODS
A prospective study was performed at the Radboud university medical center, which is 
an expert center for the treatment of vulvar cancer. In 2006, with the knowledge of the 
preliminary results of the GROINSS-V-I study (2-3% groin recurrences with poor 
prognosis) combined with the evidence for an ultrasound in the preoperative 
assessment of the lymph node status, we decided to add ultrasound of the groin to 
the routine follow-up of patients with a negative SLN. We prospectively stored data of 
patients treated with a SLN from 2006 until the moment of closure (end of 2016) of the 
GROINSS-V-II study (NCT01500512) in an electronic database.
We selected patients if they met all of the following inclusion criteria: 1) primary 
unifocal macro-invasive vulvar SCC with a diameter of < 4 cm cm and clinically non-
suspicious groin lymph nodes by palpation and without abnormality at ultrasound 
and/or fine needle aspiration cytology (FNAC), 2) SLN treatment between 2006 and 
2014 and 3) unilateral negative SLN after a unilateral procedure or bilateral negative 
SLN after a bilateral procedure. 
Patients were not engaged in the development of our study. The local ethical committee 
of the Radboud university medical centre approved this study (reference number 
2017-3191).  There was no funding for this study.
A unilateral SLN procedure was performed in patients with lateralized tumors (≥1cm 
from midline) and ipsilateral lymph flow on lymphoscintigraphy; in all other patients a 
bilateral SLN procedure was performed. The procedure was performed using the 
combined technique (radioactive tracer and blue dye) to identify the SLNs as described 
previously 9. The removed SLNs were histopathologically examined by an expert 
gynecologic pathologist, including ultrastaging if necessary 1. Patients with a (unilateral) 
positive SLN(s) had an indication for further therapy of both groins. 
Routine follow-up consisted of a three-monthly visit at the outpatient clinic within the 
first two years after the SLN procedure. These visits included  gynecologic examination 
with palpation of the groins by the gynecologist and a routine ultrasound by the 
radiologist. In patients with a unilateral SLN procedure, both groins were examined 
during follow-up. For logistical reasons, either the palpation or the ultrasound was 
performed first.  After the first two years, follow-up is less frequent (twice a year) 
without the performance of a routine ultrasound of the groin.
The ultrasound of the groin was performed by our ultrasound unit at the Department 
of Radiology. This is an expert center with a dedicated team of professionals for the 
performance of ultrasound for different types of cancer. 
Suspicious lymph nodes on ultrasound were characterized by a short-axis diameter 
≥10 mm in oval shaped lymph nodes or ≥8 mm in circular shaped lymph nodes with a 
malignant aspect. Malignant aspects visualized by ultrasound are hilar hypoecho-
genicity, general attenuation, irregularity of the margin or abnormal vascular pattern 
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on Doppler (see Figure 3A-C). If a suspicious lymph node for metastasis was present, 
FNAC was performed in the same session.  
An isolated groin recurrence was defined as a histologically proven metastasis of 
vulvar SCC in a lymph node in the groin, without a simultaneous local recurrence. In all 
patients with an isolated groin recurrence, we reviewed the indication for the SLN 
procedure and the technical aspects of the procedure itself, and an expert pathologist 
reviewed the pathological slides of the SLN(s). 
Cost analysis
In our medical center, the cost of performing an ultrasound by the radiologist applies 
€75.-, independent of inspecting one or both groins. A FNAC costs €329.-, including 
histopathologic examination. 
Statistical analysis
The start of the routine follow-up was defined as the date of the SLN procedure.
All routine and indicated visits during the follow-up period starting at 2.5 months and 
going to 25.5 months after the SLN procedure were included for analyses. Not all visits 
took place exactly at the planned time. In the analysis we assigned the data to the 
nearest targeted visit moment, using a time window of three months; visits occurring 
from 1.5 months before the planned moment of visit till 1.5 months after the planned 
moment of visit, i.e. all results from the period between 4.5 and 7.5 months are analyzed 
as the 6-month visit. Only the result of the first visit, planned at month 3, is based on 
a shorter time window, as data were included from 2.5 months till 4.5 months after the 
SLN procedure. 
The duration of total follow-up was defined as date of the SLN procedure until date of 
last follow-up or death.  
The sensitivity, specificity, positive predictive and negative predictive value of the 
ultrasound and FNAC were calculated, and the Clopper-Pearson exact method was 
used to determine the 95% confidence intervals 10. The test characteristics of palpation 
of the groin was not the aim of this study. A positive ultrasound (the presence of 
suspicious lymph nodes) and a positive FNAC was considered as truly positive if histo-
pathologic examination of the lymph nodes retrieved by IFL showed metastatic 
disease. A negative ultrasound or FNAC was considered as truly negative if there was 
no evidence of metastatic disease in the groin after at least one year of follow-up. 
Analyses were performed with SPSS version 22.0 11. 
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RESULTS
Patient characteristics
As shown in Figure 1, 139 patients underwent an SLN procedure between 2006 and 
2014. We excluded 49 patients because of a unilateral or bilateral positive SLN, two 
patients because definitive histopathologic examination showed basal cell carcinoma, 
and another 12 patients were excluded because they had a multifocal/larger tumor,
a technical inadequate SLN procedure, or were lost to follow-up. In conclusion,
we analyzed data of 76 patients with a negative SLN.
The median age was 67 years (range 37-89) and the median body mass index was 
25.6 kg/m2 (range 16.5 – 36.1). A bilateral SLN procedure was performed in 58 patients; 
a unilateral procedure was performed in 18 patients. The median number of dissected 
nodes was 3 (range 1-7) per patient after a bilateral SLN procedure and 2 (range 1-4) 
after an unilateral procedure. Median total follow-up time was 47 months (range 3-142). 
For patient- and tumor characteristics, see Table 1.
Figure 1  Study flow diagram
Footnote: SLN: sentinel lymph node, N: number of patients
Patients underwent SLN 
N=139
Negative SLN
N=88
Excluded
Positive SLN N=49
Basal cell carcinoma N=2
Inlcuded
N=76
Excluded
Lost-to-follow-up N=7
Inadequate procedure N=1
N=2Multifocal tumor 
Diameter ≥40mm N=2
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Protocol adherence
Based on a schedule of 3-monthly routine visits during 2 years, the planned number of 
routine visits would be 608 (76 x 8). Due to shorter follow-up of patients who died or 
for whom vulvar cancer recurrence was detected, the expected number of planned 
routine visits was 529. In total, 408 (77% of expected) follow-up visits were performed, 
of which 403 were routine and five were interval visits because of complaints. Figure 2 
shows the expected number of visits and the performed number of visits with and 
without an ultrasound per time period after the SLN procedure. 
During the first year, 225/279 (81%) of the expected visits were performed compared 
with 183/250 (73%) in the second year.
The median number of performed follow-up visits was 7 (range 0-8) per patient. Four 
patients did not show up at any follow-up visit for different reasons: one patient had a 
local recurrence within three months after the SLN procedure, two patients chose not 
to participate, and in one patient the reason is unknown.
As shown in Table 2, in 348 of the 408 (85%) visits an ultrasound was performed; 29 
(8%) ultrasounds showed one or more suspicious lymph nodes in the groin(s). As a 
consequence an FNAC was performed of all suspected lymph nodes. In one patient, 
cytologic examination was inconclusive; however, there was no evidence of a groin 
recurrence during a follow-up at 92 months and therefore the FNAC was considered as 
Table 1 Patient- and tumor characteristics
Patient- and tumor characteristics Median (range) N (%)
Age (years) 67 (37-89)
Body mass index (kg/m2) 25.5 (16.5-36.1)
FIGO stage (2009)
- IA
- IB
1 (1)
75 (99)
Localization
- central
- lateral (≥1 cm from midline)
58 (76)
18 (24)
Tumor diameter (mm) 14.5 (1.0-40.0)
Depth of invasion (mm) 3.0 (1.0-13.2)
Grade of differentiation
- I
- II
- III
25 (33)
43 (57)
8 (10)
Number of dissected sentinel nodes per 
patient
- Bilateral procedure
- Unilateral procedure
3 (1-7)
2 (1-4)
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negative.  In two patients, cytologic examination of the FNAC showed a groin recurrence 
(see Isolated groin recurrences). In both patients, an ultrasound was performed during 
a routine follow-up visit and a suspicious lymph node was identified in the groin, and 
a subsequent FNAC was performed. However, in one patient there was a suspected 
lymph node in the groins at palpation. All ultrasound and/or FNAC negative patients 
were followed for at least one additional year and did not show a groin recurrence.
Isolated groin recurrences 
Using ultrasound, isolated groin recurrence of the vulvar SCC was diagnosed in two of 
76 patients (2.6%); both recurrences were diagnosed within eight months after the 
SLN procedure during a routine follow-up visit, see Table 3. Groin recurrence did not 
occur in any of the other patients. recurrence occurred. 
The patient (see Table 3, patient A) was diagnosed with a lateralized tumor (≥ 1 cm 
from midline) on the left side of the vulva, during clinical examination and an ultrasound 
of both groins, there was no suspicious lymph node identified and a unilateral SLN 
procedure was performed; the lymphoscintigram showed ipsilateral lymph flow and 
two SLNs were identified and removed. The SLN procedure was adequate and no 
substandard factors could be identified afterwards. The patient went for a routine 
follow-up visit four months after treatment, she had no complaints and no abnormal 
lymph nodes were palpated by the gynecologist. However, ultrasound showed one 
Figure 2  Protocol adherence
Footnote:*number of expected visits was corrected for the actual follow-up time of each patient by taking 
into consideration the date of death or detection of a vulvar cancer recurrence. 
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suspicious lymph node in the contralateral groin (see Figure 3B) and FNAC was 
performed; cytologic examination showed  SCC. Treatment consisted of bilateral IFL. 
Histopathologic examination showed five lymph nodes in the left side without evidence 
of disease, and eight lymph nodes in the right groin; in one lymph node there was a 
metastasis of the known vulvar SCC, with a diameter of seven millimeters without 
extranodal growth. Cloquet’s node from both the left and right did not contain 
metastatic disease. Adjuvant radiotherapy was given. This patient is alive without 
evidence of disease 120 months after the diagnosis of the groin recurrence.
The patient (See Table 3, patient B) was diagnosed with a midline tumor, without 
suspicious groin lymph nodes by palpation and ultrasound,  and was treated by a 
bilateral SLN procedure; in total three SLNs were identified and removed. The procedure 
was adequate and no substandard factors could be identified afterwards. However, 
eight months later, this patient visited the outpatient clinic for routine follow-up. The 
gynecologist identified a suspicious lymph node in the right groin at palpation and 
subsequently an ultrasound of both groins was performed. This ultrasound showed 
one suspicious lymph node in the right groin (see Figure 3C) and one suspicious lymph 
node in the left groin; a FNAC of both lymph nodes was performed. Cytologic 
Table 2 Summary of results of palpation, ultrasound and FNAC
Time 
after SLN 
procedure 
in months 
Number of 
visits 
Number of 
patients 
with 
suspicious 
groins by 
palpation
Number of 
patients 
in which 
ultrasound 
was 
performed
Number of 
patients 
with 
suspicious 
lymph 
nodes on 
ultrasound
Number of 
patients 
in which 
FNAC was 
performed
Number of 
patients 
with 
positive 
cytology* 
3 53 2a 43 6d 6d 1
6 60 3b 52 4e 4e 1
19 59 3b 51 7e 7e 0
12 53 4c 43 3d 3d 0
15 51 1a 42 2 2 0
18 55 3c 51 4 4 0
21 45 2a 41 2 2 0
24 32 1a 25 1 1 0
Total 408 19 348 29 29 2
Footnote: FNAC: fine needle aspiration cytology, SLN: sentinel lymph node, ain all patients also suspicious 
on ultrasound, b in one patient not suspicious on ultrasound, c in two patients not suspicious on ultrasound, 
din two patients bilateral, e in one patient bilateral, *for more detailed information see Table 3.
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Table 3 Characteristics of patients with an isolated groin recurrence
Patient characteristics Patient  A  Patient B
Age (years) 60 77
BMI (kg/m2) 27.1 23.5
Primary tumor
Tumor localization Lateral, left Midline
FIGO stage IB IB
Tumor diameter (mm) 5 20
Depth of invasion (mm) 4.3 8.0
Grade of differentiation I II
Primary treatment
Procedure adequate after revision Yes Yes 
Dissected SLNs
- Left
- Right
2
-
1
2
Isolated groin recurrence
Groin recurrence Right Right
Time to recurrence (months) 3.8 7.4
Moment of diagnosis Routine visit Routine visit
Complaints No No
Palpable suspicious lymph nodes No Yes, right
Number of lymph node metastases 1 1
Diameter lymph node metastasis (mm) 7 34
Extranodal growth No No
Treatment
Bilateral inguinofemoral lymphadenectomy
- Number of lymph nodes removed right (number of lymph 
nodes with metastatic disease)
- Number of lymph nodes removed left 
(number of lymph nodes with metastatic disease)
9 (1)
6 (0)
17 (1)
11 (0)
Adjuvant radiotherapy Yes Yes 
Survival
Patient status Alive without 
evidence of 
disease (120 
months)
Alive without 
evidence of 
disease (39 
months) 
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examination showed malignant cells fitted with SCC in the right groin, no evidence of 
malignant disease was seen in the cytologic material of the left groin.
Bilateral IFL was performed and histopathologic examination showed 17 lymph nodes 
from the right groin, with one lymph node metastasis measuring 34 millimeters 
without extranodal growth. Examination of the removed tissue of the left  groin showed 
11 lymph nodes, without metastatic disease.  Adjuvant radiotherapy was performed 
and the patient is without evidence of disease 39 months after the groin recurrence.
Test characteristics
Test characteristics of the ultrasound in the follow-up were as follows: the sensitivity 
of ultrasound to detect a groin metastasis was 100% (2/2; 95% CI 16-100) , the 
specificity 92% (319/346; 95% CI 89-95), positive predictive value (PPV) 6.8% (2/29; 
95% CI 0.9-23) and negative predictive value (NPV) 100% (346/346; 95% CI 99-100). 
For paired ultrasound and FNAC (FNAC after a positive ultrasound), the sensitivity was 
100% (2/2;  95% CI 16-100), specificity 100% (27/27; 95% CI 87-100) as well as PPV and 
NPV were 100%  (PPV: 2/2; 95% CI 16-100), NPV: 27/27; 95% CI 87-100). 
Costs
In this study, one isolated nonpalpable groin recurrence was  identified by the routine 
ultrasound of the groin. The other groin recurrence would have been detected by a 
follow-up regimen without a routine ultrasound of the groin, as this recurrence was 
palpable during clinical examination. The detection of the non-palpable asymptomatic 
groin recurrence required 348 ultrasounds (€26 100) and a FNAC in 29 patients 
(€9 541), generating total costs of €35 641. This results in additional costs of €469 
per patient.
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Figure 3  Ultrasound images
A Ultrasound image of a normal lymph node in the groin  
(measurement A: 1.4 mm, B: 4.6 mm)
B Ultrasound image of a metastatic lymph node (patient A): enlarged (diameter  
5.9 mm), focal cortical thicking on the left side and loss of echogenic hilar sinus fat
C Ultrasound image of a metastatic lymph node (patient B): enlarged oval shaped, 
loss of echogenic hilar sinus fat (measurement A: 23.1 mm, B: 14.3 mm)
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DISCUSSION
Main findings
We evaluated the diagnostic value of ultrasound of the groins in the follow-up of 76 
vulvar SCC patients after a negative SLN. Routine ultrasound in the follow-up during 
the first two years resulted in the early diagnosis of one asymptomatic, nonpalpable 
groin recurrence. In our study, 348 ultrasounds and a FNAC in 29 patients were 
necessary to detect this recurrence. The sensitivity of ultrasound to detect a groin 
metastasis was 100% (95% CI 16-100) and specificity 92% (95% CI 89-95). 
Strengths and limitations
Our prospective study is the first determining the efficacy of ultrasound in the follow-up 
of patients after a negative SLN. In addition to obvious limitations such as low number 
of patients and low number of events,  the single center design is a possible drawback. 
Furthermore, the ultrasounds were performed by different radiologists working in our 
specialized ultrasound unit; this may have introduced bias because ultrasound 
examination and interpretation of the ultrasound features as the indication for a 
metastatic lymph node are radiologist dependent. However, this reflects daily clinical 
practice. Furthermore, the cost analyses were performed with the costs of an 
ultrasound and FNAC at our Dutch medical center and therefore may not be reproducible 
for all medical centers in other countries.
Interpretation
A groin recurrence in vulvar SCC patients is nearly always fatal; published literature 
reports a 5-year survival of only 0-10% 12-15. More recently, a 7-year survival of 50% 
was reported in one study 16; this retrospective study described all 30 patients treated 
for a groin recurrence (isolated or a groin and pelvic recurrence). Primary groin treatment 
could be either an IFL or an SLN. Follow-up consisted of clinical examination and,
if needed, imaging of the groin.
The reported seven-year survival of 50% is much higher than the previously reported 
0-10% 12-16. This might imply that patients with a groin recurrence after a negative SLN 
procedure, may have a better prognosis compared with patients with a groin recurrence 
after an IFL. This difference  may be explained by either the (multimodal) treatment 
options available and/or pathogenesis. An isolated groin recurrence after an IFL can be 
caused by in-transit metastases in lymph channels, as all lymph nodes are removed. 
On the contrary, an isolated groin recurrence after an SLN is more likely to be the result 
of remaining (isolated) tumor cells in the lymph nodes, probably with less spread 
outside the lymph node. However,  all patients with a groin recurrence after a negative 
SLN in the GROINSS-V-I study, in whom follow-up only consisted of palpation of the 
groin, died of disease 3. In contrast, in our study both patients with a groin recurrence 
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are still alive. Therefore, early detection and resection of a groin recurrence, for example 
by routine ultrasound may be of  importance for improved survival. 
In penile SCC patients, the effect of early versus late resection of lymph node metastases 
was evaluated 17. This study retrospectively selected 40 patients with clinically node 
negative groin lymph node metastases treated with lymphadenectomy. The first 20 
patients were treated with a ‘wait and see’ policy  and strict follow-up; when the lymph 
node(s) became clinically apparent  and metastases were cytologically proven, lymph-
adenectomy. The other 20 patients were treated using the SLN procedure, and if a 
positive SLN was present, an additional lymphadenectomy. The disease specific 3-year 
survival of the first group was 35% versus 84% for the second group (p = 0.0017). These 
results underline the importance of early diagnosis and resection of groin lymph node 
metastases.Besides, the SLN procedure is also common practice in breast cancer 
patients. In these patients, the axillary recurrence rate after a negative SLN is only 0.3% 
18. This is much lower compared with vulvar SCC and might be explained by differences 
in treatment; breast cancer patients more often receive (neo)adjuvant chemotherapy 
after a negative SLN. Furthermore, Leikola et al. concluded that, due to the low incidence 
of axillary recurrence, routine ultrasound of the axilla after a negative SLN was unlikely 
to be cost-effective19. We diagnosed two isolated groin recurrences within eight months 
after the SLN procedure; one might question if the lymph node metastases have been 
missed in preoperative workup and/or the SLN was false negative. In depth analyses of 
the indication for this SLN procedure, the pre-operative workup and the procedure itself, 
revealed no substandard factors. Therefore, these isolated groin recurrences may be the 
result of a false negative SLN, in which (isolated) tumor cells have not been identified.
In our study, both patients with a groin recurrence were asymptomatic, and remarkably, 
both patients are still alive without evidence of disease. Since the number of patients 
with a groin recurrence in our study was small, we were not able to calculate quali-
ty-adjusted life years (QALY) and perform a cost-effectiveness analysis. However, the 
ultrasound in patient A detected a nonpalpable groin recurrence, and this patient is 
still alive ten years after diagnosis. The costs for the ultrasounds and subsequent 
FNACs were €35 641. Given the fact that patient A survived at least ten years after 
diagnosis of the groin recurrence, the accepted threshold (in the Netherlands) of 
€50,000 per QALY is by far not reached.
To minimize the possible burden for the patient of a false positive ultrasound and the 
subsequent ‘unnecessary’ FNAC, ultrasound features that most accurately identify 
groin lymph node metastasis should be identified. In patients with breast cancer, 
ultrasound of the lymph nodes in the axilla to identify metastatic lymph nodes is 
frequently performed. In these patients, cortical thickness (with a 3 mm cut-off)  is 
shown to be the most reliable ultrasound feature predicting a lymph node metastasis 
20-22. This characteristic is not routinely used in the evaluation of groin lymph nodes in 
patients with vulvar cancer but might be an  option. 
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Future follow-up schedules should be personalized and risk-based;  this can be based 
on body mass index, as this patient-related factor can negatively influence the detection 
of a (small) groin recurrence by palpation. More research is needed to identify patients 
at high risk for a groin recurrence to offer a personalized risk-based follow-up. 
The best way to evaluate the value of using ultrasound in terms of better survival is a 
randomized controlled trial comparing a follow-up protocol with and without routine 
ultrasound. However, such a trial is not realistic given the low incidence of vulvar SCC 
on the one hand, and the limited number of groin recurrences on the other. The most 
suitable design is a prospective multicenter phase II study. Furthermore, with current 
concerns over rising healthcare costs, further evaluation is needed to determine the 
most cost-effective evidence-based follow-up schedule for patients with a negative SLN. 
Conclusion
The performance of a routine ultrasound in the follow-up of 76 vulvar SCC patients 
with negative SLNs resulted in the early diagnosis of one nonpalpable groin recurrence, 
this patient is still alive without evidence of disease ten years after diagnosis. In our 
study, 348 ultrasounds and 29 FNACs were performed to detect this recurrence. In our 
view, this is counterbalanced by the earliest possible detection of groin recurrences 
leading to the best possible survival for the individual patient. 
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IMPROVING LOCAL TREATMENT
There are indications for a different biological behavior of human papilloma virus 
(HPV) related and non HPV-related vulvar squamous cell carcinoma (SCC); HPV-related 
carcinomas are smaller with less invasion depth, less frequently associated with groin 
lymph node metastases and comes with a better prognosis compared to non-HPV 
related carcinomas 1, 2. Currently, there is no difference in treatment for both disease 
entities. The pathogenesis for the HPV-related vulvar SCC resembles the oncogenesis 
of the premalignancy cervical intraepithelial neoplasia (CIN) into cervical cancer.
In HPV-related vulvar SCC, high grade squamous intraepithelial lesion (HSIL) is the 
precursor, which has a causal relationship with HPV in nearly 100% of the lesions. 
Among HPV-related vulvar SCC and HSIL, HPV 16 is the predominant type 3. Substantial 
number of these lesions may be avoided by prophylactic vaccination against HPV and 
might decrease the incidence of HPV-related vulvar SCC in the future. In contrast, 
prophylactic vaccination will not affect the incidence of non HPV-related vulvar SCC, 
which are the majority of all vulvar SCCs. For the future, the main challenge is to 
understand pathogenesis of non-HPV related vulvar SCC.
DVIN is the precursor of non human papilloma virus related vulvar SCC
Non HPV-related vulvar SCC mainly arises in a background of the chronic inflammatory 
vulvar skin disease lichen sclerosus (LS) and/or differentiated vulvar intraepithelial 
neoplasia (dVIN). Because of the rarity of dVIN outside the setting of invasive vulvar 
SCC, the question raised whether dVIN should be considered as a true precursor lesion 4. 
In Chapter 2 we provide genetic evidence that vulvar SCC originate from single precursor 
cells of LS and/or dVIN in which a subset of the genetic alterations detected in the 
carcinoma, possibly driving premalignant events, were already present in the precursor 
lesion. We identified copy number alterations in all vulvar SCCs, and in one patient 
three copy number alterations were shared between the vulvar SCC and the paired 
dVIN lesion. Besides, we identified identical TP53 mutations in five vulvar SCCs and the 
paired dVIN lesion and in one patient also in the paired LS lesion. This genetic evidence 
for dVIN and/or LS as precursor lesion for vulvar SCC is supported by a recent study 
which showed shared somatic mutations in TP53, NOTCH1 and HRAS between dVIN,
LS and vulvar SCC 5. 
Given the genetic evidence that dVIN is a precursor lesion of vulvar SCC, it is important 
to recognize dVIN by the clinician and the pathologist at an early phase. However,
dVIN is a difficult diagnosis, both clinically and histopathologically. This contributes 
to a considerable underdiagnosis of (solitary) dVIN lesions; a study showed that 42% 
of the biopsies diagnosed as LS taken from patients who progressed to vulvar SCC, 
were classified as dVIN after histopathologic review by an expert gynecopathologist 6. 
Attempts were made to improve the histopathologic recognition of dVIN lesions by 
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formulating diagnostic criteria to identify dVIN. Van den Einden et al. 7 formulated 
guidelines consisting of histopathologic characteristics of dVIN, and showed that 
agreement between pathologists slightly increased after studying these guidelines, 
especially among gynecopathologists. 
In contrast to the high malignant potential of dVIN of around 33% 8, patients with LS 
have a relatively lower lifetime risk for vulvar SCC of around 4-7% 9, 10. It is generally 
accepted that all patients with LS may have a life-long indication for yearly follow-up 
to early detect dVIN and/or vulvar SCC. A deeper understanding of the carcinogenesis 
of non HPV-related vulvar SCC might lead to a better identification of a specific 
subgroup of patients with LS at high-risk for progression to vulvar SCC, contributing to 
more personalized care.
Surgical margins
The recommended surgical tumor-free margin distance varies between different 
guidelines, ranging between one and two centimeters 11-14. Tissue shrinkage after 
excision in cervical and head and neck carcinoma is reported to be around 10-15%, 
due to formalin fixation and/or intrinsic tissue properties 15, 16. Worldwide a pathologic 
tumor free margin of ≥8 mm has been advocated as safe to minimize the risk for local 
recurrence. However, surgery to reach this margin can be mutilating, especially when 
the tumor is located close to important midline structures such as the clitoris, urethra 
and anus.  As a consequence, smaller margins might result in less treatment related 
morbidity. The pathologic tumor margin distance with a cut-off value of 8 mm has 
frequently been challenged as a prognostic factor and is an increasing topic of debate. 
In Chapter 4 and 5 we show that patients treated for primary vulvar SCC have an 
ongoing risk for local recurrent disease, with a local recurrence rate as high as 43% 
within 10 years after treatment. The local recurrence rate was not associated with a 
pathologic tumor free margin of less than 8, 5 or 3 mm, but with dVIN in the pathological 
margin. In our cohort, in which a surgical margin distance of >10 mm was pursued, 
approximately 7% of the patients had a tumor positive margin and 8% a tumor free 
margin between 0 and 3 mm at primary excision. We recommend an intended surgical 
tumor free margin of 10 mm, but not to excise unnecessary tissue close to important 
midline structures such as the clitoris (see flowchart Figure 1). The results of our study 
should lead to implementation of a pathologic tumor free margin distance of ≥3 mm.  
Ideally, a prospective randomized controlled trial comparing the differences in local 
recurrence rates between patients with a tumor free margin of < 8 mm with follow-up 
versus adjuvant therapy can provide the highest level of evidence regarding the 
question of whether a tumor fee margin of < 8 mm leads to a higher local recurrence 
rate. Based on the current evidence, it is not ethical in our opinion to expose patients 
with a tumor free margin between 3 and 8 mm to potential harmful adjuvant therapy 
such as re-excision and/or radiotherapy. 
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Some previous studies reported more local recurrences in patients with a pathologic 
tumor free margin distance < 8 mm compared to a wider margin. In our study, the local 
recurrence rate was not associated with a pathologic tumor free margin of less than 8 
mm. A possible explanation for this contradictory finding might be the fact that in 
patients with a tumor free margin ≥ 8 mm the precursor lesion is more often excised 
with a clear margin. However, none of these studies reported data regarding the 
presence of a precursor lesion in the surgical margin. We showed in Chapter 5 that the 
presence of dVIN or dVIN in combination with LS in the margin resulted in a significantly 
higher local recurrence rate compared to patients without any precursor lesion in the 
margin. In our study, the presence of dVIN with or without LS was equally distributed 
between the groups of patients with a pathological margin < 8 mm versus ≥ 8 mm. 
Local recurrences occur in 43% of the patients within ten years after treatment and 
have a negative impact on the prognosis 17. A local recurrence can develop from either 
remaining tumor cells called a ‘true’ recurrence, or a ‘de novo’ tumor from a precursor 
lesion that was also the source of the primary tumor. The second can be explained by 
the concept of ‘field cancerization’, as first introduced by Slaughter et al. 18 in head and 
neck SCC: these genetically altered fields surround the tumor and can have a diameter 
of over seven centimeters 19. A retrospective study including 13 patients with local 
recurrent head and neck SCC shows that in 5 cases (39%) a precursor lesion was 
absent and the primary and recurrent SCC had genetic similarity, providing evidence 
that residual cancer cells were the origin of recurrence. For the remaining eight cases 
(61%) a genetically related field was detected, and for five of these cases, evidence 
was found that both the primary and recurrent carcinoma originated from this field 20. 
In addition, we showed a clonal relationship between vulvar SCC and the precursor 
lesions dVIN and LS in Chapter 2. In contrast to dVIN which are solitary lesions, LS is a 
field with large dimensions as it may affect the skin of the whole vulva.
The fact that the local recurrence rate is still 30% in patients without a precursor lesion 
in the margin might be explained by a premalignant field outside the margins, or early 
malignant changes in the margin not visible by histopathologic examination. Knowledge 
on molecular markers representing early malignant changes in the histopathologically 
normal epithelium might be helpful to identify the presence of such a cancerized field. 
In addition, molecular techniques might be an option for a more accurate risk 
assessment of these fields, to select patients with a high risk field for progression to a 
‘de novo’ tumor. A drawback of assessing the margins to identify the presence of a 
cancerized field is the fact that the borders of a surgical excision specimen are large 
and not all surgical margins are included in the tissue blocks for histopathological 
examination. In addition, there might be a difference in the lateral and the basal 
resection margins in relation to the presence of a cancerized field. There is no literature 
concerning this. However, logically the lateral margins are more likely to contain a 
precursor lesion or the cancerized field rather than the basal margin. 
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An important clinical implication of the concept of field cancerization is that the 
cancerized field often remains after wide local excision of the primary tumor, and the 
risk for a ‘de novo’ tumor is relatively high for these patients. This hypothesis is 
supported by the higher local recurrence rate after wide local excision compared to 
radical vulvectomy, as summarized in Chapter 3. 
LS, itself a very itchy condition, contributes to a vicious cycle of itching and scratching 
which may lead to superimposed lichens simplex, squamous cell hyperplasia and 
ultimately vulvar SCC; the itch-scratch hypothesis 21. This hypothesis is supported by 
a recent prospective cohort study including 507 women with histologically proved LS, 
with the aim to evaluate the effect of preventive treatment with topical corticosteroid 
on the disease symptoms and the risk for dVIN and/or vulvar SCC 22. In patients 
compliant to the prescribed topical corticosteroid treatment, there were less LS-related 
symptoms (itching, pain and dyspareunia) and less progression of adhesion or 
scarring, and a significantly lower incidence of dVIN and/or vulvar SCC compared to 
non-compliant patients.  
In conclusion, treatment with topical corticosteroids in patients with LS may reduce 
the risk for developing vulvar carcinoma. Treatment of the cancerized field might reduce the 
risk of progression towards a ‘de novo’ tumor. However, surgery is not a real option 
because the large dimensions, in combination with the fact that it might not be clinically 
visible. Topical application might be an option and can be applied to the whole field. 
IMPROVING GROIN TREATMENT
Determination of the inguinofemoral lymph node status by inguinofemoral lymph-
adenectomy (IFL) plays an important role in the treatment of vulvar SCC. This procedure 
is finally indicated in around half of the patients as part of treatment for primary 
(multifocal disease or tumor > 4 cm) or local recurrent vulvar SCC (if IFL was no part
of primary treatment). Unfortunately, IFL has significant short- and long-term 
complications, which are reported in up to 85% of the patients 23-25. In Chapter 7,
we show that volume-controlled drainage resulted in significantly less complications 
compared to short drainage of the groin, and should be considered as standard of 
care. However, morbidity remains high and therefore new treatment strategies to 
replace IFL with less treatment-related morbidity but the same effectiveness and 
safety will be a big step forward for vulvar SCC patients. We will discuss how a reduction of 
the number IFLs can be achieved, taking in account accurate prediction of the presence 
of inguinofemoral lymph node metastases and new treatment strategies to replace 
IFL. In the second part, we will discuss how morbidity associated with IFL might be 
further reduced.
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Prediction of inguinofemoral lymph node metastases
A reduction of the number of patients with an indication for groin surgery can be 
achieved by adequate prediction of the presence of lymph node metastases. Around 
70% of the patients undergoing a SLN procedure has no lymph node metastases 26. 
These patients will not benefit from the SLN procedure in terms of improved survival 
and do not have the benefits of reduced morbidity of the SLN anymore at time of local 
recurrence. On the other hand, not detecting a groin lymph node metastasis results in 
a very poor survival. Ideally, there is a non-invasive test which can safely exclude 
lymph node metastases with a high negative predictive value. 
Until now, the depth of invasion is the only predictive histopathological factor in the 
staging and for the presence of lymph node metastases; patients with vulvar SCC 
with a depth of invasion of ≤1 mm (microinvasive growth) have a negligible risk for 
inguinofemoral lymph node metastases of less than 1%, and are therefore excluded 
from groin surgery. The depth of invasion is measured as recommended by the FIGO: 
measured from the epithelial-stromal junction of the most superficial adjacent dermal 
papillae to the deepest point of invasion. However, in  many carcinomas such as 
cervical cancer, the depth of invasion is measured from the nearest dysplastic crypt or 
surface epithelium 27, because tumor cells will originate from the nearest rete ridges 
instead of the most superficial dysplastic epithelium. In vulvar SCC, this alternative 
measurement method was recently introduced and studied by Van den Einden et al. 28. 
They showed that the alternative method to measure the depth of invasion might 
provide a better reflection of the prognosis. In addition, it results in microinvasive 
instead of macroinvasive growth in 19% of the patients, in turn resulting in a lower 
number of patients with an indication for groin surgery 28. However, in one patient with 
a carcinoma assessed as microinvasive by the alternative method, there was a micro-
metastasis present in the groin. To determine the exact prognostic value of the depth 
of invasion classified by the alternative measurement method, further studies with a 
higher number of patients are needed in which the depth of invasion is measured 
using both methods. Such a study can give the answer of whether the alternative 
method gives a better reflection of the biological behavior of the carcinoma, in terms 
of presence or absence of lymph node metastases. Besides, the optimal cutoff for 
determining a group of patients with a negligible risk for lymph node metastases 
should be defined for the alternative method, as this might differ from the cut-off of 
1 mm for the conservative method. 
As the depth of invasion guides the need for groin surgery, reproducibility of these 
measurements is important.  We showed in Chapter 3 that there was similar agreement 
in classifying the depth of invasion for both measurement methods. Between 
pathologists, there was slightly higher overall agreement using the alternative method. 
In addition, the ease of use was scored similar for both methods by the pathologists. 
This implies that the alternative method is suitable for pathologists to measure and 
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classify the depth of invasion in vulvar SCC. However, the question whether this 
alternative method reflects the prognosis should be answered first.
Besides the depth of invasion no other histopathologic parameters are known to 
define such a low risk group for inguinofemoral lymph node metastases in patients 
with vulvar SCC that inguinofemoral lymph node staging can be safely omitted. Better 
understanding of the driving force behind tumor growth by molecular and/or genetic 
analyses might lead towards better prediction of the presence of inguinofemoral 
lymph node metastases.
Replace IFL by new treatment strategies
Alternative treatment regimens instead of IFL for patients with a positive SLN are 
currently studied. The GROINSS-VII study (NCT01500512) aims to a assess the safety 
of replacing IFL by radiotherapy in patients with a micrometastasis (<2 mm) in the 
sentinel lymph node. Inclusions are completed and results are expected. The GROINSS 
study group will continue to study the safety of chemoradiation for macrometastases
(>2 mm) in the SLN. 
Nowadays, the SLN technique is implemented for a selected group of patients with 
primary vulvar SCC. There will be a substantial advantage in terms of reduced morbidity 
if the SLN can also be performed in patients with local recurrent disease, since a high 
number of patients will develop local recurrent disease. The repeat SLN procedure for 
vulvar SCC patients with local recurrent disease is technically feasible, but the accuracy 
of this procedure has not been investigated in vulvar SCC yet 29. A meta-analysis 
including breast cancer patients showed that in patients with local recurrent disease a 
repeat SLN procedure is safe if the SLN is negative at time of primary carcinoma 30. To 
investigate the safety of repeat SLN procedure in recurrent vulvar SCC, the incidence of 
inguinofemoral lymph node metastases at time of local recurrence should be 
determined first. These data are needed to optimally counsel patients and should 
serve as a basis for a prospective multicenter study to answer the question of whether 
a repeat SLN in patients with local recurrent vulvar SCC is a safe alternative for IFL.
Reducing morbidity associated with IFL
In previous years, minimally invasive techniques are developed to reduce postoperative 
morbidity of inguinofemoral lymphadenectomy and promising results are published. 
However, one study reported complication rates after minimally invasive IFL 31 which 
are even higher compared to the complication rate in our studies after open IFL.
In addition, the oncologic safety of this new approach is unclear. A prospective study 
with a minimum of two years follow-up, can answer the question regarding the oncologic 
safety of minimally invasive IFL.  
In laparoscopic surgery electrothermal bipolar vessel sealing devices are used, in 
contrast to sharp knife dissection and/or bipolar diathermy in open IFL. One might 
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question if the minimally invasive procedure itself or the device used during this 
procedure are key for reducing morbidity. To investigate the role of the sealing device 
LigaSure in reducing the postoperative morbidity, we designed the prospective 
MAMBO-IC study (Chapter 8)  to assess the differences in the incidence of short-term 
complications (wound infection, wound breakdown and lymphocele) using LigaSure 
versus the conventional performance of IFL randomized within each individual patient. 
We included  20 patients and showed that LigaSure for IFL is feasible and results in 
significantly lower estimated incidence of ≥1 complication per groin compared to 
conservative IFL. Patients’ reported restriction of daily living activities and maximum 
pain score were scored equal for both treatment methods. There were no notable 
differences in the surgeons’ reported workload scores. Future research, preferably a 
nationwide randomized controlled trial in a large cohort, comparing LigaSure versus 
conservative IFL is needed to validate our findings regarding the difference in post-
operative morbidity between both surgical methods.
IMPROVING FOLLOW-UP
In patients treated for vulvar SCC, routine follow-up is performed with the primary aim 
to identify locoregional recurrences as early as possible. In this thesis, we focused on 
both local and groin recurrences. 
In Chapter 4 and 5, we show that patients have an ongoing risk for local recurrence.
In these studies we were not able to identify a subgroup of patients not at risk for local 
recurrence of vulvar SCC, but patients with dVIN in the surgical margin are at higher 
risk for local recurrent disease. Furthermore, the aim of routine follow-up should also 
be to detect a new precursor lesion as early as possible, to prevent progression to 
vulvar SCC. There is a lack of knowledge on the incidence and time to a new precursor 
lesion after the diagnosis and treatment of vulvar SCC. Future research should identify 
these important questions and thereafter, the follow-up regimen may be further 
individualized.  In addition, identification of high-risk patients may further improve 
patient empowerment, patient education and may also contribute to individualized 
follow-up schedules. The (early) detection of a local recurrence might be improved by 
self-examination by the patient and/or her partner. 
Besides detecting local disease, follow-up is performed to detect regional recurrent 
disease. The main purpose of close follow up in patients with a negative SLN is to 
detect groin recurrence in asymptomatic patients as early as possible to achieve 
better survival, preferably with limited morbidity. In Chapter 9 we showed that routine 
follow-up including an ultrasound of the groin led to early detection of two 
asymptomatic isolated groin recurrences, of which one was non-palpable. 
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One might question whether this close follow-up is indicated as a groin recurrence is 
considered as palliative. However, in our study both patients are still alive 39 and 120 
months after diagnosis, and this finding is supported by Frey et al., reporting a 7-years 
survival of 50% in patients with groin recurrence after a SLN or IFL. This supports the 
hypothesis that patients with a groin recurrence after a SLN might have a better 
prognosis compared to a groin recurrence after IFL. Future research should focus on 
in-depth analyses and survival of patients with groin recurrence after a SLN. 
FUTURE PERSPECTIVES
Based on the immune microenvironment and/or somatic mutations, we might identify 
different etiologic pathways within the group of non HPV-related vulvar SCC. Identifying 
different subtypes has only additional clinical value if it reflects different tumor 
behavior and/or facilitates tumor-based treatment strategies.   
A many studied immunosuppressive mechanism of cancer cells is by programmed cell 
death protein 1 (PD-1) and its ligand PD-L1 . There are few publications regarding PD-L1 
expression in vulvar SCC and its precursor lesions. A study including 103 vulvar SCCs 
reported that PD-L1 is expressed in 10% and was more often present in non-HPV 
related vulvar SCC. In addition, PD-L1 expression was associated with significantly 
lower recurrence-free survival, both in univariate and multivariate Cox regression 
analyses 32. Another study showed PD-L1 expression in 32% (27/84) of the vulvar SCC 
and significantly more often observed in p16-negative carcinomas 33. PD-L1 expression 
was rare among HSIL (n=13) and dVIN (n=2) lesions; one HSIL lesion adjacent to a 
HPV-related carcinoma showed PD-L1 expression 34. As PD-L1 is predominantly 
expressed in non HPV-related vulvar SCC and associated with a worse prognosis, 
PD-L1 blockade might improve prognosis in this subset of patients. There are no 
studies about therapeutic use of PD/PD-L1 blockade in vulvar SCC. Future research 
should identify the tumor immune microenvironment including PD-L1 expression in 
order to distinguish different tumor subtypes and to explore opportunities for immu-
notherapeutic treatment options for vulvar SCC. 
Recently, based on the assessment of molecular alterations a third etiologic pathway 
of vulvar SCC was suggested. Within the group of non HPV-related vulvar SCC, there 
were two different subtypes identified based on somatic mutations: in around 
two-third a TP53 mutation was present and in one-third no TP53 mutation was detected 
but a high frequency of NOTCH1 and HRAS mutations 5. In this study, targeted next 
generation sequencing (NGS) was performed of 36 vulvar SCC and revealed somatic 
mutations in 89% of the carcinomas and was equally distributed between HPV-related 
and non HPV-related vulvar SCC. TP53 mutations more frequently in non HPV-related 
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compared to HPV-related vulvar SCC, 28% and 65% respectively. Besides TP53, 
NOTCH1 and HRAS were frequently detected as mutation, in 33% and 28% of the 
carcinomas respectively. A NOTCH1 mutation was only detected in non HPV-related 
vulvar SCC, and co-occurred with TP53 mutations but was also identified in carcinomas 
that did not carry a TP53 mutation. Zieba et al. 35 performed NGS including hotspot 
mutations in 50 genes on 81 vulvar SCC, of which 64% was HPV-related and 36% non 
HPV-related vulvar SCC. A pathogenic mutation was present in 61% of the carcinomas. 
The most frequently identified mutations were TP53 and CDKN2A, with frequencies 
equally distributed between HPV-related and non HPV-related vulvar SCC. 
Driver mutations enable outgrowth of cancerous cell populations. It can be challenging 
to differentiate cancer-driving mutations from passenger mutations 36, 37. In addition, 
cancer genotype is increasingly recognized as only part of the puzzle, and other 
aspects such as the tumor microenvironment might be equally important in determining 
behavior of tumor cells. Combined interpretation of cancer genotype and phenotype, 
including histology, might better characterize an individual tumor. 
The signaling pathway activation status is determined not only by errors in the cancer 
cell (epi-) genome, but to a large extent by interactions between the cancer cell and its 
microenvironment 38. Currently, ten to twelve cellular signal transduction pathways 
are known, relatively independent of the cancer cell type of origin. Knowledge of these 
cellular signal pathways on cancer cell behavior is rapidly growing, but it has not been 
evaluated in vulvar SCC yet. 
Based on understanding of the driving force behind tumor growth it might be possible 
to predict tumor behavior, especially predicting spread to the inguinofemoral lymph 
nodes. In addition, it might identify new targets for personalized and tumor based 
treatment strategies.
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SUMMARY
In this thesis, we describe our studies with the aim to optimize treatment and follow-up 
of patients with vulvar squamous cell carcinoma (SCC). Chapter 1 introduces the 
pathogenesis, treatment and follow-up of vulvar SCC and outlines the research aims of 
this thesis.
Differentiated vulvar intraepithelial neoplasia (dVIN) is mostly found in a background 
of lichen sclerosus (LS) and can give rise to non HPV-related vulvar SCC, but genetic 
evidence is currently still lacking. In Chapter 2, we aimed to study the genetic 
relationship between LS, dVIN and vulvar SCC. We compared genomic abnormalities 
of vulvar SCC and patient-matched dVIN and LS lesions of twelve patients using 
genome-wide copy number profiling and targeted sequencing of TP53. High-resolution 
genome-wide copy number analysis was performed on six vulvar SCCs and three 
paired dVIN samples, and identified copy number alterations in all vulvar SCCs. In one 
patient, three copy number alterations were shared between the vulvar SCC and the 
dVIN lesion. Subsequent targeted sequencing of TP53 in eight vulvar SCC samples 
identified mutations in five vulvar SCCs. All these five mutations were traced back in 
the paired dVIN lesions and in one paired LS lesion with frequencies of the mutation 
ranged from 3 to 19%, suggesting that mosaic subpopulations of cells in the LS and 
dVIN lesions gave rise to the vulvar SCC. In conclusion, our data provide genetic 
evidence for a clonal relationship between the precursor lesions LS, dVIN and non 
HPV-related vulvar SCC. 
The depth of invasion is an important prognostic factor for patients with vulvar SCC 
and guides the need for groin surgery. In patients with a microinvasive SCC (depth of 
invasion ≤1 mm) treatment consists of wide local excision of the vulvar tumor only, 
while in patients with a macroinvasive SCC (depth of invasion >1 mm) a sentinel lymph 
node procedure and/or a full inguinofemoral lymphadenectomy is indicated. There are 
several methods described to measure the depth of invasion. The conventional 
standard method for vulvar SCC is recommended by the International Federation of 
Gynecology and Obstetrics (FIGO). This methods measures the distance between the 
epithelial-stromal junction of the most superficial adjacent dermal papillae and the 
deepest point of invasion. In carcinomas from other sites such as cervical cancer, the 
depth of invasion is measured in a different way. The depth of invasion is measured 
from the basement membrane of the deepest adjacent tumor-free rete ridge to the 
deepest point of invasion. This alternative method might give a better reflection of the 
prognosis. As the depth of invasion guides treatment, a high interobserver agreement 
in classifying the depth of invasion is crucial. In Chapter 3, we aimed to study the 
interobserver agreement for classifying the depth of invasion into ≤ 1 mm or > 1 mm for 
both measurement methods, to identify pitfalls and to formulate recommendations. 
Fifty slides with vulvar SCC with a depth of invasion around 1 mm were assessed by ten 
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pathologists and four pathologists in training. The depth of invasion was measured by 
each participant using both methods. We showed moderate agreement (kappa 0.57 
(95%CI 0.45-0.68)) between pathologists classifying the depth of invasion using the 
conventional measurement method and similar agreement using the alternative 
method. We identified six pitfalls in assessing the depth of invasion: disagreement 
which invasive nest is deepest, recognition of invasive growth and where it starts, 
curved surface, carcinoma situated on the edge of the tissue block, ulceration and 
different methods used to determine the depth of invasion. We propose the following 
recommendations: optimizing and standardizing of sampling, measuring the least 
favorable depth of invasion if different locations are present, measuring from the floor 
of the tumor ulcer, and using the conventional method as standard method. In 
conclusion, we showed moderate agreement in assessing the depth of invasion using 
the conventional method, without a notable difference using the alternative method. 
This study showed that the alternative method is suitable for pathologists and already 
in use. However, before implementing this method in daily clinical practice, future 
research should be performed to determine if the alternative method leads to a better 
reflection of the prognosis, and of whether a new threshold needs te be defined to 
reflect biological tumor behavior.  
Local recurrence of vulvar SCC is an important clinical issue; in patients with a local 
recurrence the disease-specific survival decreases significantly from 90% to 69% and 
all patients have an indication for inguinofemoral lymphadenectomy (IFL) if not 
performed as part of treatment for the primary vulvar SCC. The most debated prognostic 
factor for local recurrence is the tumor free margin. Currently, the recommended 
surgical tumor-free margin distance varies between different guidelines ranging 
between one to two centimeters, and a pathologic tumor fee margin of ≥8 mm has 
been advocated as safe. However, surgery to reach this margin can be mutilating, 
especially if the tumor is close to important midline structures such as the clitoris, 
urethra and anus. Knowledge on prognostic factors related to local recurrences should 
be helpful to select high risk patients and/or to develop strategies to prevent local 
recurrences. In Chapter 4, we summarized the current knowledge on the incidence of 
local recurrences related to clinicopathologic and cellbiologic variables. We indicated 
an estimated local recurrence rate of 4% per year without plateauing. The prognostic 
relevance for local recurrence of vulvar SCC of all analyzed variables remains equivocal, 
including pathologic tumor free margin distance <8 mm, presence of lichen sclerosus, 
groin lymph node metastases and a variety of primary tumor characteristics (grade of 
differentiation, tumor size, tumor focality, depth of invasion, lymphovascular space 
invasion, tumor localization and presence of human papillomavirus). We concluded 
that the current evidence on prognostic factors for local recurrence of vulvar cancer is 
not sufficiently robust to allow evidence-based clinical decision making. 
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In Chapter 5, we present our multicenter study to determine the incidence of local 
recurrence of vulvar SCC in relation to tumor and/or precursor lesion free pathologic 
margins. This study was performed in a clinically well-defined consecutive patients 
series (N=287) of two oncology centers with pathology review. We show that patients 
treated for primary vulvar SCC have an ongoing risk for local recurrent disease, and the 
local recurrence rate is as high as 43% within 10 years after treatment. The results of 
our study showed that a pathologic tumor free margin distance of less than 8, 5 or 3 
mm was not associated with a higher local recurrence rate compared to a wider tumor 
free margin. Multivariable analyses showed a higher local recurrence rate in patients 
with dVIN and LS in the margin, in patients with dVIN in the margin, and a FIGO stage 
II or higher. Based on these results, we propose to change the current guidelines and 
to implement a intended surgical tumor free margin of 10 mm, but also not to excise 
unnecessary tissue close to important midline structures. Besides, we propose to 
lower the cut-off for a save pathological tumor free margin distance to ≥ 3 mm, and to 
consider re-excision if dVIN is present in the pathologic margin. As our study showed 
that patients have an ongoing risk for local recurrence and we were not able to identify 
a subgroup of patients not at risk for local recurrence, we recommend to continue 
life-long follow-up for all patients. 
Determination of the inguinofemoral lymph node status by IFL plays an important role 
in the treatment of vulvar SCC. Eventually, this procedure is indicated in around half of 
the patients with vulvar SCC, either at time of primary disease or at time of local 
recurrent disease. IFL has significant short- and long-term complications, which are 
reported in up to 85% of the patients. In Chapter 6, we created an up-to-date summary 
of the modifications of the surgical techniques and peri- and postoperative care 
protocols which were studied in order to reduce the treatment associated morbidity. 
We concluded that after the implementation of several adjustments of the surgical 
techniques the morbidity after IFL decreased but remains high and clinically 
meaningful. In Chapter 7, we aimed to assess the feasibility and the incidence of 
short-term complications after volume-controlled versus short drainage of the groin; 
the MAMBO-IA and IB studies (Morbidity And Measurement of the Body). In this 
nationwide prospective study, we included 77 patients for volume-controlled and 64 
patients for short drainage. Both treatment protocols were feasible but the vol-
ume-controlled protocol was more difficult to follow: in around half of the groins the 
drain was removed in deviation of the protocol due to wound complications, drain 
problems or logistic difficulties. Volume-controlled drainage was associated with 
significantly less lymphoceles compared to short drainage, without a difference in the 
incidence of wound infection or primary wound dehiscence. The estimated incidence 
of one or more complications per groin was 46% after volume-controlled drainage 
versus 75% after short drainage, (RD 29% (95% CI 8, 49) p= 0.006). We therefore 
recommend volume-controlled drainage as the standard of care. 
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Nevertheless, after volume-controlled drainage complications are still present in a 
significant proportion of the groins. Adaptations in the surgical approach may play a 
key role in reducing morbidity associated with IFL. In Chapter 8, we aimed to study the 
feasibility of LigaSure for IFL and to assess the  incidence of short-term complications, 
using LigaSure versus the conventional performance of IFL. Moreover, we aimed to 
evaluate patients’ and surgeons’ experience for both surgical methods. In this 
MAMBO-IC study we randomized in 20 patients for which groin the LigaSure was used, 
for the other groin the conventional IFL was performed. To reduce patient-related 
potential confounders, we randomized within each individual patient. The incidence of 
a wound infection, primary wound dehiscence and lymphocele per groin did not differ 
between the two surgical treatment methods. The estimated incidence of ≥1 
complication(s) per groin was 29% after LigaSure versus 70% after conventional IFL 
(risk difference 41% (95% CI 19-62), p < 0.001). Patients’ reported restriction of daily 
living activities and maximum pain score were scored equal for both treatment 
methods. There were no differences in the surgeons’ reported workload scores. In 
conclusion, LigaSure is feasible and possibly associated with significantly less 
short-term complications compared to conventional IFL. Validation in a large cohort is 
needed before implementing this new technique in clinical practice.
Isolated groin recurrences after a negative sentinel lymph node (SLN) occur in 2-3% of 
the patients. The consequences of a groin recurrence are significant, with a five year 
survival of 0-10%. After a negative SLN close follow-up is performed to identify 
locoregional recurrences as early as possible to achieve better survival rates, 
preferably with limited morbidity. In Chapter 9 we aimed to determine the efficacy of 
the addition of an ultrasound of the groins in the routine follow-up of patients with 
vulvar SCC after a negative SLN. This study included 76 patients undergoing 
three-monthly follow-up visits which consisted of physical examination combined 
with an ultrasound of the groins by a radiologist. Two asymptomatic isolated groin 
recurrences were detected by ultrasound, of which one was non-palpable. The 
sensitivity of ultrasound to detect a groin metastasis was 100% (95% CI 16%-100%) 
and specificity 92% (95% CI 89%-95%). Both patients with an isolated groin recurrence 
were treated by inguinofemoral lymphadenectomy and adjuvant radiotherapy and are 
alive without evidence of disease 39 and 120 months after diagnosis. In total, 348 
ultrasounds and 29 fine needle aspiration cytology procedures were necessary to 
detect these two recurrences. In our view, this is counterbalanced by the earliest 
possible detection of groin recurrences leading to the best possible survival for the 
individual patient. Future research should focus on developing personalized and 
risk-based follow-up schedules; this might be based on body mass index, as this 
patient-related factor can negatively influence the detection of a (small) groin 
recurrence by palpation. Besides, future research should focus on the survival after a 
groin recurrence, as patients with a groin recurrence after a (negative) SLN procedure 
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may have a better prognosis compared with patients with a groin recurrence after 
an IFL.
Finally, in Chapter 10 the content of this thesis is discussed in a broader sense. 
Furthermore, we provide clinical implications and possible directions for future 
research.
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In dit proefschrift beschrijven wij onze studies met het doel om de behandeling en 
follow-up van patiënten met een plaveiselcelcarcinoom van de vulva te optimaliseren. 
In hoofdstuk 1 geven wij een overzicht van de pathogenese, behandeling en follow-up 
van het plaveiselcelcarcinoom van de vulva, tezamen met onze onderzoeksdoelen en 
de hoofdlijnen van dit proefschrift. 
Gedifferentieerde vulvaire intraepitheliale neoplasie (dVIN) wordt vaak gezien in een 
achtergrond van de huidziekte lichen sclerosus (LS) en kan ontaarden in een plaveisel-
celcarcinoom van de vulva. Dit type vulvacarcinoom wordt niet veroorzaakt door het 
humaan papillomavirus (HPV). Echter, genetisch bewijs dat dVIN en LS een voorloper-
stadium zijn van het plaveiselcelcarcinoom ontbreekt. Het doel van hoofdstuk 2 is om 
de genetische relatie van zowel  LS als dVIN met  het niet-HPV-gerelateerde plaveisel-
celcarcinoom te bestuderen. In deze studie hebben wij van twaalf patiënten het DNA 
van het plaveiselcelcarcinoom vergeleken met het DNA van de LS en dVIN. Dit hebben 
wij gedaan met behulp van genomisch analyse waarbij wij ons hebben gericht op 
veranderingen in kopie aantallen van chromosomen en chromosoom segmenten,
en gerichte en zeer gevoelige sequentie bepaling van het gen TP53. De genoombrede 
genoom analyse van de plaveiselcelcarcinomen heeft geleid tot het vaststellen van 
afwijkingen in genomische kopie aantallen in alle plaveiselcelcarcinomen. In het weefsel 
van één patiënt waren enkele genomische afwijkingen zoals gevonden in het plaveisel-
celcarcinoom identiek aanwezig in de dVIN-laesie. Daarnaast vonden wij in vijf 
plaveiselcelcarcinomen TP53 mutaties, die ook aanwezig waren in de dVIN-laesie van 
eenzelfde patiënt en in LS van één patiënt met mutatie frequenties variërend tussen 
de 3 en 19%. Deze data bewijzen dat er een genetische relatie is tussen enerzijds de 
voorlopers LS en dVIN en anderzijds het  niet-HPV-gerelateerde plaveiselcelcarcinoom 
van de vulva.
De invasiediepte is een belangrijke prognostische factor voor patiënten met een pla-
veiselcelcarcinoom van de vulva en speelt een heel belangrijke rol bij de keuze van de 
behandeling. Indien de invasiediepte ≤ 1 mm is, bestaat de behandeling uit ruime 
lokale excisie van de vulvaire tumor. Indien de invasiediepte  > 1 mm is, wordt er lies-
klierchirurgie toegevoegd aan de behandeling bestaande uit hetzij een schildwacht-
klierprocedure dan wel een liesklierdissectie. De invasiediepte kan op verschillende 
manieren gemeten worden. Door de International Federation of Gynecology and 
Obstetrics (FIGO) wordt aanbevolen om te meten met behulp van de conservatieve 
methode: vanaf de meest oppervlakkige dermale papil tot het diepste punt van 
invasie. In verschillende andere carcinomen, waaronder het cervixcarcinoom, wordt 
de invasiediepte met de alternatieve methode gemeten. Deze methode meet van de 
diepste en meest dichtbij gelegen tumorvrije papil tot het diepste punt van invasie. 
Deze alternatieve methode reflecteert mogelijk beter de prognose van de individuele 
533164-L-sub01-bw-Pouwer
Processed on: 24-7-2019 PDF page: 218
218
CHAPTER 11
patiënt. Gezien het feit dat de invasiediepte leidend is voor het al dan niet chirurgisch 
behandelen van de lies, is het cruciaal dat er een goede overeenstemming is tussen de 
pathologen bij het beoordelen van de invasiediepte. Hoofdstuk 3 heeft tot doel om 
de interobserverovereenstemming te bepalen voor het indelen van de invasiediepte 
in ≤ 1 mm of > 1 mm voor beide meetmethodes. Het tweede doel van deze studie is 
om valkuilen te identificeren bij het bepalen van de invasiediepte, om vervolgens 
aanbevelingen te formuleren voor pathologen. Voor deze studie hebben wij 50 coupes met 
een plaveiselcelcarcinoom van de vulva geselecteerd waarin de invasiediepte rond de 
1 mm is.In deze coupes is de invasiediepte met beide methoden gemeten door tien 
pathologen en vier pathologen in opleiding. Dit resulteerde in een matige overeen-
stemming (kappa 0.57 (95%CI 0.45-0.68)) tussen de pathologen indien de conservatieve 
methode is gebruikt en een vergelijkbare overeenstemming indien de alternatieve 
methode is gebruikt. Wij stelden zes valkuilen vast bij de beoordeling van de invasie-
diepte: verschil in de keuze van de diepste invasieve nest, herkenning van (het begin 
van) invasieve groei, onregelmatig oppervlakte, positie van het plaveiselcelcarcinoom 
aan de rand van het weefselblok, ulceratie, en het gebruik van verschillende 
meetmethodes. Wij hebben een aantal aanbevelingen: het insluiten van weefsel 
standaardiseren, de minst gunstige invasiediepte meten indien er verschillende 
mogelijkheden zijn, meten vanaf de bodem van het ulcus en om de conservatieve methode 
als standaard te gebruiken. Samenvattend laten wij een matige overeenstemming zien 
tussen pathologen bij het meten van de invasiediepte, zonder een opvallend verschil 
tussen beide meet- methodes. Onze studie laat zien dat de alternatieve methode 
bruikbaar is voor pathologen en ook al gebruikt wordt. Alvorens deze methode te 
implementeren in de dagelijkse klinische praktijk is er meer onderzoek nodig om te 
bepalen of deze methode inderdaad een optimale reflectie geeft van het biologische 
gedrag van de tumor.   
Het lokaal recidief van het vulvaire plaveiselcelcarcinoom is een belangrijk klinisch 
probleem. De ziekte specifieke overleving daalt significant van 90% bij patiënten 
zonder lokaal recidief naar 69% bij patiënten met een lokaal recidief. Daarnaast 
hebben alle patiënten met een lokaal recidief een indicatie voor een liesklierdissectie 
indien deze niet is verricht ten tijde van de behandeling van het primaire plaveisel-
celcarcinoom van de vulva. De meest bediscussieerde prognostische factor voor een 
lokaal recidief is de tumorvrije marge. De huidige richtlijnen adviseren een chirurgische 
tumorvrije marge wisselend tussen de één en twee centimeter, en een pathologische 
tumorvrije marge van ≥8 mm. Echter, de chirurgische ingreep om deze tumorvrije 
marges te halen kan erg mutilerend zijn, met name wanneer de tumor dichtbij 
belangrijke functionele structuren ligt zoals de clitoris, anus en urethra. Meer kennis 
over prognostische factoren voor een lokaal recidief zal leiden tot een betere
herkenning van hoogrisicopatiënten en/of de ontwikkeling van preventieve behandelingen. 
In hoofdstuk 4 geven wij een samenvatting van de huidige literatuur omtrent klinische, 
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pathologische en celbiologische factoren in relatie tot de incidentie van het lokaal 
recidief. Hierin laten wij een geschat lokaal recidiefcijfer zien van 4% per jaar, dat op 
gelijk niveau blijft in de tijd. Daarnaast is de prognostische waarde van alle geanalyseerde 
variabelen twijfelachtig, inclusief de tumorvrije marge van < 8 mm, de aanwezigheid 
van lichen sclerosus, lymfekliermetastasen in de lies, en meerdere tumorkarakteristieken 
van de primaire tumor (differentiatiegraad, diameter, focaliteit, invasiediepte, lymp-
hangioinvasie, lokalisatie en de aanwezigheid van HPV). Wij concluderen dat het 
bewijs in de huidige literatuur omtrent de prognostische factoren voor een lokaal 
recidief onvoldoende is om het huidige behandelbeleid aan te passen. 
In hoofdstuk 5 beschrijven wij de resultaten van onze studie met het doel de incidentie 
van het lokaal recidief te bepalen in relatie tot tumor- en voorloperstadiumvrije 
pathologische marges. In deze studie hebben wij een groep van 287 opeenvolgende 
patiënten geïncludeerd die zijn behandeld in een van de twee deelnemende centra 
(UMCG en Radboudumc). Van alle geïncludeerde patiënten zijn de coupes gereviseerd 
door twee expertgynaecopathologen. Wij laten zien dat het lokaal recidiefcijfer 43% is 
binnen tien jaar na behandeling van het primaire plaveiselcelcarcinoom. Daarnaast 
kunnen wij op basis van de resultaten van deze studie concluderen dat een tumorvrije 
marge van minder dan 3, 5 of 8 mm niet gerelateerd is aan meer lokale recidieven 
vergeleken met een marge boven deze afkappunten. Daarnaast laten multivariabele 
analyses zien dat er een hoger lokaal recidiefcijfer is bij patiënten met dVIN en LS in de 
marge, dVIN in de marge en/of een FIGO stadium II of hoger. Op basis van bovenstaande 
resultaten adviseren wij een chirurgische tumorvrije marge van 1 cm zonder onnodig 
weefsel te verwijderen van belangrijke functionele structuren zoals de urethra en/of 
clitoris. Tevens adviseren wij om een pathologische tumorvrije marge van ≥ 3 mm te 
implementeren en een re-exisie te overwegen indien dVIN aanwezig is in de pathologische 
marge. Gezien de aanhoudende kans voor een lokaal recidief gedurende de jaren na 
het primaire plaveiselcelcarcinoom van de vulva en er geen subgroep patiënten 
geïdentificeerd kon worden die niet at-risk zijn voor een lokaal recidief, adviseren wij 
het continueren van levenslange follow-up voor alle patiënten die zijn behandeld voor 
een plaveiselcelcarcinoom van de vulva. 
Het bepalen van de aan- of afwezigheid van lymfekliermetastasen door middel van 
een liesklierdissectie heeft een belangrijke rol in de behandeling van patiënten met 
een plaveiselcelcarcinoom van de vulva. Een liesklierdissectie is uiteindelijk geïndiceerd
in ongeveer de helft van de patiënten ten tijde van het primaire carcinoom of ten tijde 
van het lokaal recidief. Deze ingreep gaat gepaard met forse morbiditeit: korte- 
en/of langetermijncomplicaties zijn gerapporteerd tot bij 85% van de patiënten.
In hoofdstuk 6 hebben wij de huidige literatuur samengevat omtrent de aanpassingen 
van de chirurgische techniek van de liesklierdissectie en de peri- en postoperatieve 
zorg met het doel de morbiditeit van deze ingreep te verminderen. Wij concluderen dat 
na de aanpassing van de chirurgische techniek de morbiditeit enigszins is afgenomen, 
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maar nog steeds aanzienlijk is. In hoofdstuk 7 beschrijven wij de resultaten van onze 
prospectieve landelijke achtereenvolgende MAMBO-IA/IB-studies (Morbidity And 
Measurement of the BOdy). Deze studies hebben tot doel de haalbaarheid en het 
verschil in de incidentie van postoperatieve complicaties te bepalen van twee 
verschillende drainageprotocollen van de lies: op basis van volume (volume-controlled) 
versus korte drainage gedurende vijf dagen. In deze studie zijn 77 patiënten geïncludeerd 
voor de volume-controlled drainage en 64 patiënten voor de korte drainage.
Wij concludeerden dat beide drainageprotocollen haalbaar zijn, alhoewel het volume-
controlled drainageprotocol lastiger uit te voeren is. Bij ongeveer de helft van de patiënten 
behandeld met volume-controlled drainage is de drain niet volgens het protocol 
verwijderd vanwege wond complicaties, drain problemen of om logistieke redenen. 
Volume-controlled drainage resulteerde in significant minder lymphoceles zonder een 
verschil in de incidentie van wondinfecties en/of het spontaan opengaan van de wond. 
Tevens was de geschatte incidentie van een of meer complicaties per lies significant 
lager na volume-controlled drainage in vergelijking tot korte drainage van de lies:
46% versus 75% (RD 29% (95% CI 8, 49) p= 0.006). Gebaseerd op onze onderzoeks-
resultaten raden wij volume-controlled drainage aan als standaard behandeling.
Alhoewel volume-controlled drainage leidt tot minder complicaties, zijn er nog steeds 
een fors aantal liezen waarin een complicatie optreedt. Aanpassingen aan de 
chirurgische techniek van de klierdissectie kunnen een belangrijke rol spelen in het 
verder verminderen van de incidentie van postoperatieve complicaties. In hoofdstuk 8
bestuderen wij in de MAMBO-IC-studie de haalbaarheid van het gebruik van LigaSure 
voor de liesklierdissectie. Tevens vergelijken wij in deze studie de incidentie van korte-
termijncomplicaties na het gebruik van LigaSure in vergelijking met de conservatieve 
liesklierdissectie met behulp van een mes en/of diathermie. Daarnaast heeft deze 
studie het doel de ervaring van zowel de patiënt als de operateur voor beide methodes 
te evalueren. In deze studie zijn twintig patiënten geïncludeerd die allen een 
dubbelzijdige liesklierdissectie hebben ondergaan. Voorafgaand aan de liesklier-
dissectie is er gerandomiseerd binnen een patiënt voor welke lies (links of rechts) de 
LigaSure gebruikt werd. In de andere lies is de conventionele methode gebruikt. 
Er is gekozen voor randomisatie binnen een patiënt om mogelijk verstorende patiënt-
factoren te reduceren. Bij beide liezen werd de volume-controlled drainage uitgevoerd. 
De incidentie van een lymphocele, wondinfectie en het spontaan opengaan van de 
wond, verschilde niet significant tussen beide behandelmethoden. Wel was er een 
significant verschil tussen de geschatte incidentie van een of meer complicaties per 
lies, namelijk 29% na LigaSure versus 70% na conservatieve liesklierdissectie (risk 
difference 41% (95% CI 19-62), p < 0.001). Er in geen verschil in de door de patiënt 
gerapporteerde beperking in dagelijkse activiteiten en de maximale postoperatieve 
pijnscore, en de door de operateur gerapporteerde werklastscore. Wij concluderen 
dat LigaSure haalbaar is voor de liesklierdissectie en leidt tot een significant lager 
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geschatte incidentie van liezen met een of meer complicaties. Alvorens deze techniek 
te implementeren in de dagelijkse praktijk is validatie van onze resultaten in een groter 
cohort patiënten nodig.
Na een negatieve schildwachtklier als onderdeel van de behandeling van een primair 
plaveiselcelcarcinoom van de vulva, treden geïsoleerde liesrecidieven op bij 2-3% van 
de patiënten. Een geïsoleerd liesrecidief heeft een erg slechte prognose, met een 
vijfjaars overleving van 0-10%. Na een negatieve schildwachtklierprocedure ondergaan 
patiënten strikte follow-up om een lokaal of regionaal recidief zo vroeg mogelijk te 
diagnosticeren, met het doel om betere overlevingscijfers te bereiken met zo min 
mogelijk morbiditeit. In hoofdstuk 9 evalueren wij de waarde van het toevoegen van 
een echo van de lies aan de follow-upbezoeken bij patiënten met een negatieve 
schildwachtklier. In deze studie includeerden wij 76 patiënten die driemaandelijks 
voor een follow-upbezoek kwamen en waarbij er lichamelijk onderzoek werd verricht 
in combinatie met een echo van beide liezen door een radioloog. Deze echo’s van de 
lies resulteerden in de diagnose van een asymptomatisch geïsoleerd liesrecidief bij 
twee patiënten, waarvan bij één patiënt het recidief niet palpabel was. De sensitiviteit 
van de echo om een liesmetastase op te sporen was 100% (95% CI 16%-100%) en de 
specificiteit 92% (95% CI 89%-95%). Beide patiënten met een geïsoleerd liesrecidief 
zijn behandeld met een liesklierdissectie met adjuvante radiotherapie en zijn 39 en 
120 maanden na diagnose in leven zonder tekenen van een nieuw liesrecidief. Er waren 
in totaal 348 echo’s en 29 cytologische puncties nodig om deze twee recidieven op te 
sporen. Naar onze mening weegt dit op tegen de zo vroeg mogelijke diagnose van een 
liesrecidief en de best mogelijke overleving voor de individuele patiënt. Vervolgonder-
zoek moet uitwijzen of de follow-up voor patiënten met een negatieve schildwachtklier 
verder gepersonaliseerd kan worden gebaseerd op het risico voor een liesrecidief, 
bijvoorbeeld op basis van de body mass index (BMI). Een hoger BMI is een mogelijke 
factor is die het opsporen van een liesrecidief door middel van lichamelijk onderzoek 
kan belemmeren. Tevens zal vervolgonderzoek uit moeten wijzen of er een verschil is 
in de overleving tussen patiënten met een liesrecidief na behandeling met een 
(negatieve) schildwachtklierprocedure of na behandeling met een liesklierdissectie. 
In het laatste hoofdstuk, hoofdstuk 10, worden op basis van de resultaten van boven- 
genoemde studies de klinische implicaties en het toekomstperspectief bediscussieerd. 
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Theuny, wij als groepje pubers hangend bij de kluisjes, moet je ons nu eens zien als 
‘grote mensen’. Timo, altijd tijd voor een biertje, ook nadat ik jou verlaten had als 
huisgenoot. Elco, mijn maatje in Nieuw-Zeeland, ik heb zoveel waardevolle herinneringen 
van onze weekendjes weg in Nieuw Zeeland. Lieve Jorieke, wat begon als een huis- 
genoot werd een mooie vriendschap. Bij jou was het prettig thuiskomen. Altijd tijd voor 
een kop thee en niet te vergeten de vele taarten, cakes en koekjes die wij samen bakken. 
Het boterkoek-accident vergeet ik nooit! Ik bewonder jouw doorzettingsvermogen.
Jij bent mijn voorbeeld.
Beste paranimfen, ik ben blij dat jullie naast mij willen staan. 
Lieve Carlijn, al vanaf ons eerste studiejaar delen wij lief en leed op de maandagavond. 
Jij kent al mijn onderzoeksperikelen en vierde elke publicatie mee. Jij bent altijd betrokken. 
Ik heb er bewondering voor hoe jij jouw opleiding met onderzoek combineert en ben 
heel benieuwd naar jouw proefschrift!
Lieve Casper,  wij waren onafscheidelijk sinds jij in het ‘vulvahoekje’ kwam werken.
We werden niet voor niks de papa en mama van de tuin genoemd. Ruim twee jaar lang 
had ik het voorrecht tegenover jou te mogen werken. Jij bracht een glimlach op mijn gezicht. 
Jij wist mij altijd weer te motiveren als mijn CMO-aanvraag voor de zoveelste keer was 
afgewezen, of als het onderzoekscontract weer niet op tafel kwam. Bedankt voor de 
ontelbare koppen ‘lekkere koffie’ en de goede gesprekken. Ik kijk er naar uit om in de 
toekomst weer samen met jou te mogen werken. Maar nu eerst borrelen.
Lieve Saartje, omdat ik dit vaak heb geroepen, krijg jij een ook plekje in dit dankwoord. 
Bedankt voor de vele keren dat ik lachend naar een aantal pagina’s vol zzzzzzzz of 
wwwwwwww stond te kijken wanneer ik even bij mijn laptop weg was geweest. 
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Lieve opa’s en oma’s, helaas heb ik al afscheid van jullie moeten nemen. Mede door 
jullie ben ik wie ik nu ben. Bedankt voor alle oppasdagen en logeerweekendjes, wat later 
bezoekjes en dagjes uit werden. Ik weet hoe graag jullie dit alles mee hadden willen 
maken en hoe trots jullie naast mij zullen hebben gestaan.  
Lieve zussen en broer, Heleen, Marianne en Mathijs, het een voorrecht om jullie als 
zussen en broer te hebben. Jullie hebben weinig woorden nodig om mij te begrijpen.
Ik kijk uit naar onze volgende vakantie samen!
Lieve Papa en Mama, jullie creëerde een warm en liefdevol thuis. Er was altijd gezelligheid 
en iedereen was welkom. Jullie lieten los waar nodig en waren er als ik jullie nodig had. 
Jullie liefde en steun is onvoorwaardelijk. Bedankt voor de kansen die jullie mij hebben 
gegeven. Zonder jullie had ik hier niet gestaan.
Lieve Ruud, ik heb je lief.
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